{"matching_results": 22256, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "teletrader.com", "matching_results": 4789, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 4789}]}]}, {"key": "americanbankingnews.com", "matching_results": 1068, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 974}, {"key": "negative", "matching_results": 88}, {"key": "neutral", "matching_results": 6}]}]}, {"key": "thelincolnianonline.com", "matching_results": 836, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 746}, {"key": "negative", "matching_results": 87}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "freelancer.com.co", "matching_results": 804, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 715}, {"key": "negative", "matching_results": 80}, {"key": "neutral", "matching_results": 9}]}]}, {"key": "watchlistnews.com", "matching_results": 767, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 688}, {"key": "negative", "matching_results": 78}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "tickerreport.com", "matching_results": 743, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 674}, {"key": "negative", "matching_results": 69}]}]}, {"key": "wkrb13.com", "matching_results": 709, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 621}, {"key": "negative", "matching_results": 87}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 628, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 572}, {"key": "negative", "matching_results": 56}]}]}, {"key": "theolympiareport.com", "matching_results": 615, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 548}, {"key": "negative", "matching_results": 67}]}]}, {"key": "dailypolitical.com", "matching_results": 530, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 475}, {"key": "negative", "matching_results": 55}]}]}]}], "results": [{"id": "bbE4GRgp6nVFB02ie_7b9gQL5uHIEXj3XY9kqkclF-k2f8bIwyPxrgQiEpEsaLG5", "result_metadata": {"score": 35.808865}, "author": "Swapna", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.380304, "label": "positive"}, "text": "Analytical Insights", "relevance": 0.33, "type": "PrintMedia"}], "sentiment": {"document": {"score": -0.386428, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Diseases and disorders", "relevance": 0.856964, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}], "categories": [{"score": 0.964785, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Fabry Disease Facts", "sentiment": {"score": -0.403699, "label": "negative"}, "relevance": 0.983681}, {"text": "Analytical Insights", "sentiment": {"score": 0.380304, "label": "positive"}, "relevance": 0.70518}, {"text": "Figures", "sentiment": {"score": 0.380304, "label": "positive"}, "relevance": 0.315692}]}, "crawl_date": "2018-11-04T01:23:18Z", "url": "https://www.findmarketresearch.org/2018/07/fabry-disease-market-facts-figures-and-analytical-insights-2016-2026/", "host": "findmarketresearch.org", "text": "Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-07-17T11:54:00+05:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.736695, "label": "negative"}, "text": "fabry disease", "relevance": 0.942054, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}, {"count": 1, "sentiment": {"score": -0.576522, "label": "negative"}, "text": "Fabry diseaseis", "relevance": 0.409139, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.786549, "label": "negative"}, "text": "APAC", "relevance": 0.171533, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.708726, "label": "negative"}, "text": "multiple organ failure", "relevance": 0.160589, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Multiple organ dysfunction syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_organ_dysfunction_syndrome"}}, {"count": 1, "sentiment": {"score": -0.581545, "label": "negative"}, "text": "Novartis Pharmaceuticals", "relevance": 0.158074, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.154605, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regional Overview", "relevance": 0.154073, "type": "PrintMedia"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.146344, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva pharmaceutical Industries Ltd.", "relevance": 0.144142, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.139231, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi-Aventis LLC", "relevance": 0.136498, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.135466, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": -0.30305, "label": "negative"}, "text": "Gene", "relevance": 0.134663, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.13377, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.130732, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.428553, "label": "negative"}, "text": "Neuraltus Pharmaceuticals", "relevance": 0.130107, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genzyme Corporation", "relevance": 0.129017, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"count": 1, "sentiment": {"score": 0.26394, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.125744, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.125541, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.123951, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.12277, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0.259075, "label": "positive"}, "text": "Western Europe", "relevance": 0.120989, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.114453, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merc & Co., Inc.", "relevance": 0.11353, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "iBio, Inc.", "relevance": 0.111172, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.109858, "type": "Company"}], "sentiment": {"document": {"score": -0.615351, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Fabry", "keywords": [{"text": "Fabry"}], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, "sentence": "Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency.", "object": {"text": "also known as Anderson-Fabry disease and alpha-galactosidase A deficiency", "keywords": [{"text": "Anderson-Fabry disease"}, {"text": "deficiency"}]}, "action": {"verb": {"text": "diseaseis", "tense": "present"}, "text": "diseaseis", "normalized": "diseaseis"}}, {"subject": {"text": "Fabry diseaseis", "keywords": [{"text": "Fabry diseaseis"}], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, "sentence": "Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency.", "object": {"text": "as Anderson-Fabry disease and alpha-galactosidase A deficiency", "keywords": [{"text": "deficiency"}, {"text": "Anderson-Fabry disease"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "It"}, "sentence": " It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "lipid metabolism"}, {"text": "rare genetic disorder"}, {"text": "deficient activity"}, {"text": "enzyme"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "deficient activity"}, {"text": "enzyme"}, {"text": "alpha-galactosidase"}]}, "sentence": " It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "lipid metabolism", "keywords": [{"text": "lipid metabolism"}]}, "action": {"verb": {"text": "result", "tense": "present"}, "text": "resulting", "normalized": "result"}}, {"subject": {"text": "by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "alterations"}, {"text": "enzyme"}, {"text": "genes"}, {"text": "cells"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "The deficiency of the enzyme", "keywords": [{"text": "deficiency"}, {"text": "enzyme"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "the alterations in the genes", "keywords": [{"text": "alterations"}, {"text": "genes"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "the cells", "keywords": [{"text": "cells"}]}, "action": {"verb": {"text": "instruct", "tense": "present"}, "text": "instructs", "normalized": "instruct"}}, {"subject": {"text": "the cells", "keywords": [{"text": "cells"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "alpha-galactosidase", "keywords": [{"text": "alpha-galactosidase"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "to make", "normalized": "to make"}}, {"subject": {"text": "Fabry disease", "keywords": [{"text": "Fabry disease"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "sentence": " Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "object": {"text": "known to cause variety of systemic symptoms and complications, one of them being metabolic disorders", "keywords": [{"text": "systemic symptoms"}, {"text": "metabolic disorders"}, {"text": "complications"}, {"text": "variety"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Fabry disease", "keywords": [{"text": "Fabry disease"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "sentence": " Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "object": {"text": "to cause variety of systemic symptoms and complications, one of them being metabolic disorders", "keywords": [{"text": "systemic symptoms"}, {"text": "metabolic disorders"}, {"text": "complications"}, {"text": "variety"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "The metabolism of sphingolipids", "keywords": [{"text": "metabolism"}, {"text": "sphingolipids"}]}, "sentence": " The metabolism of sphingolipids is minimized, in fabry disease which results in the multiple organ failure and death.", "object": {"text": "minimized, in fabry disease which results in the multiple organ failure and death", "keywords": [{"text": "multiple organ failure"}, {"text": "fabry disease"}, {"text": "death"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}, {"type": "HealthCondition", "text": "multiple organ failure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Multiple organ dysfunction syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_organ_dysfunction_syndrome"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "A enzyme, glycolipid called Gb3", "keywords": [{"text": "glycolipid"}, {"text": "enzyme"}, {"text": "Gb3"}]}, "sentence": " Owing to the deficiency of alpha galactosidase A enzyme, glycolipid called Gb3 accumulates in the blood vessels and other organs and thus results in formation of blockage or clots that leads to malfunctioning of the system.", "action": {"verb": {"text": "accumulate", "tense": "present"}, "text": "accumulates", "normalized": "accumulate"}}, {"subject": {"text": "The major drivers that drive the fabry disease market growth", "keywords": [{"text": "fabry disease market"}, {"text": "major drivers"}]}, "sentence": " The major drivers that drive the fabry disease market growth are extensive R&D activities, adoption of advanced technologies in the research practices.", "object": {"text": "extensive R&D activities, adoption of advanced technologies in the research practices", "keywords": [{"text": "extensive R&D activities"}, {"text": "advanced technologies"}, {"text": "research practices"}, {"text": "adoption"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "complications in physiological systems, such as cardiac system, urinary system and others", "keywords": [{"text": "physiological systems"}, {"text": "complications"}], "entities": []}, "sentence": " Due to hereditary nature and severity of the disease, complications in physiological systems, such as cardiac system, urinary system and others are expected to increase the demand for trustworthy treatment.", "object": {"text": "the demand for trustworthy treatment", "keywords": [{"text": "trustworthy treatment"}, {"text": "demand"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "are expected to increase", "normalized": "be expect to increase"}}, {"subject": {"text": "Extensive R&D practices", "keywords": [{"text": "Extensive R&D practices"}]}, "sentence": " Extensive R&D practices is one of the valuable drivers of the market.", "object": {"text": "one of the valuable drivers of the market", "keywords": [{"text": "valuable drivers"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "various therapeutic products, such as, PRX-102, JR-051, NP-003, GC-1119 and others,", "keywords": [{"text": "various therapeutic products"}, {"text": "JR-051"}, {"text": "NP-003"}, {"text": "GC-1119"}]}, "sentence": " Due to this, various therapeutic products, such as, PRX-102, JR-051, NP-003, GC-1119 and others, are under pipeline studies.", "object": {"text": "under pipeline studies", "keywords": [{"text": "pipeline studies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "technological limitations in certain region of the world", "keywords": [{"text": "technological limitations"}, {"text": "certain region"}, {"text": "world"}]}, "sentence": " However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "object": {"text": "some of the restraining factors that may affect the growth of the fabry disease market", "keywords": [{"text": "fabry disease market"}, {"text": "restraining factors"}, {"text": "growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some of the restraining factors", "keywords": [{"text": "restraining factors"}]}, "sentence": " However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "object": {"text": "the growth of the fabry disease market", "keywords": [{"text": "fabry disease market"}, {"text": "growth"}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "may affect", "normalized": "may affect"}}, {"subject": {"text": "The global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "been classified on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "classified on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "has been classified", "normalized": "have be classify"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs; Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "object": {"text": "divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs; Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "keywords": [{"text": "Enzyme replacement therapy"}, {"text": "global fabry disease"}, {"text": "end user type"}, {"text": "agalsidase alpha"}], "entities": [{"type": "Person", "text": "Gene"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs; Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "object": {"text": "into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs; Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "keywords": [{"text": "Enzyme replacement therapy"}, {"text": "global fabry disease"}, {"text": "end user type"}, {"text": "agalsidase alpha"}], "entities": [{"type": "Person", "text": "Gene"}]}, "action": {"verb": {"text": "divide", "tense": "past"}, "text": "is divided", "normalized": "be divide"}}, {"subject": {"text": "The enzyme replacement therapy", "keywords": [{"text": "enzyme replacement therapy"}]}, "sentence": " The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "enzyme", "keywords": [{"text": "enzyme"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "is designed to provide", "normalized": "be design to provide"}}, {"subject": {"text": "enzyme to the patients", "keywords": [{"text": "enzyme"}, {"text": "patients"}]}, "sentence": " The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "from enzyme deficiency", "keywords": [{"text": "enzyme deficiency"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "Enzyme replacement therapy", "keywords": [{"text": "Enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "the most expensive and unaffordable treatment among the treatments for fabry disease", "keywords": [{"text": "fabry disease"}, {"text": "unaffordable treatment"}, {"text": "treatments"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "enzyme replacement therapy", "keywords": [{"text": "enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "moderate growth", "keywords": [{"text": "moderate growth"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The analgesics, anticonvulsants and NSAIDs", "keywords": [{"text": "analgesics"}, {"text": "NSAIDs"}, {"text": "anticonvulsants"}]}, "sentence": " The analgesics, anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market.", "object": {"text": "for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market", "keywords": [{"text": "fabry disease"}, {"text": "pain"}, {"text": "treatment"}, {"text": "symptoms"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are generally known", "normalized": "be generally know"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Western Europe"}, {"text": "Eastern Europe"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Western Europe"}, {"text": "Eastern Europe"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America", "keywords": [{"text": "Africa.North America"}, {"text": "Western Europe"}, {"text": "Eastern Europe"}, {"text": "APAC"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "estimated to be the most lucrative region", "keywords": [{"text": "lucrative region"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Eastern Europe, APAC, Japan, Middle East and Africa.North America", "keywords": [{"text": "APAC"}, {"text": "Eastern Europe"}, {"text": "Middle East"}, {"text": "Africa.North America"}], "entities": [{"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "to be the most lucrative region", "keywords": [{"text": "lucrative region"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "by Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "the affordability of the treatment", "keywords": [{"text": "affordability"}, {"text": "treatment"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "The rare incidences in APAC and MEA countries", "keywords": [{"text": "rare incidences"}, {"text": "MEA countries"}, {"text": "APAC"}], "entities": []}, "sentence": " The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "object": {"text": "the growth of fabry disease market in these regions", "keywords": [{"text": "fabry disease market"}, {"text": "regions"}]}, "action": {"verb": {"text": "limit", "tense": "future"}, "text": "are expected to limit", "normalized": "be expect to limit"}}, {"subject": {"text": "The major players", "keywords": [{"text": "major players"}]}, "sentence": " The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc", "keywords": [{"text": "GlaxoSmithKline plc"}, {"text": "Sanofi-Aventis LLC"}, {"text": "Genzyme Corporation"}, {"text": "Neuraltus Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Sanofi-Aventis LLC"}, {"type": "Company", "text": "iBio, Inc."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Genzyme Corporation", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"type": "Company", "text": "Neuraltus Pharmaceuticals"}]}, "sentence": " The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "object": {"text": "The major players operating in this market and involved in development of new medications", "keywords": [{"text": "new medications"}, {"text": "major players"}, {"text": "market"}, {"text": "development"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Some of the existing key players in the global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "key players"}]}, "sentence": " Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd.", "object": {"text": "Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Teva pharmaceutical Industries"}, {"text": "Novartis Pharmaceuticals"}, {"text": "Pfizer Inc."}], "entities": [{"type": "Company", "text": "Novartis Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Merc & Co., Inc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Teva pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Fabry disease", "relevance": 0.97566, "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}, {"text": "Enzyme replacement therapy", "relevance": 0.9683, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_replacement_therapy"}, {"text": "Bristol-Myers Squibb", "relevance": 0.85591, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.764467, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Therapy", "relevance": 0.65353, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Clopidogrel", "relevance": 0.650208, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Metabolism", "relevance": 0.625841, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Medicine", "relevance": 0.618728, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Sphingolipidoses", "relevance": 0.601928, "dbpedia_resource": "http://dbpedia.org/resource/Sphingolipidoses"}, {"text": "Diseases and disorders", "relevance": 0.561258, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.560382, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}], "categories": [{"score": 0.8905, "label": "/health and fitness/disease"}, {"score": 0.327513, "label": "/health and fitness/disorders"}], "relations": [{"type": "hasAttribute", "sentence": "Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "score": 0.469575, "arguments": [{"text": "Fabry", "location": [370, 375], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, {"text": "metabolic disorders", "location": [468, 487], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "agentOf", "sentence": "The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "score": 0.783909, "arguments": [{"text": "Report Sample@", "location": [3673, 3687], "entities": [{"type": "Person", "text": "Report Sample@"}]}, {"text": "Request", "location": [3665, 3672], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "hasAttribute", "sentence": "Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "score": 0.782799, "arguments": [{"text": "them", "location": [457, 461], "entities": [{"type": "Person", "text": "them"}]}, {"text": "metabolic disorders", "location": [468, 487], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "locatedAt", "sentence": "However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "score": 0.243329, "arguments": [{"text": "region", "location": [1628, 1634], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "world", "location": [1642, 1647], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "The analgesics, anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market.", "score": 0.518347, "arguments": [{"text": "NSAIDs", "location": [2635, 2641], "entities": [{"type": "Person", "text": "NSAIDs"}]}, {"text": "disease hence", "location": [2729, 2742], "entities": [{"type": "HealthCondition", "text": "disease hence"}]}]}, {"type": "locatedAt", "sentence": "Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.472239, "arguments": [{"text": "regions", "location": [2847, 2854], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [2878, 2891], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.72389, "arguments": [{"text": "APAC", "location": [2925, 2929], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}, {"text": "Japan", "location": [2931, 2936], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.80263, "arguments": [{"text": "countries", "location": [3120, 3129], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "APAC", "location": [3107, 3111], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}]}, {"type": "partOf", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.651857, "arguments": [{"text": "MEA", "location": [3116, 3119], "entities": [{"type": "Organization", "text": "MEA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "countries", "location": [3120, 3129], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "score": 0.982858, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [3634, 3664], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Request", "location": [3665, 3672], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}], "keywords": [{"text": "fabry disease market", "sentiment": {"score": -0.520341, "label": "negative"}, "relevance": 0.949021}, {"text": "global fabry disease", "sentiment": {"score": -0.493604, "label": "negative"}, "relevance": 0.782339}, {"text": "enzyme replacement therapy", "sentiment": {"score": -0.703857, "label": "negative"}, "relevance": 0.716786}, {"text": "overall fabry disease", "sentiment": {"score": -0.538371, "label": "negative"}, "relevance": 0.596311}, {"text": "disease market growth", "sentiment": {"score": -0.23927, "label": "negative"}, "relevance": 0.519057}, {"text": "enzyme deficiency", "sentiment": {"score": -0.843444, "label": "negative"}, "relevance": 0.498889}, {"text": "rare genetic disorder", "sentiment": {"score": -0.649562, "label": "negative"}, "relevance": 0.491845}, {"text": "extensive r&d", "sentiment": {"score": 0.461981, "label": "positive"}, "relevance": 0.486623}, {"text": "key players", "sentiment": {"score": -0.581545, "label": "negative"}, "relevance": 0.482517}, {"text": "extensive R&D activities", "sentiment": {"score": -0.23927, "label": "negative"}, "relevance": 0.481632}, {"text": "multiple organ failure", "sentiment": {"score": -0.708726, "label": "negative"}, "relevance": 0.480199}, {"text": "Extensive R&D practices", "sentiment": {"score": 0.701252, "label": "positive"}, "relevance": 0.480118}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478185}, {"text": "various therapeutic products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477956}, {"text": "Teva pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477852}, {"text": "rare incidence rate", "sentiment": {"score": -0.300761, "label": "negative"}, "relevance": 0.47725}, {"text": "end user type", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476838}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476699}, {"text": "Request Report Sample", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473655}, {"text": "Anderson-Fabry disease", "sentiment": {"score": -0.576522, "label": "negative"}, "relevance": 0.470592}, {"text": "lipid metabolism", "sentiment": {"score": -0.649562, "label": "negative"}, "relevance": 0.457314}, {"text": "trustworthy treatment", "sentiment": {"score": 0.36224, "label": "positive"}, "relevance": 0.452346}, {"text": "deficient activity", "sentiment": {"score": -0.649562, "label": "negative"}, "relevance": 0.451923}, {"text": "unaffordable treatment", "sentiment": {"score": -0.729756, "label": "negative"}, "relevance": 0.446971}, {"text": "systemic symptoms", "sentiment": {"score": -0.797483, "label": "negative"}, "relevance": 0.446396}, {"text": "Amgen Inc.", "sentiment": {"score": 0.26394, "label": "positive"}, "relevance": 0.446146}, {"text": "agalsidase alpha", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.445755}, {"text": "metabolic disorders", "sentiment": {"score": -0.785664, "label": "negative"}, "relevance": 0.44573}, {"text": "major drivers", "sentiment": {"score": -0.23927, "label": "negative"}, "relevance": 0.445419}, {"text": "alpha galactosidase", "sentiment": {"score": -0.485789, "label": "negative"}, "relevance": 0.44531}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444834}, {"text": "Regional Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444742}, {"text": "advanced technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444453}, {"text": "research practices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444332}, {"text": "hereditary nature", "sentiment": {"score": -0.731825, "label": "negative"}, "relevance": 0.44419}, {"text": "Sanofi-Aventis LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443822}, {"text": "AbbVie Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443799}, {"text": "valuable drivers", "sentiment": {"score": 0.701252, "label": "positive"}, "relevance": 0.443611}, {"text": "physiological systems", "sentiment": {"score": -0.43068, "label": "negative"}, "relevance": 0.443601}, {"text": "Gene therapy", "sentiment": {"score": -0.30305, "label": "negative"}, "relevance": 0.443235}, {"text": "Genzyme Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442994}, {"text": "Pharmaceutical formulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442985}, {"text": "rare incidences", "sentiment": {"score": -0.786549, "label": "negative"}, "relevance": 0.442942}, {"text": "blood vessels", "sentiment": {"score": -0.691556, "label": "negative"}, "relevance": 0.442855}, {"text": "genetic sciences", "sentiment": {"score": -0.539806, "label": "negative"}, "relevance": 0.442797}, {"text": "moderate growth", "sentiment": {"score": -0.538371, "label": "negative"}, "relevance": 0.442685}, {"text": "Novartis Pharmaceuticals", "sentiment": {"score": -0.581545, "label": "negative"}, "relevance": 0.442123}, {"text": "lucrative region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442116}, {"text": "major players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441849}, {"text": "restraining factors", "sentiment": {"score": -0.704272, "label": "negative"}, "relevance": 0.44183}]}, "extracted_metadata": {"sha1": "97f9a36af7bba68c75465c2139cb04078f999e54", "filename": "1541294598257.zip-e0b12b7d4b3f0140b426321b4eca5d7f.xml", "file_type": "json"}, "external_links": ["http://www.futuremarketinsights.com/reports/fabry-disease-market", "http://www.futuremarketinsights.com/reports/sample/rep-gb-1365"], "title": "Fabry Disease Facts, Figures and Analytical Insights, 2016-2026", "forum_title": "Healthcare \u2013 Find Market Research"}, {"id": "ND5KqtjqvL3o7pbqDnQsf_vIdkkAP8nItO1e6mXs6tEDKCzjAwd6YS4mofQEyuf7", "result_metadata": {"score": 32.636765}, "author": "Donald Scott", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nektar Therapeutics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NKTR", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.73408, "label": "/science/medicine/pharmacology"}, {"score": 0.469054, "label": "/science/medicine/oncology"}], "relations": [], "keywords": [{"text": "Nektar Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975357}, {"text": "Athenex", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555169}]}, "crawl_date": "2018-11-03T16:00:13Z", "url": "https://www.thelincolnianonline.com/2018/11/03/contrasting-athenex-atnx-nektar-therapeutics-nktr.html", "host": "thelincolnianonline.com", "text": "Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited.", "main_image_url": "https://www.marketbeat.com/logos/nektar-therapeutics-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-03T14:56:00Z", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.821841, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nektar Therapeutics", "relevance": 0.814034, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.37997, "label": "negative"}, "text": "cancer", "relevance": 0.492504, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 3, "sentiment": {"score": -0.418244, "label": "negative"}, "text": "metastatic breast cancer", "relevance": 0.487251, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.538409, "label": "negative"}, "text": "non-small cell lung cancer", "relevance": 0.386381, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Non-small-cell lung carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Non-small-cell_lung_carcinoma"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Athenex, Inc.", "relevance": 0.358972, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.502021, "label": "negative"}, "text": "metastatic colorectal cancer", "relevance": 0.333515, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0.38331, "label": "positive"}, "text": "Athenex", "relevance": 0.332177, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.592611, "label": "negative"}, "text": "pancreatic cancer", "relevance": 0.332134, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Pancreatic cancer", "dbpedia_resource": "http://dbpedia.org/resource/Pancreatic_cancer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Insider Ownership", "relevance": 0.308251, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.29283, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Halozyme Therapeutics, Inc.", "relevance": 0.272287, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.254162, "label": "negative"}, "text": "actinic keratosis", "relevance": 0.260123, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom"], "name": "Actinic keratosis", "dbpedia_resource": "http://dbpedia.org/resource/Actinic_keratosis"}}, {"count": 1, "sentiment": {"score": -0.339706, "label": "negative"}, "text": "lupus erythematosus", "relevance": 0.257133, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Systemic lupus erythematosus", "dbpedia_resource": "http://dbpedia.org/resource/Systemic_lupus_erythematosus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kinex Pharmaceuticals LLC", "relevance": 0.256324, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.389344, "label": "negative"}, "text": "Hanmi Pharmaceuticals", "relevance": 0.255336, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "gastrointestinal tract", "relevance": 0.253392, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": -0.569308, "label": "negative"}, "text": "migraine", "relevance": 0.250257, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Migraine", "dbpedia_resource": "http://dbpedia.org/resource/Migraine"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca AB", "relevance": 0.236023, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "San Francisco", "relevance": 0.235307, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "USCounty", "FilmScreeningVenue", "City"], "name": "San Francisco", "dbpedia_resource": "http://dbpedia.org/resource/San_Francisco"}}, {"count": 1, "sentiment": {"score": -0.801911, "label": "negative"}, "text": "United States", "relevance": 0.233898, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0.242921, "label": "positive"}, "text": "solid tumors", "relevance": 0.233174, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}, {"count": 1, "sentiment": {"score": -0.371764, "label": "negative"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.23236, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "granisetron", "relevance": 0.231898, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.230226, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Buffalo", "relevance": 0.229711, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Buffalo, New York", "dbpedia_resource": "http://dbpedia.org/resource/Buffalo,_New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oradoxel", "relevance": 0.226403, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.22577, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 1, "sentiment": {"score": -0.502021, "label": "negative"}, "text": "irinotecan", "relevance": 0.224516, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "docetaxel", "relevance": 0.223585, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.639817, "label": "negative"}, "text": "spondylitis", "relevance": 0.223184, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease"], "name": "Ankylosing spondylitis", "dbpedia_resource": "http://dbpedia.org/resource/Ankylosing_spondylitis"}}, {"count": 1, "sentiment": {"score": -0.407234, "label": "negative"}, "text": "glioblastoma", "relevance": 0.220807, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Glioblastoma multiforme", "dbpedia_resource": "http://dbpedia.org/resource/Glioblastoma_multiforme"}}, {"count": 1, "sentiment": {"score": 0.38331, "label": "positive"}, "text": "MarketBeat.com", "relevance": 0.220525, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oraxol", "relevance": 0.218788, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oratecan", "relevance": 0.217949, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd", "relevance": 0.217037, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.246183, "label": "negative"}, "text": "Neulasta", "relevance": 0.21562, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oratopo", "relevance": 0.215149, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "topotecan", "relevance": 0.214965, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Src Kinase", "relevance": 0.214434, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.208867, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amgen Inc.", "relevance": 0.208695, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.206587, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UCB Pharma", "relevance": 0.205891, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co.", "relevance": 0.204064, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.588022, "label": "negative"}, "text": "Macugen", "relevance": 0.199477, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.789158, "label": "negative"}, "text": "MIRCERA", "relevance": 0.198927, "type": "Drug"}], "sentiment": {"document": {"score": -0.447161, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "19.9% of Athenex shares", "keywords": [{"text": "Athenex shares"}], "entities": [{"type": "Quantity", "text": "19.9"}]}, "sentence": " 19.9% of Athenex shares are held by institutional investors.", "object": {"text": "held by institutional investors", "keywords": [{"text": "institutional investors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " 19.9% of Athenex shares are held by institutional investors.", "object": {"text": "19.9% of Athenex shares", "keywords": [{"text": "Athenex shares"}], "entities": [{"type": "Quantity", "text": "19.9"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "91.9% of Nektar Therapeutics shares", "keywords": [{"text": "Nektar Therapeutics shares"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}, {"type": "Quantity", "text": "91.9"}]}, "sentence": " Comparatively, 91.9% of Nektar Therapeutics shares are held by institutional investors.", "object": {"text": "held by institutional investors", "keywords": [{"text": "institutional investors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " Comparatively, 91.9% of Nektar Therapeutics shares are held by institutional investors.", "object": {"text": "91.9% of Nektar Therapeutics shares", "keywords": [{"text": "Nektar Therapeutics shares"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}, {"type": "Quantity", "text": "91.9"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "by company insiders", "keywords": [{"text": "company insiders"}]}, "sentence": " 29.5% of Athenex shares are held by company insiders.", "object": {"text": "29.5% of Athenex shares", "keywords": [{"text": "Athenex shares"}], "entities": [{"type": "Quantity", "text": "29.5"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "by company insiders", "keywords": [{"text": "company insiders"}]}, "sentence": " Comparatively, 4.3% of Nektar Therapeutics shares are held by company insiders.", "object": {"text": "4.3% of Nektar Therapeutics shares", "keywords": [{"text": "Nektar Therapeutics shares"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}, {"type": "Quantity", "text": "4.3"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are held", "normalized": "be hold"}}, {"subject": {"text": "Strong institutional ownership", "keywords": [{"text": "Strong institutional ownership"}]}, "sentence": " Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.", "object": {"text": "an indication that large money managers", "keywords": [{"text": "indication"}, {"text": "large money managers"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "large money managers, endowments and hedge funds", "keywords": [{"text": "large money managers"}, {"text": "endowments"}, {"text": "funds"}], "entities": []}, "sentence": " Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.", "object": {"text": "a company will outperform the market over the long term", "keywords": [{"text": "long term"}, {"text": "company"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believe", "normalized": "believe"}}, {"subject": {"text": "Nektar Therapeutics", "keywords": [{"text": "Nektar Therapeutics"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}]}, "sentence": " Nektar Therapeutics beats Athenex on 12 of the 14 factors compared between the two stocks.", "object": {"text": "Athenex", "keywords": [{"text": "Athenex"}], "entities": [{"type": "Company", "text": "Athenex"}]}, "action": {"verb": {"text": "beat", "tense": "present"}, "text": "beats", "normalized": "beat"}}, {"subject": {"text": "the 14 factors", "keywords": [{"text": "factors"}]}, "sentence": " Nektar Therapeutics beats Athenex on 12 of the 14 factors compared between the two stocks.", "object": {"text": "between the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer", "keywords": [{"text": "oral dosage form"}, {"text": "metastatic breast cancer"}, {"text": "metastatic colorectal cancer"}, {"text": "various clinical studies"}], "entities": [{"type": "Company", "text": "Oraxol"}, {"type": "HealthCondition", "text": "metastatic breast cancer"}, {"type": "Location", "text": "Oratecan", "disambiguation": {"subtype": ["City"]}}, {"type": "Drug", "text": "irinotecan"}, {"type": "HealthCondition", "text": "metastatic colorectal cancer"}, {"type": "HealthCondition", "text": "glioblastoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Glioblastoma multiforme", "dbpedia_resource": "http://dbpedia.org/resource/Glioblastoma_multiforme"}}, {"type": "HealthCondition", "text": "pancreatic cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Pancreatic cancer", "dbpedia_resource": "http://dbpedia.org/resource/Pancreatic_cancer"}}]}, "sentence": " The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "object": {"text": "The company's Orascovery product candidates", "keywords": [{"text": "Orascovery product candidates"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "an oral dosage form", "keywords": [{"text": "oral dosage form"}]}, "sentence": " The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "object": {"text": "in Phase III trial", "keywords": [{"text": "Phase III trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an oral dosage form of irinotecan", "keywords": [{"text": "oral dosage form"}], "entities": [{"type": "Drug", "text": "irinotecan"}]}, "sentence": " The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "object": {"text": "in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer", "keywords": [{"text": "metastatic colorectal cancer"}, {"text": "upper gastrointestinal"}, {"text": "pancreatic cancer"}, {"text": "glioblastoma"}], "entities": [{"type": "HealthCondition", "text": "metastatic colorectal cancer"}, {"type": "HealthCondition", "text": "glioblastoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Glioblastoma multiforme", "dbpedia_resource": "http://dbpedia.org/resource/Glioblastoma_multiforme"}}, {"type": "HealthCondition", "text": "pancreatic cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Pancreatic cancer", "dbpedia_resource": "http://dbpedia.org/resource/Pancreatic_cancer"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Its Orascovery product candidates", "keywords": [{"text": "Orascovery product candidates"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate", "keywords": [{"text": "oral dosage form"}, {"text": "docetaxel"}, {"text": "clinical study"}, {"text": "prostate"}], "entities": [{"type": "Company", "text": "Oradoxel"}, {"type": "Drug", "text": "docetaxel"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprise", "normalized": "comprise"}}, {"subject": {"text": "an oral dosage form of docetaxel", "keywords": [{"text": "oral dosage form"}, {"text": "docetaxel"}], "entities": [{"type": "Drug", "text": "docetaxel"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers", "keywords": [{"text": "neck cancers"}, {"text": "clinical study"}, {"text": "prostate"}, {"text": "Phase"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an oral dosage form of topotecan", "keywords": [{"text": "oral dosage form"}], "entities": [{"type": "Drug", "text": "topotecan"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "under development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "oral eribulin co-administered with HM30181A", "keywords": [{"text": "oral eribulin"}, {"text": "HM30181A"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "under pre-clinical development", "keywords": [{"text": "pre-clinical development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "certain patients", "keywords": [{"text": "certain patients"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "with breast cancer and advanced liposarcom", "keywords": [{"text": "breast cancer"}, {"text": "advanced liposarcom"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "to treat", "normalized": "to treat"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients.", "object": {"text": "Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis", "keywords": [{"text": "Src Kinase product"}, {"text": "actinic keratosis"}], "entities": [{"type": "Company", "text": "Src Kinase"}, {"type": "HealthCondition", "text": "actinic keratosis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom"], "name": "Actinic keratosis", "dbpedia_resource": "http://dbpedia.org/resource/Actinic_keratosis"}}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "a compound", "keywords": [{"text": "compound"}]}, "sentence": " In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients.", "object": {"text": "in Phase 3 study", "keywords": [{"text": "Phase"}, {"text": "study"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a 5-hydroxytryptamine 3 receptor antagonist", "keywords": [{"text": "5-hydroxytryptamine 3 receptor antagonist"}]}, "sentence": " Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract.", "object": {"text": "chemotherapy-induced nausea and vomiting", "keywords": [{"text": "chemotherapy-induced nausea"}, {"text": "vomiting"}]}, "action": {"verb": {"text": "prevent", "tense": "future"}, "text": "to prevent", "normalized": "to prevent"}}, {"subject": {"text": "dual absorption enhancers", "keywords": [{"text": "dual absorption enhancers"}]}, "sentence": " Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract.", "object": {"text": "the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract", "keywords": [{"text": "cytochrome P450 enzymes"}, {"text": "gastrointestinal tract"}, {"text": "P-gp transporter"}], "entities": [{"type": "Anatomy", "text": "gastrointestinal tract"}]}, "action": {"verb": {"text": "inhibit", "tense": "future"}, "text": "to inhibit", "normalized": "to inhibit"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "object": {"text": "as Kinex Pharmaceuticals LLC", "keywords": [{"text": "Kinex Pharmaceuticals LLC"}], "entities": [{"type": "Company", "text": "Kinex Pharmaceuticals LLC"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "object": {"text": "its name"}, "action": {"verb": {"text": "change", "tense": "past"}, "text": "changed", "normalized": "change"}}, {"subject": {"text": "Athenex, Inc.", "entities": [{"type": "Company", "text": "Athenex, Inc."}]}, "sentence": " Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs.", "object": {"text": "a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs", "keywords": [{"text": "Hanmi Pharmaceuticals"}, {"text": "strategic partnership"}, {"text": "KX-01 programs"}, {"text": "Orascovery"}], "entities": [{"type": "Company", "text": "Hanmi Pharmaceuticals"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 2003 and is headquartered in Buffalo, New York.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 2003 and is headquartered in Buffalo, New York.", "object": {"text": "headquartered in Buffalo, New York", "keywords": [{"text": "New York"}, {"text": "Buffalo"}], "entities": [{"type": "Location", "text": "Buffalo", "disambiguation": {"subtype": ["City"], "name": "Buffalo, New York", "dbpedia_resource": "http://dbpedia.org/resource/Buffalo,_New_York"}}, {"type": "Location", "text": "New York", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 2003 and is headquartered in Buffalo, New York.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Nektar Therapeutics, a research-based biopharmaceutical company,", "keywords": [{"text": "research-based biopharmaceutical company"}, {"text": "Nektar Therapeutics"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}]}, "sentence": " Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "object": {"text": "drug candidates for cancer, auto-immune disease", "keywords": [{"text": "auto-immune disease"}, {"text": "drug candidates"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "discover", "tense": "present"}, "text": "discovers and develops", "normalized": "discover and develop"}}, {"subject": {"text": "Nektar Therapeutics, a research-based biopharmaceutical company,", "keywords": [{"text": "research-based biopharmaceutical company"}, {"text": "Nektar Therapeutics"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}]}, "sentence": " Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "object": {"text": "drug candidates", "keywords": [{"text": "drug candidates"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "discovers and develops", "normalized": "discover and develop"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain", "keywords": [{"text": "mu-opioid analgesic molecule"}, {"text": "advanced metastatic breast"}, {"text": "severe chronic pain"}, {"text": "clinical trial"}], "entities": [{"type": "Company", "text": "ONZEALD"}, {"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "I"}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology", "keywords": [{"text": "mu-opioid analgesic molecule"}, {"text": "advanced metastatic breast"}, {"text": "severe chronic pain"}, {"text": "cytokine immunostimulatory therapy"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}, {"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "inhibitor", "tense": "present"}, "text": "inhibitor", "normalized": "inhibitor"}}, {"subject": {"text": "a topoisomerase I inhibitor", "keywords": [{"text": "topoisomerase"}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases", "keywords": [{"text": "advanced metastatic breast"}, {"text": "brain metastases"}, {"text": "clinical trial"}, {"text": "Phase"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an orally-available mu-opioid analgesic molecule", "keywords": [{"text": "mu-opioid analgesic molecule"}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase III clinical trial", "keywords": [{"text": "Phase"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cytokine immunostimulatory therapy", "keywords": [{"text": "cytokine immunostimulatory therapy"}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase I/II", "keywords": [{"text": "Phase I/II"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NKTR-358"}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase I", "keywords": [{"text": "Phase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NKTR-255"}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "under research/preclinical stage", "keywords": [{"text": "research/preclinical stage"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia.", "object": {"text": "MOVANTIK", "keywords": [{"text": "MOVANTIK"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "object": {"text": "PEG-INTRON", "keywords": [{"text": "PEG-INTRON"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "anemia", "keywords": [{"text": "anemia"}]}, "sentence": " In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "object": {"text": "to chronic kidney disease", "keywords": [{"text": "kidney disease"}]}, "action": {"verb": {"text": "relate", "tense": "past"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "developing SEMPRANA", "keywords": [{"text": "SEMPRANA"}]}, "sentence": " Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia.", "object": {"text": "to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia", "keywords": [{"text": "systemic lupus erythematosus"}, {"text": "non-small cell lung"}, {"text": "tumor types"}, {"text": "dapirolizumab pegol"}], "entities": [{"type": "HealthCondition", "text": "migraine", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Migraine", "dbpedia_resource": "http://dbpedia.org/resource/Migraine"}}, {"type": "HealthCondition", "text": "lupus erythematosus", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Systemic lupus erythematosus", "dbpedia_resource": "http://dbpedia.org/resource/Systemic_lupus_erythematosus"}}, {"type": "HealthCondition", "text": "non-small cell lung cancer", "disambiguation": {"subtype": [], "name": "Non-small-cell lung carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Non-small-cell_lung_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia.", "object": {"text": "SEMPRANA", "keywords": [{"text": "SEMPRANA"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "is developing", "normalized": "be develop"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited.", "object": {"text": "collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited", "keywords": [{"text": "UCB Pharma S.A."}, {"text": "Bristol-Myers Squibb Company"}, {"text": "F. Hoffmann-La Roche"}, {"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "AstraZeneca AB", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Valeant Pharmaceuticals International", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"type": "Company", "text": "UCB Pharma"}, {"type": "Company", "text": "Roche Ltd"}, {"type": "Company", "text": "Halozyme Therapeutics, Inc."}, {"type": "Company", "text": "Baxalta Incorporated"}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "object": {"text": "founded in 1990"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "object": {"text": "headquartered in San Francisco, California", "keywords": [{"text": "San Francisco"}, {"text": "California"}], "entities": [{"type": "Location", "text": "San Francisco", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "USCounty", "CityTown", "FilmScreeningVenue", "City"], "name": "San Francisco", "dbpedia_resource": "http://dbpedia.org/resource/San_Francisco"}}, {"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}], "concepts": [{"text": "Cancer", "relevance": 0.975972, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Clinical trial", "relevance": 0.898761, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Metastasis", "relevance": 0.762148, "dbpedia_resource": "http://dbpedia.org/resource/Metastasis"}, {"text": "Pharmaceutical industry", "relevance": 0.71207, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Oncology", "relevance": 0.63482, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Pharmacology", "relevance": 0.558733, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Drug discovery", "relevance": 0.55037, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Breast cancer", "relevance": 0.513397, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Lung cancer", "relevance": 0.490146, "dbpedia_resource": "http://dbpedia.org/resource/Lung_cancer"}, {"text": "The Canon of Medicine", "relevance": 0.484132, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Epidemiology", "relevance": 0.452466, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Pre-clinical development", "relevance": 0.440163, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Tumor", "relevance": 0.437067, "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.427784, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Informed consent", "relevance": 0.425104, "dbpedia_resource": "http://dbpedia.org/resource/Informed_consent"}], "categories": [{"score": 0.886093, "label": "/health and fitness/disease/cancer"}, {"score": 0.324574, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.21105, "label": "/health and fitness/therapy"}], "relations": [{"type": "employedBy", "sentence": "93.63% Institutional and Insider Ownership 19.9% of Athenex shares are held by institutional investors.", "score": 0.286768, "arguments": [{"text": "investors", "location": [93, 102], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Athenex", "location": [52, 59], "entities": [{"type": "Organization", "text": "Athenex\nAthenex, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "subsidiaryOf", "sentence": "Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs.", "score": 0.227287, "arguments": [{"text": "Athenex, Inc.", "location": [2307, 2320], "entities": [{"type": "Organization", "text": "Athenex\nAthenex, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Hanmi Pharmaceuticals", "location": [2354, 2375], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "The company was founded in 2003 and is headquartered in Buffalo, New York.", "score": 0.512379, "arguments": [{"text": "company", "location": [2428, 2435], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "Buffalo", "location": [2480, 2487], "entities": [{"type": "GeopoliticalEntity", "text": "Buffalo"}]}]}, {"type": "locatedAt", "sentence": "The company was founded in 2003 and is headquartered in Buffalo, New York.", "score": 0.992144, "arguments": [{"text": "Buffalo", "location": [2480, 2487], "entities": [{"type": "GeopoliticalEntity", "text": "Buffalo"}]}, {"text": "New York", "location": [2489, 2497], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}]}, {"type": "hasAttribute", "sentence": "About Nektar Therapeutics Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "score": 0.831541, "arguments": [{"text": "candidates", "location": [2618, 2628], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "cancer", "location": [2633, 2639], "entities": [{"type": "HealthCondition", "text": "pancreatic cancer"}]}]}, {"type": "hasAttribute", "sentence": "About Nektar Therapeutics Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "score": 0.578507, "arguments": [{"text": "candidates", "location": [2618, 2628], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "chronic pain", "location": [2666, 2678], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.48442, "arguments": [{"text": "I", "location": [2745, 2746], "entities": [{"type": "Person", "text": "I"}]}, {"text": "brain metastases", "location": [2848, 2864], "entities": [{"type": "HealthCondition", "text": "brain metastases"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.942381, "arguments": [{"text": "patients", "location": [2834, 2842], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "breast cancer", "location": [2817, 2830], "entities": [{"type": "HealthCondition", "text": "breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.801665, "arguments": [{"text": "patients", "location": [2834, 2842], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "brain metastases", "location": [2848, 2864], "entities": [{"type": "HealthCondition", "text": "brain metastases"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.715027, "arguments": [{"text": "patients", "location": [2834, 2842], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic pain", "location": [2986, 2998], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.56452, "arguments": [{"text": "I", "location": [3114, 3115], "entities": [{"type": "Person", "text": "I"}]}, {"text": "autoimmune diseases", "location": [3125, 3144], "entities": [{"type": "HealthCondition", "text": "autoimmune diseases"}]}]}, {"type": "employedBy", "sentence": "29.5% of Athenex shares are held by company insiders.", "score": 0.662994, "arguments": [{"text": "insiders", "location": [236, 244], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "company", "location": [228, 235], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}]}, {"type": "employedBy", "sentence": "Comparatively, 4.3% of Nektar Therapeutics shares are held by company insiders.", "score": 0.708647, "arguments": [{"text": "insiders", "location": [316, 324], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "company", "location": [308, 315], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia.", "score": 0.879126, "arguments": [{"text": "patients", "location": [3331, 3339], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic non-cancer pain", "location": [3345, 3368], "entities": [{"type": "HealthCondition", "text": "chronic non-cancer pain"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia.", "score": 0.894801, "arguments": [{"text": "who", "location": [3374, 3377], "entities": [{"type": "Person", "text": "who"}]}, {"text": "chronic non-cancer pain", "location": [3345, 3368], "entities": [{"type": "HealthCondition", "text": "chronic non-cancer pain"}]}]}, {"type": "hasAttribute", "sentence": "In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "score": 0.882952, "arguments": [{"text": "Crohn", "location": [3680, 3685], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [3688, 3695], "entities": [{"type": "HealthCondition", "text": "pancreatic cancer"}]}]}, {"type": "hasAttribute", "sentence": "In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "score": 0.498644, "arguments": [{"text": "Crohn", "location": [3680, 3685], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "chronic kidney disease", "location": [3769, 3791], "entities": [{"type": "HealthCondition", "text": "chronic kidney disease"}]}]}, {"type": "hasAttribute", "sentence": "In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "score": 0.934622, "arguments": [{"text": "patients", "location": [3795, 3803], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic kidney disease", "location": [3769, 3791], "entities": [{"type": "HealthCondition", "text": "chronic kidney disease"}]}]}, {"type": "foundedOn", "sentence": "The company was founded in 1990 and is headquartered in San Francisco, California.", "score": 0.537763, "arguments": [{"text": "company", "location": [4416, 4423], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "1990", "location": [4439, 4443], "entities": [{"type": "Date", "text": "1990", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "basedIn", "sentence": "The company was founded in 1990 and is headquartered in San Francisco, California.", "score": 0.517598, "arguments": [{"text": "company", "location": [4416, 4423], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "San Francisco", "location": [4468, 4481], "entities": [{"type": "GeopoliticalEntity", "text": "San Francisco"}]}]}, {"type": "locatedAt", "sentence": "The company was founded in 1990 and is headquartered in San Francisco, California.", "score": 0.994849, "arguments": [{"text": "San Francisco", "location": [4468, 4481], "entities": [{"type": "GeopoliticalEntity", "text": "San Francisco"}]}, {"text": "California", "location": [4483, 4493], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "partOf", "sentence": "Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter . \u00ab", "score": 0.574761, "arguments": [{"text": "companies", "location": [4669, 4678], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Athenex", "location": [4649, 4656], "entities": [{"type": "Organization", "text": "Athenex\nAthenex, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "score": 0.469489, "arguments": [{"text": "I", "location": [1070, 1071], "entities": [{"type": "Person", "text": "I"}]}, {"text": "cervical", "location": [1158, 1166], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "partOfMany", "sentence": "The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "score": 0.472868, "arguments": [{"text": "pancreatic cancer", "location": [1196, 1213], "entities": [{"type": "HealthCondition", "text": "pancreatic cancer"}]}, {"text": "cervical", "location": [1158, 1166], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "employedBy", "sentence": "Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "score": 0.709292, "arguments": [{"text": "candidates", "location": [1238, 1248], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "Its", "location": [1215, 1218], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}]}, {"type": "employedBy", "sentence": "In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients.", "score": 0.427649, "arguments": [{"text": "candidates", "location": [1727, 1737], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "company", "location": [1693, 1700], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "score": 0.47141, "arguments": [{"text": "patients", "location": [1623, 1631], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cervical cancer", "location": [1502, 1517], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "hasAttribute", "sentence": "Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "score": 0.879297, "arguments": [{"text": "patients", "location": [1623, 1631], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "breast cancer", "location": [1637, 1650], "entities": [{"type": "HealthCondition", "text": "breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract.", "score": 0.760445, "arguments": [{"text": "antagonist", "location": [2000, 2010], "entities": [{"type": "Person", "text": "antagonist"}]}, {"text": "vomiting", "location": [2054, 2062], "entities": [{"type": "HealthCondition", "text": "vomiting"}]}]}, {"type": "partOf", "sentence": "The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "score": 0.544018, "arguments": [{"text": "its", "location": [2265, 2268], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "Athenex, Inc.", "location": [2277, 2290], "entities": [{"type": "Organization", "text": "Athenex\nAthenex, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Nektar Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.966976}, {"text": "oral dosage form", "sentiment": {"score": -0.272401, "label": "negative"}, "relevance": 0.847549}, {"text": "Nektar Therapeutics shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.80554}, {"text": "metastatic breast cancer", "sentiment": {"score": -0.386031, "label": "negative"}, "relevance": 0.67703}, {"text": "Orascovery product candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.617582}, {"text": "metastatic colorectal cancer", "sentiment": {"score": -0.502021, "label": "negative"}, "relevance": 0.544827}, {"text": "company", "sentiment": {"score": 0.342347, "label": "positive"}, "relevance": 0.537262}, {"text": "company insiders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537218}, {"text": "clinical trial", "sentiment": {"score": -0.418786, "label": "negative"}, "relevance": 0.536475}, {"text": "biopharmaceutical company", "sentiment": {"score": 0.342347, "label": "positive"}, "relevance": 0.521606}, {"text": "research-based biopharmaceutical company", "sentiment": {"score": 0.254379, "label": "positive"}, "relevance": 0.520297}, {"text": "Athenex shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518309}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516656}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51302}, {"text": "cell lung cancer", "sentiment": {"score": -0.538409, "label": "negative"}, "relevance": 0.503922}, {"text": "advanced metastatic breast", "sentiment": {"score": -0.454108, "label": "negative"}, "relevance": 0.502022}, {"text": "institutional investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499032}, {"text": "Kinase product candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496785}, {"text": "various clinical studies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.49184}, {"text": "solid tumor patients", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486412}, {"text": "Kinex Pharmaceuticals LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485503}, {"text": "large money managers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483423}, {"text": "Strong institutional ownership", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481833}, {"text": "Phase III trial", "sentiment": {"score": -0.317953, "label": "negative"}, "relevance": 0.47786}, {"text": "cytochrome P450 enzymes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475327}, {"text": "5-hydroxytryptamine 3 receptor antagonist", "sentiment": {"score": -0.459847, "label": "negative"}, "relevance": 0.474855}, {"text": "Valeant Pharmaceuticals International", "sentiment": {"score": -0.371764, "label": "negative"}, "relevance": 0.471317}, {"text": "chronic non-cancer pain", "sentiment": {"score": -0.812913, "label": "negative"}, "relevance": 0.4687}, {"text": "chronic kidney disease", "sentiment": {"score": -0.789158, "label": "negative"}, "relevance": 0.467595}, {"text": "severe chronic pain", "sentiment": {"score": -0.383464, "label": "negative"}, "relevance": 0.467551}, {"text": "mu-opioid analgesic molecule", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467153}, {"text": "dual absorption enhancers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466924}, {"text": "concise daily summary", "sentiment": {"score": 0.449652, "label": "positive"}, "relevance": 0.46551}, {"text": "UCB Pharma S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.465463}, {"text": "cytokine immunostimulatory therapy", "sentiment": {"score": -0.50472, "label": "negative"}, "relevance": 0.463186}, {"text": "F. Hoffmann-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.46208}, {"text": "systemic lupus erythematosus", "sentiment": {"score": -0.339706, "label": "negative"}, "relevance": 0.461115}, {"text": "age-related macular degeneration", "sentiment": {"score": -0.588022, "label": "negative"}, "relevance": 0.459369}, {"text": "Phase I/II", "sentiment": {"score": -0.50472, "label": "negative"}, "relevance": 0.457511}, {"text": "gastric cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438988}, {"text": "Halozyme Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436824}, {"text": "cervical cancer", "sentiment": {"score": -0.570877, "label": "negative"}, "relevance": 0.436194}, {"text": "pancreatic cancer", "sentiment": {"score": -0.592611, "label": "negative"}, "relevance": 0.432869}, {"text": "Amgen Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420547}, {"text": "Athenex Daily", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418295}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417719}, {"text": "oral eribulin", "sentiment": {"score": -0.482671, "label": "negative"}, "relevance": 0.415933}, {"text": "clinical study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412652}, {"text": "Hanmi Pharmaceuticals", "sentiment": {"score": -0.389344, "label": "negative"}, "relevance": 0.406016}, {"text": "drug candidates", "sentiment": {"score": -0.379916, "label": "negative"}, "relevance": 0.404401}]}, "extracted_metadata": {"sha1": "69e7a26c128ea42753de898aa454045d7c4c76ea", "filename": "1541260813330.zip-be5d6bb7b56178930ade891e59334809.xml", "file_type": "json"}, "title": "Contrasting Athenex (ATNX) & Nektar Therapeutics (NKTR)", "forum_title": "The Lincolnian Online"}, {"id": "hCltDeM2Yga7UDetys_bQJaUG9ZnughvgiKEDWJ033XCkfyjYS8kCsyc-odz-T-G", "result_metadata": {"score": 32.002815}, "author": "ABMN Staff", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nektar Therapeutics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NKTR", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.743322, "label": "/science/medicine/pharmacology"}, {"score": 0.464478, "label": "/science/medicine/oncology"}], "relations": [], "keywords": [{"text": "Nektar Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.926902}, {"text": "Athenex", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541004}, {"text": "ATNX", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539221}, {"text": "NKTR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535655}]}, "crawl_date": "2018-11-03T15:29:34Z", "url": "https://www.americanbankingnews.com/2018/11/03/reviewing-athenex-atnx-and-nektar-therapeutics-nktr.html", "host": "americanbankingnews.com", "text": "Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited.", "main_image_url": "https://www.marketbeat.com/logos/nektar-therapeutics-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-03T14:56:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.87765, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 3, "sentiment": {"score": -0.418244, "label": "negative"}, "text": "metastatic breast cancer", "relevance": 0.780096, "type": "HealthCondition"}, {"count": 4, "sentiment": {"score": -0.37997, "label": "negative"}, "text": "cancer", "relevance": 0.670748, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nektar Therapeutics", "relevance": 0.596474, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Athenex, Inc.", "relevance": 0.519171, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.538409, "label": "negative"}, "text": "non-small cell lung cancer", "relevance": 0.480614, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Non-small-cell lung carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Non-small-cell_lung_carcinoma"}}, {"count": 1, "sentiment": {"score": -0.502021, "label": "negative"}, "text": "metastatic colorectal cancer", "relevance": 0.466644, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.592611, "label": "negative"}, "text": "pancreatic cancer", "relevance": 0.455646, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Pancreatic cancer", "dbpedia_resource": "http://dbpedia.org/resource/Pancreatic_cancer"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Athenex", "relevance": 0.438687, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.366456, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.254162, "label": "negative"}, "text": "actinic keratosis", "relevance": 0.341971, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom"], "name": "Actinic keratosis", "dbpedia_resource": "http://dbpedia.org/resource/Actinic_keratosis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kinex Pharmaceuticals LLC", "relevance": 0.341724, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.389344, "label": "negative"}, "text": "Hanmi Pharmaceuticals", "relevance": 0.338634, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "gastrointestinal tract", "relevance": 0.333543, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Halozyme Therapeutics, Inc.", "relevance": 0.322878, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca AB", "relevance": 0.302702, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": -0.339706, "label": "negative"}, "text": "lupus erythematosus", "relevance": 0.302691, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Systemic lupus erythematosus", "dbpedia_resource": "http://dbpedia.org/resource/Systemic_lupus_erythematosus"}}, {"count": 1, "sentiment": {"score": 0.242921, "label": "positive"}, "text": "solid tumors", "relevance": 0.302075, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}, {"count": 1, "sentiment": {"score": -0.371764, "label": "negative"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.301873, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "granisetron", "relevance": 0.300001, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.801911, "label": "negative"}, "text": "United States", "relevance": 0.299419, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "San Francisco", "relevance": 0.298107, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "USCounty", "FilmScreeningVenue", "City"], "name": "San Francisco", "dbpedia_resource": "http://dbpedia.org/resource/San_Francisco"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Buffalo", "relevance": 0.295519, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Buffalo, New York", "dbpedia_resource": "http://dbpedia.org/resource/Buffalo,_New_York"}}, {"count": 1, "sentiment": {"score": -0.502021, "label": "negative"}, "text": "irinotecan", "relevance": 0.295147, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oradoxel", "relevance": 0.294542, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "docetaxel", "relevance": 0.293577, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.569308, "label": "negative"}, "text": "migraine", "relevance": 0.292372, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Migraine", "dbpedia_resource": "http://dbpedia.org/resource/Migraine"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.290325, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}, {"count": 1, "sentiment": {"score": -0.407234, "label": "negative"}, "text": "glioblastoma", "relevance": 0.289592, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Glioblastoma multiforme", "dbpedia_resource": "http://dbpedia.org/resource/Glioblastoma_multiforme"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.289304, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oraxol", "relevance": 0.285765, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.639817, "label": "negative"}, "text": "spondylitis", "relevance": 0.285754, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease"], "name": "Ankylosing spondylitis", "dbpedia_resource": "http://dbpedia.org/resource/Ankylosing_spondylitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oratecan", "relevance": 0.284549, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Src Kinase", "relevance": 0.283572, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oratopo", "relevance": 0.280243, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "topotecan", "relevance": 0.279977, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.246183, "label": "negative"}, "text": "Neulasta", "relevance": 0.277505, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd", "relevance": 0.277052, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.267201, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amgen Inc.", "relevance": 0.266623, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UCB Pharma", "relevance": 0.264953, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.26354, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co.", "relevance": 0.259853, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.588022, "label": "negative"}, "text": "Macugen", "relevance": 0.254652, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.789158, "label": "negative"}, "text": "MIRCERA", "relevance": 0.253854, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Baxalta Incorporated", "relevance": 0.239017, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ONZEALD", "relevance": 0.234206, "type": "Company"}], "sentiment": {"document": {"score": -0.745205, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Nektar Therapeutics", "keywords": [{"text": "Nektar Therapeutics"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}]}, "sentence": "Nektar Therapeutics beats Athenex on 12 of the 14 factors compared between the two stocks.", "object": {"text": "Athenex", "keywords": [{"text": "Athenex"}], "entities": [{"type": "Company", "text": "Athenex"}]}, "action": {"verb": {"text": "beat", "tense": "present"}, "text": "beats", "normalized": "beat"}}, {"subject": {"text": "the 14 factors", "keywords": [{"text": "factors"}]}, "sentence": "Nektar Therapeutics beats Athenex on 12 of the 14 factors compared between the two stocks.", "object": {"text": "between the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer", "keywords": [{"text": "oral dosage form"}, {"text": "metastatic breast cancer"}, {"text": "metastatic colorectal cancer"}, {"text": "various clinical studies"}], "entities": [{"type": "Company", "text": "Oraxol"}, {"type": "HealthCondition", "text": "metastatic breast cancer"}, {"type": "Location", "text": "Oratecan", "disambiguation": {"subtype": ["City"]}}, {"type": "Drug", "text": "irinotecan"}, {"type": "HealthCondition", "text": "metastatic colorectal cancer"}, {"type": "HealthCondition", "text": "glioblastoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Glioblastoma multiforme", "dbpedia_resource": "http://dbpedia.org/resource/Glioblastoma_multiforme"}}, {"type": "HealthCondition", "text": "pancreatic cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Pancreatic cancer", "dbpedia_resource": "http://dbpedia.org/resource/Pancreatic_cancer"}}]}, "sentence": " The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "object": {"text": "The company's Orascovery product candidates", "keywords": [{"text": "Orascovery product candidates"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "an oral dosage form", "keywords": [{"text": "oral dosage form"}]}, "sentence": " The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "object": {"text": "in Phase III trial", "keywords": [{"text": "Phase III trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an oral dosage form of irinotecan", "keywords": [{"text": "oral dosage form"}], "entities": [{"type": "Drug", "text": "irinotecan"}]}, "sentence": " The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "object": {"text": "in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer", "keywords": [{"text": "metastatic colorectal cancer"}, {"text": "upper gastrointestinal"}, {"text": "pancreatic cancer"}, {"text": "glioblastoma"}], "entities": [{"type": "HealthCondition", "text": "metastatic colorectal cancer"}, {"type": "HealthCondition", "text": "glioblastoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Glioblastoma multiforme", "dbpedia_resource": "http://dbpedia.org/resource/Glioblastoma_multiforme"}}, {"type": "HealthCondition", "text": "pancreatic cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Pancreatic cancer", "dbpedia_resource": "http://dbpedia.org/resource/Pancreatic_cancer"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Its Orascovery product candidates", "keywords": [{"text": "Orascovery product candidates"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate", "keywords": [{"text": "oral dosage form"}, {"text": "docetaxel"}, {"text": "clinical study"}, {"text": "prostate"}], "entities": [{"type": "Company", "text": "Oradoxel"}, {"type": "Drug", "text": "docetaxel"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprise", "normalized": "comprise"}}, {"subject": {"text": "an oral dosage form of docetaxel", "keywords": [{"text": "oral dosage form"}, {"text": "docetaxel"}], "entities": [{"type": "Drug", "text": "docetaxel"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers", "keywords": [{"text": "neck cancers"}, {"text": "clinical study"}, {"text": "prostate"}, {"text": "Phase"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an oral dosage form of topotecan", "keywords": [{"text": "oral dosage form"}], "entities": [{"type": "Drug", "text": "topotecan"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "under development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "oral eribulin co-administered with HM30181A", "keywords": [{"text": "oral eribulin"}, {"text": "HM30181A"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "under pre-clinical development", "keywords": [{"text": "pre-clinical development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "certain patients", "keywords": [{"text": "certain patients"}]}, "sentence": " Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "object": {"text": "with breast cancer and advanced liposarcom", "keywords": [{"text": "breast cancer"}, {"text": "advanced liposarcom"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "to treat", "normalized": "to treat"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients.", "object": {"text": "Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis", "keywords": [{"text": "Src Kinase product"}, {"text": "actinic keratosis"}], "entities": [{"type": "Company", "text": "Src Kinase"}, {"type": "HealthCondition", "text": "actinic keratosis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom"], "name": "Actinic keratosis", "dbpedia_resource": "http://dbpedia.org/resource/Actinic_keratosis"}}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "a compound", "keywords": [{"text": "compound"}]}, "sentence": " In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients.", "object": {"text": "in Phase 3 study", "keywords": [{"text": "Phase"}, {"text": "study"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a 5-hydroxytryptamine 3 receptor antagonist", "keywords": [{"text": "5-hydroxytryptamine 3 receptor antagonist"}]}, "sentence": " Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract.", "object": {"text": "chemotherapy-induced nausea and vomiting", "keywords": [{"text": "chemotherapy-induced nausea"}, {"text": "vomiting"}]}, "action": {"verb": {"text": "prevent", "tense": "future"}, "text": "to prevent", "normalized": "to prevent"}}, {"subject": {"text": "dual absorption enhancers", "keywords": [{"text": "dual absorption enhancers"}]}, "sentence": " Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract.", "object": {"text": "the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract", "keywords": [{"text": "cytochrome P450 enzymes"}, {"text": "gastrointestinal tract"}, {"text": "P-gp transporter"}], "entities": [{"type": "Anatomy", "text": "gastrointestinal tract"}]}, "action": {"verb": {"text": "inhibit", "tense": "future"}, "text": "to inhibit", "normalized": "to inhibit"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "object": {"text": "as Kinex Pharmaceuticals LLC", "keywords": [{"text": "Kinex Pharmaceuticals LLC"}], "entities": [{"type": "Company", "text": "Kinex Pharmaceuticals LLC"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "object": {"text": "its name"}, "action": {"verb": {"text": "change", "tense": "past"}, "text": "changed", "normalized": "change"}}, {"subject": {"text": "Athenex, Inc.", "entities": [{"type": "Company", "text": "Athenex, Inc."}]}, "sentence": " Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs.", "object": {"text": "a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs", "keywords": [{"text": "Hanmi Pharmaceuticals"}, {"text": "strategic partnership"}, {"text": "KX-01 programs"}, {"text": "Orascovery"}], "entities": [{"type": "Company", "text": "Hanmi Pharmaceuticals"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 2003 and is headquartered in Buffalo, New York.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 2003 and is headquartered in Buffalo, New York.", "object": {"text": "headquartered in Buffalo, New York", "keywords": [{"text": "New York"}, {"text": "Buffalo"}], "entities": [{"type": "Location", "text": "Buffalo", "disambiguation": {"subtype": ["City"], "name": "Buffalo, New York", "dbpedia_resource": "http://dbpedia.org/resource/Buffalo,_New_York"}}, {"type": "Location", "text": "New York", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 2003 and is headquartered in Buffalo, New York.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Nektar Therapeutics, a research-based biopharmaceutical company,", "keywords": [{"text": "research-based biopharmaceutical company"}, {"text": "Nektar Therapeutics"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}]}, "sentence": " Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "object": {"text": "drug candidates for cancer, auto-immune disease", "keywords": [{"text": "auto-immune disease"}, {"text": "drug candidates"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "discover", "tense": "present"}, "text": "discovers and develops", "normalized": "discover and develop"}}, {"subject": {"text": "Nektar Therapeutics, a research-based biopharmaceutical company,", "keywords": [{"text": "research-based biopharmaceutical company"}, {"text": "Nektar Therapeutics"}], "entities": [{"type": "Company", "text": "Nektar Therapeutics"}]}, "sentence": " Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "object": {"text": "drug candidates", "keywords": [{"text": "drug candidates"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "discovers and develops", "normalized": "discover and develop"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain", "keywords": [{"text": "mu-opioid analgesic molecule"}, {"text": "advanced metastatic breast"}, {"text": "severe chronic pain"}, {"text": "clinical trial"}], "entities": [{"type": "Company", "text": "ONZEALD"}, {"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "I"}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology", "keywords": [{"text": "mu-opioid analgesic molecule"}, {"text": "advanced metastatic breast"}, {"text": "severe chronic pain"}, {"text": "cytokine immunostimulatory therapy"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}, {"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "inhibitor", "tense": "present"}, "text": "inhibitor", "normalized": "inhibitor"}}, {"subject": {"text": "a topoisomerase I inhibitor", "keywords": [{"text": "topoisomerase"}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases", "keywords": [{"text": "advanced metastatic breast"}, {"text": "brain metastases"}, {"text": "clinical trial"}, {"text": "Phase"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an orally-available mu-opioid analgesic molecule", "keywords": [{"text": "mu-opioid analgesic molecule"}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase III clinical trial", "keywords": [{"text": "Phase"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cytokine immunostimulatory therapy", "keywords": [{"text": "cytokine immunostimulatory therapy"}]}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase I/II", "keywords": [{"text": "Phase I/II"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NKTR-358"}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "in Phase I", "keywords": [{"text": "Phase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NKTR-255"}, "sentence": " The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "object": {"text": "under research/preclinical stage", "keywords": [{"text": "research/preclinical stage"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia.", "object": {"text": "MOVANTIK", "keywords": [{"text": "MOVANTIK"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "object": {"text": "PEG-INTRON", "keywords": [{"text": "PEG-INTRON"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "anemia", "keywords": [{"text": "anemia"}]}, "sentence": " In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "object": {"text": "to chronic kidney disease", "keywords": [{"text": "kidney disease"}]}, "action": {"verb": {"text": "relate", "tense": "past"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "developing SEMPRANA", "keywords": [{"text": "SEMPRANA"}]}, "sentence": " Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia.", "object": {"text": "to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia", "keywords": [{"text": "systemic lupus erythematosus"}, {"text": "non-small cell lung"}, {"text": "tumor types"}, {"text": "dapirolizumab pegol"}], "entities": [{"type": "HealthCondition", "text": "migraine", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Migraine", "dbpedia_resource": "http://dbpedia.org/resource/Migraine"}}, {"type": "HealthCondition", "text": "lupus erythematosus", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Systemic lupus erythematosus", "dbpedia_resource": "http://dbpedia.org/resource/Systemic_lupus_erythematosus"}}, {"type": "HealthCondition", "text": "non-small cell lung cancer", "disambiguation": {"subtype": [], "name": "Non-small-cell lung carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Non-small-cell_lung_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia.", "object": {"text": "SEMPRANA", "keywords": [{"text": "SEMPRANA"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "is developing", "normalized": "be develop"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited.", "object": {"text": "collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited", "keywords": [{"text": "UCB Pharma S.A."}, {"text": "Bristol-Myers Squibb Company"}, {"text": "F. Hoffmann-La Roche"}, {"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "AstraZeneca AB", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Valeant Pharmaceuticals International", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"type": "Company", "text": "UCB Pharma"}, {"type": "Company", "text": "Roche Ltd"}, {"type": "Company", "text": "Halozyme Therapeutics, Inc."}, {"type": "Company", "text": "Baxalta Incorporated"}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "object": {"text": "founded in 1990"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "object": {"text": "headquartered in San Francisco, California", "keywords": [{"text": "San Francisco"}, {"text": "California"}], "entities": [{"type": "Location", "text": "San Francisco", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "USCounty", "CityTown", "FilmScreeningVenue", "City"], "name": "San Francisco", "dbpedia_resource": "http://dbpedia.org/resource/San_Francisco"}}, {"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The company was founded in 1990 and is headquartered in San Francisco, California.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "News & Ratings", "keywords": [{"text": "News"}, {"text": "Ratings"}]}, "sentence": " Receive News & Ratings for Athenex analysts' ratings for Athenex and related companies daily email newsletter . \u00ab", "object": {"text": "for Athenex analysts' ratings for Athenex and related companies daily email newsletter", "keywords": [{"text": "companies daily email"}, {"text": "Athenex analysts"}, {"text": "ratings"}, {"text": "newsletter"}], "entities": [{"type": "Company", "text": "Athenex"}]}, "action": {"verb": {"text": "Receive", "tense": "present"}, "text": "Receive", "normalized": "Receive"}}], "concepts": [{"text": "Cancer", "relevance": 0.989863, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Clinical trial", "relevance": 0.85766, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Metastasis", "relevance": 0.772906, "dbpedia_resource": "http://dbpedia.org/resource/Metastasis"}, {"text": "Pharmaceutical industry", "relevance": 0.739592, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Oncology", "relevance": 0.631173, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Pharmacology", "relevance": 0.602134, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Drug discovery", "relevance": 0.552969, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Breast cancer", "relevance": 0.502916, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "The Canon of Medicine", "relevance": 0.492493, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Lung cancer", "relevance": 0.475872, "dbpedia_resource": "http://dbpedia.org/resource/Lung_cancer"}, {"text": "Epidemiology", "relevance": 0.466189, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Pre-clinical development", "relevance": 0.460491, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Tumor", "relevance": 0.450882, "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}, {"text": "Rheumatoid arthritis", "relevance": 0.438821, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatoid_arthritis"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.434729, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Informed consent", "relevance": 0.432894, "dbpedia_resource": "http://dbpedia.org/resource/Informed_consent"}, {"text": "Lupus erythematosus", "relevance": 0.417178, "dbpedia_resource": "http://dbpedia.org/resource/Lupus_erythematosus"}], "categories": [{"score": 0.888088, "label": "/health and fitness/disease/cancer"}, {"score": 0.322706, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.209161, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "score": 0.469489, "arguments": [{"text": "I", "location": [569, 570], "entities": [{"type": "Person", "text": "I"}]}, {"text": "cervical", "location": [657, 665], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "locatedAt", "sentence": "The company was founded in 2003 and is headquartered in Buffalo, New York.", "score": 0.992144, "arguments": [{"text": "Buffalo", "location": [1979, 1986], "entities": [{"type": "GeopoliticalEntity", "text": "Buffalo"}]}, {"text": "New York", "location": [1988, 1996], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}]}, {"type": "hasAttribute", "sentence": "About Nektar Therapeutics Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "score": 0.831541, "arguments": [{"text": "candidates", "location": [2117, 2127], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "cancer", "location": [2132, 2138], "entities": [{"type": "HealthCondition", "text": "pancreatic cancer"}]}]}, {"type": "hasAttribute", "sentence": "About Nektar Therapeutics Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.", "score": 0.578507, "arguments": [{"text": "candidates", "location": [2117, 2127], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "chronic pain", "location": [2165, 2177], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.48442, "arguments": [{"text": "I", "location": [2244, 2245], "entities": [{"type": "Person", "text": "I"}]}, {"text": "brain metastases", "location": [2347, 2363], "entities": [{"type": "HealthCondition", "text": "brain metastases"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.942381, "arguments": [{"text": "patients", "location": [2333, 2341], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "breast cancer", "location": [2316, 2329], "entities": [{"type": "HealthCondition", "text": "breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.801665, "arguments": [{"text": "patients", "location": [2333, 2341], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "brain metastases", "location": [2347, 2363], "entities": [{"type": "HealthCondition", "text": "brain metastases"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.715027, "arguments": [{"text": "patients", "location": [2333, 2341], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic pain", "location": [2485, 2497], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "hasAttribute", "sentence": "The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.", "score": 0.56452, "arguments": [{"text": "I", "location": [2613, 2614], "entities": [{"type": "Person", "text": "I"}]}, {"text": "autoimmune diseases", "location": [2624, 2643], "entities": [{"type": "HealthCondition", "text": "autoimmune diseases"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia.", "score": 0.879126, "arguments": [{"text": "patients", "location": [2830, 2838], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic non-cancer pain", "location": [2844, 2867], "entities": [{"type": "HealthCondition", "text": "chronic non-cancer pain"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia.", "score": 0.894801, "arguments": [{"text": "who", "location": [2873, 2876], "entities": [{"type": "Person", "text": "who"}]}, {"text": "chronic non-cancer pain", "location": [2844, 2867], "entities": [{"type": "HealthCondition", "text": "chronic non-cancer pain"}]}]}, {"type": "partOfMany", "sentence": "The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.", "score": 0.472868, "arguments": [{"text": "pancreatic cancer", "location": [695, 712], "entities": [{"type": "HealthCondition", "text": "pancreatic cancer"}]}, {"text": "cervical", "location": [657, 665], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "hasAttribute", "sentence": "In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "score": 0.882952, "arguments": [{"text": "Crohn", "location": [3179, 3184], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [3187, 3194], "entities": [{"type": "HealthCondition", "text": "pancreatic cancer"}]}]}, {"type": "hasAttribute", "sentence": "In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "score": 0.498644, "arguments": [{"text": "Crohn", "location": [3179, 3184], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "chronic kidney disease", "location": [3268, 3290], "entities": [{"type": "HealthCondition", "text": "chronic kidney disease"}]}]}, {"type": "hasAttribute", "sentence": "In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis.", "score": 0.934622, "arguments": [{"text": "patients", "location": [3294, 3302], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic kidney disease", "location": [3268, 3290], "entities": [{"type": "HealthCondition", "text": "chronic kidney disease"}]}]}, {"type": "foundedOn", "sentence": "The company was founded in 1990 and is headquartered in San Francisco, California.", "score": 0.537763, "arguments": [{"text": "company", "location": [3915, 3922], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "1990", "location": [3938, 3942], "entities": [{"type": "Date", "text": "1990", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "basedIn", "sentence": "The company was founded in 1990 and is headquartered in San Francisco, California.", "score": 0.517598, "arguments": [{"text": "company", "location": [3915, 3922], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "San Francisco", "location": [3967, 3980], "entities": [{"type": "GeopoliticalEntity", "text": "San Francisco"}]}]}, {"type": "locatedAt", "sentence": "The company was founded in 1990 and is headquartered in San Francisco, California.", "score": 0.994849, "arguments": [{"text": "San Francisco", "location": [3967, 3980], "entities": [{"type": "GeopoliticalEntity", "text": "San Francisco"}]}, {"text": "California", "location": [3982, 3992], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "employedBy", "sentence": "Receive News & Ratings for Athenex analysts' ratings for Athenex and related companies daily email newsletter . \u00ab", "score": 0.832543, "arguments": [{"text": "analysts", "location": [4029, 4037], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "Athenex", "location": [4021, 4028], "entities": [{"type": "Organization", "text": "Athenex\nAthenex, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "score": 0.709292, "arguments": [{"text": "candidates", "location": [737, 747], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "Its", "location": [714, 717], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}]}, {"type": "employedBy", "sentence": "In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients.", "score": 0.427649, "arguments": [{"text": "candidates", "location": [1226, 1236], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "company", "location": [1192, 1199], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "score": 0.47141, "arguments": [{"text": "patients", "location": [1122, 1130], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cervical cancer", "location": [1001, 1016], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "hasAttribute", "sentence": "Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom.", "score": 0.879297, "arguments": [{"text": "patients", "location": [1122, 1130], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "breast cancer", "location": [1136, 1149], "entities": [{"type": "HealthCondition", "text": "breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract.", "score": 0.760445, "arguments": [{"text": "antagonist", "location": [1499, 1509], "entities": [{"type": "Person", "text": "antagonist"}]}, {"text": "vomiting", "location": [1553, 1561], "entities": [{"type": "HealthCondition", "text": "vomiting"}]}]}, {"type": "partOf", "sentence": "The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.", "score": 0.544018, "arguments": [{"text": "its", "location": [1764, 1767], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "Athenex, Inc.", "location": [1776, 1789], "entities": [{"type": "Organization", "text": "Athenex\nAthenex, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "subsidiaryOf", "sentence": "Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs.", "score": 0.227287, "arguments": [{"text": "Athenex, Inc.", "location": [1806, 1819], "entities": [{"type": "Organization", "text": "Athenex\nAthenex, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Hanmi Pharmaceuticals", "location": [1853, 1874], "entities": [{"type": "Organization", "text": "Hanmi Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "The company was founded in 2003 and is headquartered in Buffalo, New York.", "score": 0.512379, "arguments": [{"text": "company", "location": [1927, 1934], "entities": [{"type": "Organization", "text": "Nektar Therapeutics\nNektar Therapeutics"}]}, {"text": "Buffalo", "location": [1979, 1986], "entities": [{"type": "GeopoliticalEntity", "text": "Buffalo"}]}]}], "keywords": [{"text": "oral dosage form", "sentiment": {"score": -0.272401, "label": "negative"}, "relevance": 0.987062}, {"text": "metastatic breast cancer", "sentiment": {"score": -0.386031, "label": "negative"}, "relevance": 0.826918}, {"text": "Orascovery product candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.79952}, {"text": "Nektar Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.75971}, {"text": "metastatic colorectal cancer", "sentiment": {"score": -0.502021, "label": "negative"}, "relevance": 0.681527}, {"text": "clinical trial", "sentiment": {"score": -0.418786, "label": "negative"}, "relevance": 0.659901}, {"text": "biopharmaceutical company", "sentiment": {"score": 0.342347, "label": "positive"}, "relevance": 0.639232}, {"text": "research-based biopharmaceutical company", "sentiment": {"score": 0.254379, "label": "positive"}, "relevance": 0.635966}, {"text": "advanced metastatic breast", "sentiment": {"score": -0.454108, "label": "negative"}, "relevance": 0.630587}, {"text": "cell lung cancer", "sentiment": {"score": -0.538409, "label": "negative"}, "relevance": 0.626949}, {"text": "Kinase product candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625632}, {"text": "various clinical studies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616533}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616373}, {"text": "Phase III trial", "sentiment": {"score": -0.317953, "label": "negative"}, "relevance": 0.612024}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611651}, {"text": "Kinex Pharmaceuticals LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610794}, {"text": "solid tumor patients", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610699}, {"text": "cytochrome P450 enzymes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598213}, {"text": "5-hydroxytryptamine 3 receptor antagonist", "sentiment": {"score": -0.459847, "label": "negative"}, "relevance": 0.596943}, {"text": "chronic non-cancer pain", "sentiment": {"score": -0.812913, "label": "negative"}, "relevance": 0.59068}, {"text": "severe chronic pain", "sentiment": {"score": -0.383464, "label": "negative"}, "relevance": 0.59052}, {"text": "dual absorption enhancers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.588196}, {"text": "chronic kidney disease", "sentiment": {"score": -0.789158, "label": "negative"}, "relevance": 0.587474}, {"text": "mu-opioid analgesic molecule", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586017}, {"text": "Phase I/II", "sentiment": {"score": -0.50472, "label": "negative"}, "relevance": 0.584683}, {"text": "cytokine immunostimulatory therapy", "sentiment": {"score": -0.50472, "label": "negative"}, "relevance": 0.580544}, {"text": "Valeant Pharmaceuticals International", "sentiment": {"score": -0.371764, "label": "negative"}, "relevance": 0.579917}, {"text": "systemic lupus erythematosus", "sentiment": {"score": -0.339706, "label": "negative"}, "relevance": 0.57844}, {"text": "age-related macular degeneration", "sentiment": {"score": -0.588022, "label": "negative"}, "relevance": 0.576764}, {"text": "companies daily email", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573485}, {"text": "UCB Pharma S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572766}, {"text": "F. Hoffmann-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568318}, {"text": "gastric cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559074}, {"text": "cervical cancer", "sentiment": {"score": -0.570877, "label": "negative"}, "relevance": 0.555298}, {"text": "pancreatic cancer", "sentiment": {"score": -0.592611, "label": "negative"}, "relevance": 0.550735}, {"text": "oral eribulin", "sentiment": {"score": -0.482671, "label": "negative"}, "relevance": 0.535093}, {"text": "Athenex", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527348}, {"text": "clinical study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527214}, {"text": "Amgen Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526376}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523243}, {"text": "Hanmi Pharmaceuticals", "sentiment": {"score": -0.389344, "label": "negative"}, "relevance": 0.521928}, {"text": "Halozyme Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519735}, {"text": "drug candidates", "sentiment": {"score": -0.379916, "label": "negative"}, "relevance": 0.519263}, {"text": "chemotherapy-induced nausea", "sentiment": {"score": -0.459847, "label": "negative"}, "relevance": 0.516143}, {"text": "pre-clinical development", "sentiment": {"score": -0.482671, "label": "negative"}, "relevance": 0.515445}, {"text": "actinic keratosis", "sentiment": {"score": -0.254162, "label": "negative"}, "relevance": 0.515408}, {"text": "certain patients", "sentiment": {"score": -0.482671, "label": "negative"}, "relevance": 0.515287}, {"text": "related conditions", "sentiment": {"score": -0.350038, "label": "negative"}, "relevance": 0.515273}, {"text": "advanced malignances", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513993}, {"text": "Athenex analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513903}]}, "extracted_metadata": {"sha1": "5a62bdbeb614b35568e7a4b0428ee3759655a22e", "filename": "1541258974948.zip-a42cbdc5c99eb4d156b17f6e280b93d2.xml", "file_type": "json"}, "title": "Reviewing Athenex (ATNX) and Nektar Therapeutics (NKTR)", "forum_title": "American Banking News"}, {"id": "WYUjDkGxbWcnGDcl9lw4WCZrkFhcn9KbL1yE9Bu1FtP_BDvUleldEpz0ncFIXcOY", "result_metadata": {"score": 31.704706}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9072, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.579949, "label": "/health and fitness/drugs"}, {"score": 0.468919, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.450642, "label": "/health and fitness/men's health"}], "relations": [], "keywords": [{"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.976842}, {"text": "Alliances Profile Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.82724}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380735}]}, "crawl_date": "2018-11-04T14:19:41Z", "url": "https://www.bioportfolio.com/news/article/3804618/Roivant-Sciences-Ltd-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-Report-Updated-27092018.html", "host": "bioportfolio.com", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250 08:58 Reports Summary Roivant Sciences Ltd Roivant Sciences focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-04T13:58:00Z", "enriched_text": {"entities": [{"count": 30, "sentiment": {"score": 0.254958, "label": "positive"}, "text": "target Company", "relevance": 0.894432, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences Ltd Roivant Sciences", "relevance": 0.360354, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.426454, "label": "positive"}, "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare", "relevance": 0.317376, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.241391, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences", "relevance": 0.210906, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.723415, "label": "negative"}, "text": "farber disease", "relevance": 0.184905, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Farber disease", "dbpedia_resource": "http://dbpedia.org/resource/Farber_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.181263, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.42829, "label": "negative"}, "text": "Arena Pharmaceuticals", "relevance": 0.179608, "type": "Company", "disambiguation": {"subtype": [], "name": "Arena Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Arena_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.804125, "label": "negative"}, "text": "alzheimer's disease", "relevance": 0.174284, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.426454, "label": "positive"}, "text": "Alliances Profile", "relevance": 0.174022, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.163305, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bermuda", "relevance": 0.162695, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hamilton", "relevance": 0.160809, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.5972, "label": "positive"}, "text": "US", "relevance": 0.160289, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Duke University", "relevance": 0.158411, "type": "Organization", "disambiguation": {"subtype": ["Company", "CollegeUniversity", "University"], "name": "Duke University", "dbpedia_resource": "http://dbpedia.org/resource/Duke_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.158385, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hospital Medical Center", "relevance": 0.157432, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.157224, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.154397, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.15364, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.150593, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Arbutus Biopharma", "relevance": 0.149901, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.147171, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.143258, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.139857, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cincinnati Children", "relevance": 0.136506, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.136506, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 08", "relevance": 0.136506, "type": "Quantity"}], "sentiment": {"document": {"score": 0.425406, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Roivant Sciences Ltd Roivant Sciences", "keywords": [{"text": "Roivant Sciences"}], "entities": [{"type": "Company", "text": "Roivant Sciences Ltd Roivant Sciences"}]}, "sentence": " Roivant Sciences Ltd Roivant Sciences focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas.", "object": {"text": "biomedical research", "keywords": [{"text": "biomedical research"}]}, "action": {"verb": {"text": "deliver", "tense": "future"}, "text": "delivering", "normalized": "deliver"}}, {"subject": {"text": "Roivant Sciences Ltd Roivant Sciences", "keywords": [{"text": "Roivant Sciences"}], "entities": [{"type": "Company", "text": "Roivant Sciences Ltd Roivant Sciences"}]}, "sentence": " Roivant Sciences Ltd Roivant Sciences focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas.", "object": {"text": "commercializing novel therapies across diverse therapeutic areas", "keywords": [{"text": "diverse therapeutic areas"}, {"text": "novel therapies"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "Roivant Sciences Ltd Roivant Sciences", "keywords": [{"text": "Roivant Sciences"}], "entities": [{"type": "Company", "text": "Roivant Sciences Ltd Roivant Sciences"}]}, "sentence": " Roivant Sciences Ltd Roivant Sciences focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas.", "object": {"text": "novel therapies", "keywords": [{"text": "novel therapies"}]}, "action": {"verb": {"text": "commercialize", "tense": "present"}, "text": "commercializing", "normalized": "commercialize"}}, {"subject": {"text": "intepirdine, nelotanserin, RVT103 and RVT104,relugolix, RVT602, RVT801, RVT501, RVT201, RVT701 and RVT702", "keywords": [{"text": "intepirdine"}, {"text": "nelotanserin"}, {"text": "RVT104,relugolix"}]}, "sentence": " The company's pipeline compounds portfolio includes intepirdine, nelotanserin, RVT103 and RVT104,relugolix, RVT602, RVT801, RVT501, RVT201, RVT701 and RVT702.", "object": {"text": "The company's pipeline compounds portfolio", "keywords": [{"text": "pipeline"}, {"text": "company"}, {"text": "portfolio"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Its pipeline compounds", "keywords": [{"text": "pipeline compounds"}]}, "sentence": " Its pipeline compounds find application in various therapeutic areas such as oncology , rare diseases, alzheimer's disease, prostate cancer and farber disease, among others.", "object": {"text": "application", "keywords": [{"text": "application"}]}, "action": {"verb": {"text": "find", "tense": "present"}, "text": "find", "normalized": "find"}}, {"subject": {"text": "Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center", "keywords": [{"text": "Arbutus Biopharma"}, {"text": "Arena Pharmaceuticals"}, {"text": "Hospital Medical Center"}, {"text": "Duke University"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Arena Pharmaceuticals", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Arena Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Arena_Pharmaceuticals"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Arbutus Biopharma"}, {"type": "Organization", "text": "Duke University", "disambiguation": {"subtype": ["Company", "CollegeUniversity", "University"], "name": "Duke University", "dbpedia_resource": "http://dbpedia.org/resource/Duke_University"}}, {"type": "Organization", "text": "Cincinnati Children"}, {"type": "Facility", "text": "Hospital Medical Center"}]}, "sentence": " Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center.", "object": {"text": "academic institutions and pharmaceutical companies", "keywords": [{"text": "academic institutions"}, {"text": "pharmaceutical companies"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company has operational presence in the US, and Switzerland.", "object": {"text": "operational presence", "keywords": [{"text": "operational presence"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Roivant Sciences", "keywords": [{"text": "Roivant Sciences"}], "entities": [{"type": "Company", "text": "Roivant Sciences Ltd Roivant Sciences"}]}, "sentence": " Roivant Sciences is headquartered in Hamilton, Bermuda.", "object": {"text": "headquartered in Hamilton, Bermuda", "keywords": [{"text": "Bermuda"}, {"text": "Hamilton"}], "entities": [{"type": "Location", "text": "Hamilton", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Bermuda", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Roivant Sciences", "keywords": [{"text": "Roivant Sciences"}], "entities": [{"type": "Company", "text": "Roivant Sciences Ltd Roivant Sciences"}]}, "sentence": " Roivant Sciences is headquartered in Hamilton, Bermuda.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile", "keywords": [{"text": "Pharmaceuticals Healthcare Deals"}, {"text": "Alliances Profile"}, {"text": "Roivant"}, {"text": "Sciences"}], "entities": [{"type": "Company", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "proprietary inhouse Pharma eTrack", "keywords": [{"text": "inhouse Pharma eTrack"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "database", "keywords": [{"text": "database"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deals", "normalized": "deal"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Company", "text": "target Company"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Finance", "relevance": 0.921224, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Venture capital", "relevance": 0.910105, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Mergers and acquisitions", "relevance": 0.838057, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Corporate finance", "relevance": 0.727149, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Investment", "relevance": 0.701337, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Corporation", "relevance": 0.695373, "dbpedia_resource": "http://dbpedia.org/resource/Corporation"}], "categories": [{"score": 0.640725, "label": "/finance/financial news"}, {"score": 0.462683, "label": "/business and industrial/business operations"}, {"score": 0.394373, "label": "/business and industrial/business operations/management/business process"}], "relations": [{"type": "agentOf", "sentence": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250 08:58 Reports Summary Roivant Sciences Ltd Roivant Sciences focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas.", "score": 0.845595, "arguments": [{"text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals", "location": [0, 53], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Report", "location": [77, 83], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOfMany", "sentence": "Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center.", "score": 0.784253, "arguments": [{"text": "Arena Pharmaceuticals", "location": [852, 873], "entities": [{"type": "Organization", "text": "Arena Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [793, 817], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center.", "score": 0.469537, "arguments": [{"text": "GlaxoSmithKline", "location": [875, 890], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [793, 817], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center.", "score": 0.503578, "arguments": [{"text": "Duke University", "location": [911, 926], "entities": [{"type": "Organization", "text": "Duke University", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "pharmaceutical companies", "location": [793, 817], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center.", "score": 0.553566, "arguments": [{"text": "Cincinnati Children's Hospital Medical Center", "location": [931, 976], "entities": [{"type": "Organization", "text": "Cincinnati Children's Hospital Medical Center", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [793, 817], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Roivant Sciences is headquartered in Hamilton, Bermuda.", "score": 0.85502, "arguments": [{"text": "Roivant Sciences", "location": [1043, 1059], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Hamilton", "location": [1080, 1088], "entities": [{"type": "GeopoliticalEntity", "text": "Hamilton"}]}]}, {"type": "locatedAt", "sentence": "Roivant Sciences is headquartered in Hamilton, Bermuda.", "score": 0.98727, "arguments": [{"text": "Hamilton", "location": [1080, 1088], "entities": [{"type": "GeopoliticalEntity", "text": "Hamilton"}]}, {"text": "Bermuda", "location": [1090, 1097], "entities": [{"type": "GeopoliticalEntity", "text": "Bermuda"}]}]}, {"type": "productOf", "sentence": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.86209, "arguments": [{"text": "Mergers", "location": [1243, 1250], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1233, 1240], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "productOf", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.535319, "arguments": [{"text": "Mergers", "location": [1860, 1867], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1824, 1831], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.564807, "arguments": [{"text": "Type Chart", "location": [2123, 2133], "entities": [{"type": "Organization", "text": "Type Chart"}]}, {"text": "Deals", "location": [2114, 2119], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.576002, "arguments": [{"text": "Deals", "location": [2298, 2303], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Region Chart", "location": [2307, 2319], "entities": [{"type": "Organization", "text": "Region Chart"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.706156, "arguments": [{"text": "Asia", "location": [2459, 2463], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2464, 2471], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "timeOf", "sentence": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250 08:58 Reports Summary Roivant Sciences Ltd Roivant Sciences focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas.", "score": 0.126713, "arguments": [{"text": "08:58", "location": [124, 129], "entities": [{"type": "Time", "text": "08:58", "disambiguation": {"subtype": ["Starting"]}}]}, {"text": "Reports", "location": [130, 137], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "partOf", "sentence": "Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "score": 0.740638, "arguments": [{"text": "Subsector Chart", "location": [2540, 2555], "entities": [{"type": "Organization", "text": "Subsector Chart"}]}, {"text": "Deals", "location": [2531, 2536], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [2839, 2848], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2816, 2823], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.438716, "arguments": [{"text": "executives", "location": [2985, 2995], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [3003, 3010], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.713979, "arguments": [{"text": "subsidiaries", "location": [3108, 3120], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "company", "location": [3128, 3135], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.689884, "arguments": [{"text": "competitors", "location": [3171, 3182], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3190, 3197], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.374818, "arguments": [{"text": "you", "location": [3350, 3353], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3372, 3379], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3446, 3449], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3453, 3460], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "employedBy", "sentence": "Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "score": 0.284605, "arguments": [{"text": "customers", "location": [4186, 4195], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "company", "location": [4143, 4150], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "locatedAt", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.337955, "arguments": [{"text": "company", "location": [4236, 4243], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "locations", "location": [4266, 4275], "entities": [{"type": "Location", "text": "locations"}]}]}, {"type": "partOf", "sentence": "Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events.", "score": 0.68684, "arguments": [{"text": "company", "location": [4384, 4391], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Recent", "location": [4392, 4398], "entities": [{"type": "Organization", "text": "Recent"}]}]}, {"type": "agentOf", "sentence": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250 08:58 Reports Summary Roivant Sciences Ltd Roivant Sciences focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas.", "score": 0.620915, "arguments": [{"text": "Summary\nRoivant Sciences Ltd Roivant Sciences", "location": [138, 183], "entities": [{"type": "Organization", "text": "Summary\nRoivant Sciences Ltd Roivant Sciences"}]}, {"text": "Reports", "location": [130, 137], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "partOf", "sentence": "The company's pipeline compounds portfolio includes intepirdine, nelotanserin, RVT103 and RVT104,relugolix, RVT602, RVT801, RVT501, RVT201, RVT701 and RVT702.", "score": 0.936885, "arguments": [{"text": "company", "location": [314, 321], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "pipeline compounds", "location": [324, 342], "entities": [{"type": "Organization", "text": "pipeline compounds", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Its pipeline compounds find application in various therapeutic areas such as oncology , rare diseases, alzheimer's disease, prostate cancer and farber disease, among others.", "score": 0.920815, "arguments": [{"text": "pipeline compounds", "location": [473, 491], "entities": [{"type": "Organization", "text": "pipeline compounds", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Its", "location": [469, 472], "entities": [{"type": "Organization", "text": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "hasAttribute", "sentence": "Its pipeline compounds find application in various therapeutic areas such as oncology , rare diseases, alzheimer's disease, prostate cancer and farber disease, among others.", "score": 0.780089, "arguments": [{"text": "alzheimer", "location": [572, 581], "entities": [{"type": "Person", "text": "alzheimer"}]}, {"text": "diseases", "location": [562, 570], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "Its pipeline compounds find application in various therapeutic areas such as oncology , rare diseases, alzheimer's disease, prostate cancer and farber disease, among others.", "score": 0.520126, "arguments": [{"text": "alzheimer", "location": [572, 581], "entities": [{"type": "Person", "text": "alzheimer"}]}, {"text": "prostate cancer", "location": [593, 608], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center.", "score": 0.455892, "arguments": [{"text": "Takeda", "location": [829, 835], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "pharmaceutical companies", "location": [793, 817], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center.", "score": 0.582913, "arguments": [{"text": "Vertex", "location": [844, 850], "entities": [{"type": "Organization", "text": "Vertex", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [793, 817], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "deals", "sentiment": {"score": 0.44458, "label": "positive"}, "relevance": 0.951311}, {"text": "financial deals", "sentiment": {"score": 0.572001, "label": "positive"}, "relevance": 0.936017}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.426454, "label": "positive"}, "relevance": 0.845142}, {"text": "company", "sentiment": {"score": -0.0149467, "label": "negative"}, "relevance": 0.830027}, {"text": "Roivant Sciences", "sentiment": {"score": 0.426454, "label": "positive"}, "relevance": 0.804417}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.599052}, {"text": "Financial Deals Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595579}, {"text": "eTrack deals database", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.591943}, {"text": "major financial deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.588724}, {"text": "detailed major deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558849}, {"text": "recent financial deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.556611}, {"text": "major recent deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547809}, {"text": "various therapeutic areas", "sentiment": {"score": -0.204142, "label": "negative"}, "relevance": 0.512845}, {"text": "key deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.471899}, {"text": "detailed information", "sentiment": {"score": 0.677039, "label": "positive"}, "relevance": 0.430274}, {"text": "key competitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406186}, {"text": "business segments", "sentiment": {"score": -0.352689, "label": "negative"}, "relevance": 0.376334}, {"text": "Alliances Profile", "sentiment": {"score": 0.426454, "label": "positive"}, "relevance": 0.365404}, {"text": "key financial metrics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.365108}, {"text": "target company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363171}, {"text": "Roivant Sciences pipeline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358188}, {"text": "Sciences Ltd Pharmaceuticals", "sentiment": {"score": 0.426454, "label": "positive"}, "relevance": 0.358038}, {"text": "diverse therapeutic areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345104}, {"text": "Private Equity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34169}, {"text": "Venture Financing", "sentiment": {"score": 0.489186, "label": "positive"}, "relevance": 0.341082}, {"text": "detailed comparative data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338138}, {"text": "Equity/Debt Offerings", "sentiment": {"score": 0.343645, "label": "positive"}, "relevance": 0.337702}, {"text": "Hospital Medical Center", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.336665}, {"text": "Gain key insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332303}, {"text": "Access elaborate information", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.330767}, {"text": "key executives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32822}, {"text": "major public companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325654}, {"text": "core business segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324042}, {"text": "business research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.294215}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278586}, {"text": "Sciences Ltd Roivant", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260266}, {"text": "Subsector Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259335}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249351}, {"text": "key centers", "sentiment": {"score": 0.539694, "label": "positive"}, "relevance": 0.248469}, {"text": "Key elements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244544}, {"text": "Report Updated", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.243406}, {"text": "strategic alliances", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238857}, {"text": "Arbutus Biopharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238822}, {"text": "biomedical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236323}, {"text": "Acquisitions MAs", "sentiment": {"score": 0.426454, "label": "positive"}, "relevance": 0.235071}, {"text": "novel therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232895}, {"text": "Type Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231226}, {"text": "rare diseases", "sentiment": {"score": -0.689233, "label": "negative"}, "relevance": 0.230451}, {"text": "comprehensive data", "sentiment": {"score": 0.426454, "label": "positive"}, "relevance": 0.230347}, {"text": "academic institutions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229668}]}, "extracted_metadata": {"sha1": "0e0b096c4da7cf83d873341e8c2b86e6ae3f77f9", "filename": "1541341181768.zip-e9a4e6cf108584ce95ecceeb73ddfd58.xml", "file_type": "json"}, "title": "Roivant Sciences Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27092018 Prices from USD $250", "forum_title": "BioPortfolio Kinex Pharmaceuticals Announces First Patient Dosed with Phase News"}, {"id": "AjLPdaBggYcp4yJrop1mZtec-MnDJk-i_E0_cvgNFJjdY_XRQK3PWrEIsIYEnf9s", "result_metadata": {"score": 31.507538}, "author": "Linda Rogers", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Envestnet Asset Management INC", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.00 Million", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Investment", "relevance": 0.896224, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}], "categories": [{"score": 0.543355, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.50321, "label": "/finance/investing/beginning investing"}, {"score": 0.453461, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Envestnet Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.958882}, {"text": "Shire Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.918259}, {"text": "Share Value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.66457}, {"text": "Trimmed", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620135}, {"text": "Million", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485533}, {"text": "SHPG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343988}, {"text": "Rose", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341415}]}, "crawl_date": "2018-11-03T17:27:58Z", "url": "https://www.mmahotstuff.com/2018/11/03/envestnet-asset-management-inc-trimmed-its-shire-plc-shpg-holding-by-3-00-million-as-share-value-rose.html", "host": "mmahotstuff.com", "text": "The institutional investor held 16,636 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $2.81M, down from 34,516 at the end of the previous reported quarter.", "main_image_url": "http://teletechwire.com/wp-content/uploads/logos/Logos/SHPG.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-03T17:31:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": -0.0716387, "label": "negative"}, "text": "Shire Plc", "relevance": 0.881856, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 5, "sentiment": {"score": -0.0545131, "label": "negative"}, "text": "Envestnet Asset Management Inc", "relevance": 0.632184, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Linda Rogers", "relevance": 0.265649, "type": "Person", "disambiguation": {"subtype": [], "name": "Linda Rogers", "dbpedia_resource": "http://dbpedia.org/resource/Linda_Rogers"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ishares Tr", "relevance": 0.187108, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Apple Inc", "relevance": 0.179871, "type": "Company", "disambiguation": {"subtype": ["Brand", "OperatingSystemDeveloper", "ProcessorManufacturer", "ProgrammingLanguageDesigner", "ProgrammingLanguageDeveloper", "ProtocolProvider", "SoftwareDeveloper", "VentureFundedCompany", "VideoGameDeveloper", "VideoGamePublisher"], "name": "Apple Inc.", "dbpedia_resource": "http://dbpedia.org/resource/Apple_Inc."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.17617, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.536798, "label": "negative"}, "text": "SEC", "relevance": 0.1751, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 1, "sentiment": {"score": 0.311873, "label": "positive"}, "text": "Tower Semiconductor Ltd", "relevance": 0.16456, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.296529, "label": "positive"}, "text": "US", "relevance": 0.147256, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.137556, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$43.79 billion", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$87.75 million", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.00 Million", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$176.28", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "51.07%", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.66", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.07M", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.58%", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.81M", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "51.8%", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.31%", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7.09%", "relevance": 0.137556, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.31%", "relevance": 0.137556, "type": "Quantity"}], "sentiment": {"document": {"score": 0.118308, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Envestnet Asset Management Inc", "keywords": [{"text": "Envestnet Asset Management"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}]}, "sentence": " Envestnet Asset Management Inc decreased its stake in Shire Plc (SHPG) by 51.8% based on its latest 2018Q2 regulatory filing with the SEC.", "object": {"text": "its stake", "keywords": [{"text": "stake"}]}, "action": {"verb": {"text": "decrease", "tense": "past"}, "text": "decreased", "normalized": "decrease"}}, {"subject": {"text": "Envestnet Asset Management Inc", "keywords": [{"text": "Envestnet Asset Management"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}]}, "sentence": " Envestnet Asset Management Inc sold 17,880 shares as the company\u2019s stock rose 7.09% with the market.", "object": {"text": "17,880 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Envestnet Asset Management Inc sold 17,880 shares as the company\u2019s stock rose 7.09% with the market.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}]}, "sentence": " Envestnet Asset Management Inc sold 17,880 shares as the company\u2019s stock rose 7.09% with the market.", "object": {"text": "7.09%", "entities": [{"type": "Quantity", "text": "7.09"}]}, "action": {"verb": {"text": "rise", "tense": "past"}, "text": "rose", "normalized": "rise"}}, {"subject": {"text": "The institutional investor", "keywords": [{"text": "institutional investor"}]}, "sentence": " The institutional investor held 16,636 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $2.81M, down from 34,516 at the end of the previous reported quarter.", "object": {"text": "16,636 shares of the major pharmaceuticals company", "keywords": [{"text": "major pharmaceuticals company"}, {"text": "shares"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "2018Q2"}, "sentence": " The institutional investor held 16,636 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $2.81M, down from 34,516 at the end of the previous reported quarter.", "object": {"text": "at $2.81M", "entities": [{"type": "Quantity", "text": "2.81M"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "valued", "normalized": "value"}}, {"subject": {"text": "quarter", "keywords": [{"text": "quarter"}]}, "sentence": " The institutional investor held 16,636 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $2.81M, down from 34,516 at the end of the previous reported quarter.", "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Envestnet Asset Management Inc", "keywords": [{"text": "Envestnet Asset Management"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}]}, "sentence": " Envestnet Asset Management Inc who had been investing in Shire Plc for a number of months, seems to be less bullish one the $52.85B market cap company.", "object": {"text": "been investing in Shire Plc", "keywords": [{"text": "Shire Plc"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Envestnet Asset Management Inc", "keywords": [{"text": "Envestnet Asset Management"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}]}, "sentence": " Envestnet Asset Management Inc who had been investing in Shire Plc for a number of months, seems to be less bullish one the $52.85B market cap company.", "object": {"text": "investing in Shire Plc", "keywords": [{"text": "Shire Plc"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Envestnet Asset Management Inc", "keywords": [{"text": "Envestnet Asset Management"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}]}, "sentence": " Envestnet Asset Management Inc who had been investing in Shire Plc for a number of months, seems to be less bullish one the $52.85B market cap company.", "action": {"verb": {"text": "invest", "tense": "past"}, "text": "had been investing", "normalized": "have be invest"}}, {"subject": {"text": "Envestnet Asset Management Inc who had been investing in Shire Plc for a number of months,", "keywords": [{"text": "Shire Plc"}, {"text": "Envestnet Asset Management"}, {"text": "number"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}, {"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " Envestnet Asset Management Inc who had been investing in Shire Plc for a number of months, seems to be less bullish one the $52.85B market cap company.", "object": {"text": "less bullish one the $52.85B market cap company", "keywords": [{"text": "market cap company"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "seems to be", "normalized": "seem to be"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock decreased 2.58% or $4.66 $176.28.", "object": {"text": "2.58%", "entities": [{"type": "Quantity", "text": "2.58"}]}, "action": {"verb": {"text": "decrease", "tense": "past"}, "text": "decreased", "normalized": "decrease"}}, {"subject": {"text": "SHPG)", "keywords": [{"text": "SHPG"}]}, "sentence": " Shire plc (NASDAQ:SHPG) has risen 6.31% uptrending.", "object": {"text": "6.31% uptrending", "entities": [{"type": "Quantity", "text": "6.31"}]}, "action": {"verb": {"text": "rise", "tense": "past"}, "text": "has risen", "normalized": "have rise"}}, {"subject": {"text": "It"}, "sentence": " It has underperformed by 9.31% the S&P500.", "object": {"text": "underperformed by 9.31% the S&P500", "entities": [{"type": "Quantity", "text": "9.31"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "by 9.31% the S&P500", "entities": [{"type": "Quantity", "text": "9.31"}]}, "sentence": " It has underperformed by 9.31% the S&P500.", "object": {"text": "It"}, "action": {"verb": {"text": "underperform", "tense": "past"}, "text": "has underperformed", "normalized": "have underperform"}}, {"subject": {"text": "Envestnet Asset Management Inc", "keywords": [{"text": "Envestnet Asset Management"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}]}, "sentence": " Envestnet Asset Management Inc, which manages about $60.39B and $43.79 billion US Long portfolio, upped its stake in Apple Inc (NASDAQ:AAPL) by 219,505 shares to 474,038 shares, valued at $87.75 million in 2018Q2, according to the filing.", "object": {"text": "about $60.39B and $43.79 billion US Long portfolio", "keywords": [{"text": "Long portfolio"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "$43.79 billion"}]}, "action": {"verb": {"text": "manage", "tense": "present"}, "text": "manages", "normalized": "manage"}}, {"subject": {"text": "Envestnet Asset Management Inc, which manages about $60.39B and $43.79 billion US Long portfolio,", "keywords": [{"text": "Envestnet Asset Management"}, {"text": "Long portfolio"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "$43.79 billion"}]}, "sentence": " Envestnet Asset Management Inc, which manages about $60.39B and $43.79 billion US Long portfolio, upped its stake in Apple Inc (NASDAQ:AAPL) by 219,505 shares to 474,038 shares, valued at $87.75 million in 2018Q2, according to the filing.", "object": {"text": "its stake in Apple Inc (NASDAQ", "keywords": [{"text": "stake"}, {"text": "Apple"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "Apple Inc", "disambiguation": {"subtype": ["Brand", "OperatingSystemDeveloper", "ProcessorManufacturer", "ProgrammingLanguageDesigner", "ProgrammingLanguageDeveloper", "ProtocolProvider", "SoftwareDeveloper", "VentureFundedCompany", "VideoGameDeveloper", "VideoGamePublisher"], "name": "Apple Inc.", "dbpedia_resource": "http://dbpedia.org/resource/Apple_Inc."}}]}, "action": {"verb": {"text": "up", "tense": "past"}, "text": "upped", "normalized": "up"}}, {"subject": {"text": "474,038 shares", "keywords": [{"text": "shares"}]}, "sentence": " Envestnet Asset Management Inc, which manages about $60.39B and $43.79 billion US Long portfolio, upped its stake in Apple Inc (NASDAQ:AAPL) by 219,505 shares to 474,038 shares, valued at $87.75 million in 2018Q2, according to the filing.", "object": {"text": "at $87.75 million in 2018Q2", "entities": [{"type": "Quantity", "text": "$87.75 million"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "valued", "normalized": "value"}}, {"subject": {"text": "Envestnet Asset Management Inc, which manages about $60.39B and $43.79 billion US Long portfolio, upped its stake in Apple Inc (NASDAQ:AAPL) by 219,505 shares to 474,038 shares, valued at $87.75 million in 2018Q2", "keywords": [{"text": "Envestnet Asset Management"}, {"text": "Long portfolio"}, {"text": "stake"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Envestnet Asset Management Inc"}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Apple Inc", "disambiguation": {"subtype": ["Brand", "OperatingSystemDeveloper", "ProcessorManufacturer", "ProgrammingLanguageDesigner", "ProgrammingLanguageDeveloper", "ProtocolProvider", "SoftwareDeveloper", "VentureFundedCompany", "VideoGameDeveloper", "VideoGamePublisher"], "name": "Apple Inc.", "dbpedia_resource": "http://dbpedia.org/resource/Apple_Inc."}}, {"type": "Quantity", "text": "$43.79 billion"}, {"type": "Quantity", "text": "$87.75 million"}]}, "sentence": " Envestnet Asset Management Inc, which manages about $60.39B and $43.79 billion US Long portfolio, upped its stake in Apple Inc (NASDAQ:AAPL) by 219,505 shares to 474,038 shares, valued at $87.75 million in 2018Q2, according to the filing.", "object": {"text": "to the filing", "keywords": [{"text": "filing"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "It"}, "sentence": " It also increased its holding in Ishares Tr (USMV) by 1.07M shares in the quarter, for a total of 4.67 million shares, and has risen its stake in Tower Semiconductor Ltd (NASDAQ:TSEM).", "object": {"text": "its holding", "keywords": [{"text": "holding"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "risen its stake", "keywords": [{"text": "stake"}]}, "sentence": " It also increased its holding in Ishares Tr (USMV) by 1.07M shares in the quarter, for a total of 4.67 million shares, and has risen its stake in Tower Semiconductor Ltd (NASDAQ:TSEM).", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "SHPG) news", "keywords": [{"text": "SHPG"}, {"text": "news"}]}, "sentence": " More notable recent Shire plc (NASDAQ:SHPG) news were published by: Seekingalpha.com which released: \u201cFDA Ad Com backs Shire\u2019s prucalopride for CIC\u201d on October 19, 2018, also Seekingalpha.com with their article: \u201cShire/Takeda expect EC Phase 1 approval \u2013 dealReporter\u201d published on October 22, 2018, Seekingalpha.com published: \u201cTakeda secures \u00a5500B loan to help fund Shire transaction\u201d on October 26, 2018.", "object": {"text": "published by: Seekingalpha.com which released: \u201cFDA Ad Com backs Shire\u2019s prucalopride for CIC", "keywords": [{"text": "FDA Ad Com"}, {"text": "CIC"}, {"text": "Shire"}, {"text": "Seekingalpha.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "by: Seekingalpha.com which released: \u201cFDA Ad Com backs Shire\u2019s prucalopride for CIC\u201d on October 19, 2018, also Seekingalpha.com with their article: \u201cShire/Takeda expect EC Phase 1 approval \u2013 dealReporter\u201d published on October 22, 2018, Seekingalpha.com published: \u201cTakeda secures \u00a5500B loan to help fund Shire transaction\u201d on October 26, 2018", "keywords": [{"text": "FDA Ad Com"}, {"text": "Takeda secures \u00a5500B"}, {"text": "fund Shire transaction"}, {"text": "EC Phase"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " More notable recent Shire plc (NASDAQ:SHPG) news were published by: Seekingalpha.com which released: \u201cFDA Ad Com backs Shire\u2019s prucalopride for CIC\u201d on October 19, 2018, also Seekingalpha.com with their article: \u201cShire/Takeda expect EC Phase 1 approval \u2013 dealReporter\u201d published on October 22, 2018, Seekingalpha.com published: \u201cTakeda secures \u00a5500B loan to help fund Shire transaction\u201d on October 26, 2018.", "object": {"text": "SHPG) news", "keywords": [{"text": "SHPG"}, {"text": "news"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "were published", "normalized": "be publish"}}, {"subject": {"text": "Shire\u2019s", "keywords": [{"text": "Shire"}]}, "sentence": " More notable recent Shire plc (NASDAQ:SHPG) news were published by: Seekingalpha.com which released: \u201cFDA Ad Com backs Shire\u2019s prucalopride for CIC\u201d on October 19, 2018, also Seekingalpha.com with their article: \u201cShire/Takeda expect EC Phase 1 approval \u2013 dealReporter\u201d published on October 22, 2018, Seekingalpha.com published: \u201cTakeda secures \u00a5500B loan to help fund Shire transaction\u201d on October 26, 2018.", "action": {"verb": {"text": "prucalopride", "tense": "present"}, "text": "prucalopride", "normalized": "prucalopride"}}, {"subject": {"text": "Shire/Takeda", "keywords": [{"text": "Shire/Takeda"}]}, "sentence": " More notable recent Shire plc (NASDAQ:SHPG) news were published by: Seekingalpha.com which released: \u201cFDA Ad Com backs Shire\u2019s prucalopride for CIC\u201d on October 19, 2018, also Seekingalpha.com with their article: \u201cShire/Takeda expect EC Phase 1 approval \u2013 dealReporter\u201d published on October 22, 2018, Seekingalpha.com published: \u201cTakeda secures \u00a5500B loan to help fund Shire transaction\u201d on October 26, 2018.", "object": {"text": "EC Phase 1 approval \u2013 dealReporter\u201d published on October 22", "keywords": [{"text": "EC Phase"}, {"text": "approval"}, {"text": "dealReporter"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "EC Phase 1 approval \u2013 dealReporter\u201d", "keywords": [{"text": "EC Phase"}, {"text": "approval"}, {"text": "dealReporter"}]}, "sentence": " More notable recent Shire plc (NASDAQ:SHPG) news were published by: Seekingalpha.com which released: \u201cFDA Ad Com backs Shire\u2019s prucalopride for CIC\u201d on October 19, 2018, also Seekingalpha.com with their article: \u201cShire/Takeda expect EC Phase 1 approval \u2013 dealReporter\u201d published on October 22, 2018, Seekingalpha.com published: \u201cTakeda secures \u00a5500B loan to help fund Shire transaction\u201d on October 26, 2018.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "More interesting news about Shire plc (NASDAQ:SHPG)", "keywords": [{"text": "Shire plc"}, {"text": "interesting news"}, {"text": "NASDAQ"}, {"text": "SHPG"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \u201cTakeda gets Shire clearance from Japan\u201d published on October 18, 2018 as well as Seekingalpha.com \u2018s news article titled: \u201cShire Plc (SHPG) Q3 2018 Results \u2013 Earnings Call Transcript\u201d with publication date: November 01, 2018. - Linda Rogers", "object": {"text": "released by: Seekingalpha.com and their article", "keywords": [{"text": "Seekingalpha.com"}, {"text": "article"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "by: Seekingalpha.com and their article", "keywords": [{"text": "Seekingalpha.com"}, {"text": "article"}]}, "sentence": " More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \u201cTakeda gets Shire clearance from Japan\u201d published on October 18, 2018 as well as Seekingalpha.com \u2018s news article titled: \u201cShire Plc (SHPG) Q3 2018 Results \u2013 Earnings Call Transcript\u201d with publication date: November 01, 2018. - Linda Rogers", "object": {"text": "SHPG)", "keywords": [{"text": "SHPG"}]}, "action": {"verb": {"text": "release", "tense": "past"}, "text": "were released", "normalized": "be release"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}]}, "sentence": " More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \u201cTakeda gets Shire clearance from Japan\u201d published on October 18, 2018 as well as Seekingalpha.com \u2018s news article titled: \u201cShire Plc (SHPG) Q3 2018 Results \u2013 Earnings Call Transcript\u201d with publication date: November 01, 2018. - Linda Rogers", "object": {"text": "Shire clearance", "keywords": [{"text": "clearance"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "gets", "normalized": "get"}}, {"subject": {"text": "Seekingalpha.com", "keywords": [{"text": "Seekingalpha.com"}]}, "sentence": " More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \u201cTakeda gets Shire clearance from Japan\u201d published on October 18, 2018 as well as Seekingalpha.com \u2018s news article titled: \u201cShire Plc (SHPG) Q3 2018 Results \u2013 Earnings Call Transcript\u201d with publication date: November 01, 2018. - Linda Rogers", "object": {"text": "news article", "keywords": [{"text": "news article"}]}, "action": {"verb": {"text": "\u2018s", "tense": "present"}, "text": "\u2018s", "normalized": "\u2018s"}}, {"subject": {"text": "Seekingalpha.com \u2018s news article", "keywords": [{"text": "news article"}, {"text": "Seekingalpha.com"}]}, "sentence": " More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \u201cTakeda gets Shire clearance from Japan\u201d published on October 18, 2018 as well as Seekingalpha.com \u2018s news article titled: \u201cShire Plc (SHPG) Q3 2018 Results \u2013 Earnings Call Transcript\u201d with publication date: November 01, 2018. - Linda Rogers", "object": {"text": "Shire Plc (SHPG) Q3 2018 Results \u2013 Earnings Call Transcript\u201d with publication date", "keywords": [{"text": "Earnings Call Transcript"}, {"text": "Shire Plc"}, {"text": "Q3"}, {"text": "publication date"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "title", "tense": "past"}, "text": "titled", "normalized": "title"}}], "concepts": [{"text": "Investment", "relevance": 0.916783, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Stock market", "relevance": 0.778436, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Stock", "relevance": 0.635615, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "The Quarter at Tropicana", "relevance": 0.557248, "dbpedia_resource": "http://dbpedia.org/resource/The_Quarter_at_Tropicana"}, {"text": "Article", "relevance": 0.542029, "dbpedia_resource": "http://dbpedia.org/resource/Article_(publishing)"}], "categories": [{"score": 0.565897, "label": "/finance/investing"}, {"score": 0.565897, "label": "/finance/investing/beginning investing"}, {"score": 0.370456, "label": "/finance/financial news"}], "relations": [{"type": "employedBy", "sentence": "[ / Log in ] Envestnet Asset Management INC Trimmed Its Shire Plc (SHPG) Holding by $3.00 Million as Share Value Rose  Linda Rogers Envestnet Asset Management Inc decreased its stake in Shire Plc (SHPG) by 51.8% based on its latest 2018Q2 regulatory filing with the SEC.", "score": 0.668457, "arguments": [{"text": "Rose\n Linda Rogers", "location": [131, 149], "entities": [{"type": "Person", "text": "Rose\n Linda Rogers"}]}, {"text": "Envestnet Asset Management Inc", "location": [150, 180], "entities": [{"type": "Organization", "text": "Envestnet Asset Management Inc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \"Takeda gets Shire clearance from Japan\" published on October 18, 2018 as well as Seekingalpha.com \u02bbs news article titled: \"Shire Plc (SHPG) Q3 2018 Results - Earnings Call Transcript\" with publication date: November 01, 2018.", "score": 0.611153, "arguments": [{"text": "Q3", "location": [2009, 2011], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "their", "location": [1853, 1858], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "locatedAt", "sentence": "More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \"Takeda gets Shire clearance from Japan\" published on October 18, 2018 as well as Seekingalpha.com \u02bbs news article titled: \"Shire Plc (SHPG) Q3 2018 Results - Earnings Call Transcript\" with publication date: November 01, 2018.", "score": 0.470833, "arguments": [{"text": "Takeda", "location": [1869, 1875], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Japan", "location": [1902, 1907], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "[ / Log in ] Envestnet Asset Management INC Trimmed Its Shire Plc (SHPG) Holding by $3.00 Million as Share Value Rose  Linda Rogers Envestnet Asset Management Inc decreased its stake in Shire Plc (SHPG) by 51.8% based on its latest 2018Q2 regulatory filing with the SEC.", "score": 0.564582, "arguments": [{"text": "Rose\n Linda Rogers", "location": [131, 149], "entities": [{"type": "Person", "text": "Rose\n Linda Rogers"}]}, {"text": "decreased", "location": [181, 190], "entities": [{"type": "EventCommunication", "text": "decreased"}]}]}, {"type": "employedBy", "sentence": "Envestnet Asset Management Inc who had been investing in Shire Plc for a number of months, seems to be less bullish one the $52.85B market cap company.", "score": 0.268713, "arguments": [{"text": "who", "location": [606, 609], "entities": [{"type": "Person", "text": "who"}]}, {"text": "Envestnet Asset Management Inc", "location": [575, 605], "entities": [{"type": "Organization", "text": "Envestnet Asset Management INC Trimmed Its Shire Plc"}]}]}, {"type": "hasAttribute", "sentence": "Shire plc (NASDAQ:SHPG) has risen 6.31% uptrending.", "score": 0.872144, "arguments": [{"text": "Shire plc", "location": [835, 844], "entities": [{"type": "Organization", "text": "Envestnet Asset Management INC Trimmed Its Shire Plc"}]}, {"text": "SHPG", "location": [853, 857], "entities": [{"type": "Ticker", "text": "SHPG"}]}]}, {"type": "hasAttribute", "sentence": "Envestnet Asset Management Inc, which manages about $60.39B and $43.79 billion US Long portfolio, upped its stake in Apple Inc (NASDAQ:AAPL) by 219,505 shares to 474,038 shares, valued at $87.75 million in 2018Q2, according to the filing.", "score": 0.49836, "arguments": [{"text": "which", "location": [962, 967], "entities": [{"type": "Organization", "text": "Envestnet Asset Management INC Trimmed Its Shire Plc"}]}, {"text": "$60.39B", "location": [982, 989], "entities": [{"type": "Money", "text": "$60.39B"}]}]}, {"type": "hasAttribute", "sentence": "It also increased its holding in Ishares Tr (USMV) by 1.07M shares in the quarter, for a total of 4.67 million shares, and has risen its stake in Tower Semiconductor Ltd (NASDAQ:TSEM).", "score": 0.92711, "arguments": [{"text": "Tower Semiconductor Ltd", "location": [1315, 1338], "entities": [{"type": "Organization", "text": "Tower Semiconductor Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TSEM", "location": [1347, 1351], "entities": [{"type": "Ticker", "text": "TSEM"}]}]}, {"type": "partOfMany", "sentence": "More notable recent Shire plc (NASDAQ:SHPG) news were published by: Seekingalpha.com which released: \"FDA Ad Com backs Shire's prucalopride for CIC\" on October 19, 2018, also Seekingalpha.com with their article: \"Shire/Takeda expect EC Phase 1 approval - dealReporter\" published on October 22, 2018, Seekingalpha.com published: \"Takeda secures $500B loan to help fund Shire transaction\" on October 26, 2018.", "score": 0.888383, "arguments": [{"text": "Takeda", "location": [1573, 1579], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [1551, 1556], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \"Takeda gets Shire clearance from Japan\" published on October 18, 2018 as well as Seekingalpha.com \u02bbs news article titled: \"Shire Plc (SHPG) Q3 2018 Results - Earnings Call Transcript\" with publication date: November 01, 2018.", "score": 0.580257, "arguments": [{"text": "Takeda", "location": [1869, 1875], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [1853, 1858], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "More notable recent Shire plc (NASDAQ:SHPG) news were published by: Seekingalpha.com which released: \"FDA Ad Com backs Shire's prucalopride for CIC\" on October 19, 2018, also Seekingalpha.com with their article: \"Shire/Takeda expect EC Phase 1 approval - dealReporter\" published on October 22, 2018, Seekingalpha.com published: \"Takeda secures $500B loan to help fund Shire transaction\" on October 26, 2018.", "score": 0.884313, "arguments": [{"text": "Seekingalpha.com", "location": [1654, 1670], "entities": [{"type": "Web", "text": "Seekingalpha.com"}]}, {"text": "published", "location": [1671, 1680], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "hasAttribute", "sentence": "More interesting news about Shire plc (NASDAQ:SHPG) were released by: Seekingalpha.com and their article: \"Takeda gets Shire clearance from Japan\" published on October 18, 2018 as well as Seekingalpha.com \u02bbs news article titled: \"Shire Plc (SHPG) Q3 2018 Results - Earnings Call Transcript\" with publication date: November 01, 2018.", "score": 0.570806, "arguments": [{"text": "Shire plc", "location": [1790, 1799], "entities": [{"type": "Organization", "text": "Envestnet Asset Management INC Trimmed Its Shire Plc"}]}, {"text": "SHPG", "location": [1808, 1812], "entities": [{"type": "Ticker", "text": "SHPG"}]}]}], "keywords": [{"text": "Envestnet Asset Management", "sentiment": {"score": -0.109026, "label": "negative"}, "relevance": 0.900844}, {"text": "shire plc", "sentiment": {"score": -0.143277, "label": "negative"}, "relevance": 0.793471}, {"text": "recent Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431887}, {"text": "fund Shire transaction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.400897}, {"text": "Linda Rogers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364419}, {"text": "Takeda secures \u00a5500B", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35427}, {"text": "major pharmaceuticals company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350369}, {"text": "market cap company", "sentiment": {"score": -0.544145, "label": "negative"}, "relevance": 0.343921}, {"text": "FDA Ad Com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339666}, {"text": "Shire clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335753}, {"text": "shares", "sentiment": {"score": 0.151323, "label": "positive"}, "relevance": 0.307763}, {"text": "Management INC Trimmed", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.295059}, {"text": "Share Value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.292869}, {"text": "SHPG", "sentiment": {"score": -0.226716, "label": "negative"}, "relevance": 0.288199}, {"text": "regulatory filing", "sentiment": {"score": -0.536798, "label": "negative"}, "relevance": 0.285702}, {"text": "Ishares Tr", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285443}, {"text": "institutional investor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.28036}, {"text": "EC Phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278313}, {"text": "Long portfolio", "sentiment": {"score": 0.296529, "label": "positive"}, "relevance": 0.278285}, {"text": "Results \u2013 Earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277279}, {"text": "publication date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.275641}, {"text": "Tower Semiconductor", "sentiment": {"score": 0.311873, "label": "positive"}, "relevance": 0.273438}, {"text": "interesting news", "sentiment": {"score": 0.421115, "label": "positive"}, "relevance": 0.271848}, {"text": "news article", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270369}, {"text": "stake", "sentiment": {"score": -0.252519, "label": "negative"}, "relevance": 0.259828}, {"text": "NASDAQ", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.258981}, {"text": "Seekingalpha.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256914}, {"text": "stock", "sentiment": {"score": -0.16121, "label": "negative"}, "relevance": 0.232178}, {"text": "quarter", "sentiment": {"score": -0.362161, "label": "negative"}, "relevance": 0.229021}, {"text": "end", "sentiment": {"score": -0.362161, "label": "negative"}, "relevance": 0.227391}, {"text": "Million", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.223623}, {"text": "visitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.218102}, {"text": "Q3", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.217842}, {"text": "CIC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.217585}, {"text": "Log", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.216705}, {"text": "S&P500", "sentiment": {"score": -0.359022, "label": "negative"}, "relevance": 0.215241}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.214838}, {"text": "average", "sentiment": {"score": -0.304043, "label": "negative"}, "relevance": 0.21441}, {"text": "approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.214359}, {"text": "Shire/Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.214029}, {"text": "dealReporter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.213999}, {"text": "Apple", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.213975}, {"text": "AAPL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.213955}, {"text": "USMV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.213729}, {"text": "total", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.213684}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.213665}]}, "extracted_metadata": {"sha1": "2b9514e9fd6c3d3385dcc2893f113a7ca0914f67", "filename": "1541266078800.zip-ab482650795b141ace68eefa7ba6c10f.xml", "file_type": "json"}, "external_links": ["https://seekingalpha.com/news/3398309-takeda-gets-shire-clearance-japan", "https://seekingalpha.com/news/3398811-fda-ad-com-backs-shires-prucalopride-cic", "https://seekingalpha.com/article/4217067-shire-plc-shpg-q3-2018-results-earnings-call-transcript", "https://seekingalpha.com/news/3399357-shire-takeda-expect-ec-phase-1-approval-dealreporter", "https://seekingalpha.com/news/3401567-takeda-secures-500b-loan-help-fund-shire-transaction"], "title": "Envestnet Asset Management INC Trimmed Its Shire Plc (SHPG) Holding by $3.00 Million as Share Value Rose", "forum_title": "Money Making Articles Hot Stuff"}, {"id": "Jl92zIbuG0WhlV4c6jycuB17nYt-ZP9oNpKvb1vhJrfQ1AcNGBnV-CweEiLd574v", "result_metadata": {"score": 27.719343}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.905389, "label": "/science/weather/meteorological disaster/hurricane"}], "relations": [], "keywords": [{"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.946453}, {"text": "TKPYY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497657}, {"text": "TeleTrader.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477891}]}, "crawl_date": "2018-11-04T14:30:43Z", "url": "https://www.teletrader.com/takeda-pharmaceutical-co-ltd/stocks/details/tts-23200839", "host": "teletrader.com", "text": "Teletrader is not affiliated with Charles Schwab & CO., Inc.", "main_image_url": "http://www.teletrader.com/Caching/ChartsCache/FacebookCharts/fb_tts-23200839.png", "country": "AT", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-04T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TeleTrader Software GmbH", "relevance": 0.916001, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Charles Schwab & CO.", "relevance": 0.890748, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teletrader", "relevance": 0.685049, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "15 minutes", "relevance": 0.685049, "type": "Quantity"}], "sentiment": {"document": {"score": 0.23363, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "I"}, "sentence": "I wish this area would...", "object": {"text": "this area would", "keywords": [{"text": "area"}]}, "action": {"verb": {"text": "wish", "tense": "present"}, "text": "wish", "normalized": "wish"}}, {"subject": {"text": "We"}, "sentence": " We would appreciate your inputs about what would improve our service Thank you for your input!", "object": {"text": "your inputs about what would improve our service Thank you for your input", "keywords": [{"text": "inputs"}, {"text": "input"}, {"text": "service"}]}, "action": {"verb": {"text": "appreciate", "tense": "future"}, "text": "would appreciate", "normalized": "would appreciate"}}, {"subject": {"text": "account", "keywords": [{"text": "account"}]}, "sentence": " Take account of the Terms of Use and Data Protection Policies .", "object": {"text": "of the Terms of Use and Data Protection Policies", "keywords": [{"text": "Data Protection Policies"}, {"text": "Terms"}], "entities": []}, "action": {"verb": {"text": "Take", "tense": "present"}, "text": "Take", "normalized": "Take"}}, {"subject": {"text": "Teletrader", "keywords": [{"text": "Teletrader"}], "entities": [{"type": "Person", "text": "Teletrader"}]}, "sentence": " Teletrader is not affiliated with Charles Schwab & CO., Inc.", "object": {"text": "not affiliated with Charles Schwab & CO., Inc", "keywords": [{"text": "Charles Schwab"}, {"text": "CO."}], "entities": [{"type": "Company", "text": "Charles Schwab & CO."}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Teletrader", "keywords": [{"text": "Teletrader"}], "entities": [{"type": "Person", "text": "Teletrader"}]}, "sentence": " Teletrader is not affiliated with Charles Schwab & CO., Inc.", "object": {"text": "with Charles Schwab & CO., Inc", "keywords": [{"text": "Charles Schwab"}, {"text": "CO."}], "entities": [{"type": "Company", "text": "Charles Schwab & CO."}]}, "action": {"verb": {"text": "affiliate", "tense": "past", "negated": true}, "text": "affiliated", "normalized": "affiliate"}}, {"subject": {"text": "The price information", "keywords": [{"text": "price information"}]}, "sentence": " The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.", "object": {"text": "to the regulations of the selected stock exchange and/or licensors and the type of securities", "keywords": [{"text": "stock exchange"}, {"text": "licensors"}, {"text": "securities"}, {"text": "regulations"}], "entities": []}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "you"}, "sentence": " If you wish to receive reply to your feedback, please provide your email address.", "object": {"text": "to receive reply to your feedback", "keywords": [{"text": "reply"}, {"text": "feedback"}]}, "action": {"verb": {"text": "wish", "tense": "present"}, "text": "wish", "normalized": "wish"}}, {"subject": {"text": "you"}, "sentence": " If you wish to receive reply to your feedback, please provide your email address.", "object": {"text": "reply to your feedback", "keywords": [{"text": "reply"}, {"text": "feedback"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "wish to receive", "normalized": "wish to receive"}}], "concepts": [{"text": "E-mail", "relevance": 0.974158, "dbpedia_resource": "http://dbpedia.org/resource/E-mail"}, {"text": "Stock market", "relevance": 0.807183, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Charles R. Schwab", "relevance": 0.786246, "dbpedia_resource": "http://dbpedia.org/resource/Charles_R._Schwab"}, {"text": "All rights reserved", "relevance": 0.771899, "dbpedia_resource": "http://dbpedia.org/resource/All_rights_reserved"}, {"text": "Stock", "relevance": 0.735748, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Cybernetics", "relevance": 0.705667, "dbpedia_resource": "http://dbpedia.org/resource/Cybernetics"}, {"text": "Security", "relevance": 0.704978, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Stock exchange", "relevance": 0.674757, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "E-mail address", "relevance": 0.673353, "dbpedia_resource": "http://dbpedia.org/resource/E-mail_address"}, {"text": "Microsoft", "relevance": 0.573608, "dbpedia_resource": "http://dbpedia.org/resource/Microsoft"}, {"text": "Output", "relevance": 0.572337, "dbpedia_resource": "http://dbpedia.org/resource/Output"}, {"text": "Microsoft Exchange Server", "relevance": 0.566868, "dbpedia_resource": "http://dbpedia.org/resource/Microsoft_Exchange_Server"}, {"text": "Law", "relevance": 0.563743, "dbpedia_resource": "http://dbpedia.org/resource/Law"}, {"text": "Input", "relevance": 0.534, "dbpedia_resource": "http://dbpedia.org/resource/Input"}, {"text": "Charles M. Schwab", "relevance": 0.533646, "dbpedia_resource": "http://dbpedia.org/resource/Charles_M._Schwab"}, {"text": "All rights reversed", "relevance": 0.519299, "dbpedia_resource": "http://dbpedia.org/resource/All_rights_reversed"}, {"text": "Rulemaking", "relevance": 0.51, "dbpedia_resource": "http://dbpedia.org/resource/Rulemaking"}], "categories": [{"score": 0.532524, "label": "/finance/investing/day trading"}, {"score": 0.487983, "label": "/technology and computing/software"}, {"score": 0.479461, "label": "/finance/investing/brokerages"}], "relations": [{"type": "residesIn", "sentence": "I wish this area would... We would appreciate your inputs about what would improve our service Thank you for your input!", "score": 0.443227, "arguments": [{"text": "I", "location": [0, 1], "entities": [{"type": "Person", "text": "your"}]}, {"text": "area", "location": [12, 16], "entities": [{"type": "GeopoliticalEntity", "text": "area"}]}]}, {"type": "agentOf", "sentence": "If you wish to receive reply to your feedback, please provide your email address.", "score": 0.681616, "arguments": [{"text": "you", "location": [503, 506], "entities": [{"type": "Person", "text": "your"}]}, {"text": "reply", "location": [523, 528], "entities": [{"type": "EventCommunication", "text": "reply"}]}]}], "keywords": [{"text": "TeleTrader Software GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.979291}, {"text": "Data Protection Policies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.966988}, {"text": "Charles Schwab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.850123}, {"text": "price information", "sentiment": {"score": -0.286644, "label": "negative"}, "relevance": 0.75286}, {"text": "stock exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.74111}, {"text": "email address", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.725587}, {"text": "extents", "sentiment": {"score": -0.286644, "label": "negative"}, "relevance": 0.513741}, {"text": "licensors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.490305}, {"text": "inputs", "sentiment": {"score": 0.899909, "label": "positive"}, "relevance": 0.476409}, {"text": "reply", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434858}, {"text": "input", "sentiment": {"score": 0.899909, "label": "positive"}, "relevance": 0.424157}, {"text": "rule", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4003}, {"text": "feedback", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39445}, {"text": "area", "sentiment": {"score": -0.314976, "label": "negative"}, "relevance": 0.393417}, {"text": "securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392537}, {"text": "rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383596}, {"text": "service", "sentiment": {"score": 0.899909, "label": "positive"}, "relevance": 0.383213}, {"text": "account", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376552}, {"text": "E-mail", "sentiment": {"score": -0.3546, "label": "negative"}, "relevance": 0.376497}, {"text": "Terms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376329}, {"text": "CO.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374261}, {"text": "time", "sentiment": {"score": -0.286644, "label": "negative"}, "relevance": 0.372804}, {"text": "15 minutes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37193}]}, "extracted_metadata": {"sha1": "61320d0612b0ae10371056c163b7ab136bc576c7", "filename": "1541341843186.zip-57c097bb40db15bd6b5a99f26b61bd53.xml", "file_type": "json"}, "title": "TKPYY 20.04 USD - TeleTrader.com"}, {"id": "7zBce48Z6TD5C1J_Kj2fla4sgq1suKBIvgBWjS3tzvEXsLI4F1FAG3ae4WchA3nq", "result_metadata": {"score": 25.475502}, "author": "Ankush Nikam", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13.0%", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Next Generation Antibody Therapeutics", "keywords": [{"text": "Generation Antibody"}, {"text": "Therapeutics"}]}, "sentence": "Next Generation Antibody Therapeutics is expected to expand at a CAGR of 13.0% during 2015 \u2013 2022", "action": {"verb": {"text": "expand", "tense": "future"}, "text": "is expected to expand", "normalized": "be expect to expand"}}], "concepts": [{"text": "Antibody", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Antibody"}], "categories": [{"score": 0.552296, "label": "/science/medicine/immunology"}, {"score": 0.486704, "label": "/health and fitness/disease"}, {"score": 0.460891, "label": "/science/medicine/pharmacology"}], "relations": [{"type": "populationOf", "sentence": "Next Generation Antibody Therapeutics is expected to expand at a CAGR of 13.0% during 2015 - 2022", "score": 0.674426, "arguments": [{"text": "13.0", "location": [73, 77], "entities": [{"type": "Cardinal", "text": "13.0"}]}, {"text": "CAGR of", "location": [65, 72], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}], "keywords": [{"text": "Generation Antibody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.990426}, {"text": "Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.826072}, {"text": "CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.645886}]}, "crawl_date": "2018-11-04T02:55:38Z", "url": "https://www.findmarketresearch.org/2018/07/next-generation-antibody-therapeutics-market-is-expected-to-expand-at-a-cagr-of-13-0-during-2015-2022/", "host": "findmarketresearch.org", "text": "Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-07-31T07:25:00+05:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Persistence Market Research", "relevance": 0.723051, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.698758, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.385777, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.37779, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.653964, "label": "negative"}, "text": "cancer", "relevance": 0.373767, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 1, "sentiment": {"score": 0.289131, "label": "positive"}, "text": "Kyowa Hakko Kirin Co., Ltd.", "relevance": 0.353071, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.297971, "label": "positive"}, "text": "Seattle", "relevance": 0.340532, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Immunogen", "relevance": 0.333144, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.330087, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amgen, Inc.", "relevance": 0.325361, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dyax Corp.", "relevance": 0.307718, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Xencor, Inc", "relevance": 0.298761, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.276356, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13.0%", "relevance": 0.276356, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "14.5%", "relevance": 0.276356, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.276356, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.0429206, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "by Persistence Market Research \u201cGlobal Market Study on Next-Generation Antibody Therapeutics", "keywords": [{"text": "Next-Generation Antibody"}, {"text": "Persistence Market Research"}, {"text": "Global Market Study"}, {"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": "According to a new market report published by Persistence Market Research \u201cGlobal Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022\u201d, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.", "object": {"text": "a new market report", "keywords": [{"text": "new market report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Biosimilar Antibody Products", "keywords": [{"text": "Biosimilar Antibody"}, {"text": "Products"}]}, "sentence": "According to a new market report published by Persistence Market Research \u201cGlobal Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022\u201d, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.", "object": {"text": "Highest Growth", "keywords": [{"text": "Highest Growth"}]}, "action": {"verb": {"text": "Witness", "tense": "future"}, "text": "to Witness", "normalized": "to Witness"}}, {"subject": {"text": "the global next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}]}, "sentence": "According to a new market report published by Persistence Market Research \u201cGlobal Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022\u201d, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.", "object": {"text": "project to be valued at US$ 2,250.0 Mn", "keywords": [{"text": "Mn"}, {"text": "project"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}]}, "sentence": "According to a new market report published by Persistence Market Research \u201cGlobal Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022\u201d, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.", "object": {"text": "valued at US$ 2,250.0 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "for US$ 6,761.1 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "According to a new market report published by Persistence Market Research \u201cGlobal Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022\u201d, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.", "action": {"verb": {"text": "account", "tense": "future"}, "text": "to account", "normalized": "to account"}}, {"subject": {"text": "Next-generation antibody therapeutics", "keywords": [{"text": "Next-generation antibody"}, {"text": "therapeutics"}]}, "sentence": " Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery.", "object": {"text": "to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery", "keywords": [{"text": "antibody therapeutics"}, {"text": "enhanced efficiency"}, {"text": "greater safety"}, {"text": "delivery"}]}, "action": {"verb": {"text": "refer", "tense": "present"}, "text": "refers", "normalized": "refer"}}, {"subject": {"text": "Advancements in monoclonal antibody technologies", "keywords": [{"text": "monoclonal antibody"}, {"text": "Advancements"}, {"text": "technologies"}]}, "sentence": " Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity.", "object": {"text": "led to the development of next-generation therapeutic antibodies", "keywords": [{"text": "next-generation therapeutic antibodies"}, {"text": "development"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Next-generation antibody-based therapeutics", "keywords": [{"text": "Next-generation antibody-based therapeutics"}]}, "sentence": " Next-generation antibody-based therapeutics enhances existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases.", "object": {"text": "existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases", "keywords": [{"text": "various medical conditions"}, {"text": "therapeutic antibodies"}, {"text": "autoimmune diseases"}, {"text": "infectious diseases"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "enhance", "tense": "present"}, "text": "enhances", "normalized": "enhance"}}, {"subject": {"text": "the next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}]}, "sentence": " Globally, the next-generation antibody therapeutics market is witnessing significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases.", "object": {"text": "witnessing significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases", "keywords": [{"text": "antibody therapeutics"}, {"text": "technological advancements"}, {"text": "significant growth"}, {"text": "chronic diseases"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}]}, "sentence": " Globally, the next-generation antibody therapeutics market is witnessing significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases.", "object": {"text": "significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases", "keywords": [{"text": "antibody therapeutics"}, {"text": "technological advancements"}, {"text": "significant growth"}, {"text": "chronic diseases"}]}, "action": {"verb": {"text": "witness", "tense": "present"}, "text": "is witnessing", "normalized": "be witness"}}, {"subject": {"text": "rising healthcare expenditure and growing R & D activities", "keywords": [{"text": "healthcare expenditure"}, {"text": "activities"}]}, "sentence": " In addition, rising healthcare expenditure and growing R & D activities are driving the growth of the next-generation antibody therapeutics market.", "object": {"text": "the growth of the next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "are driving", "normalized": "be drive"}}, {"subject": {"text": "stringent regulatory requirements and long approval time for new drug", "keywords": [{"text": "stringent regulatory requirements"}, {"text": "long approval time"}, {"text": "new drug"}]}, "sentence": " However, stringent regulatory requirements and long approval time for new drug restrains the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "restrain", "tense": "present"}, "text": "restrains", "normalized": "restrain"}}, {"subject": {"text": "high costs of next-generation antibody therapeutics", "keywords": [{"text": "next-generation antibody"}, {"text": "high costs"}, {"text": "therapeutics"}]}, "sentence": " Similarly, high costs of next-generation antibody therapeutics is a major concern for the market.", "object": {"text": "a major concern for the market", "keywords": [{"text": "major concern"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The North America next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The North America next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%.", "object": {"text": "valued at US$ 1,104.4 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The North America next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%.", "object": {"text": "at US$ 1,104.4 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "is projected to be valued", "normalized": "be project to be value"}}, {"subject": {"text": "for US$ 3,691.8 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%.", "action": {"verb": {"text": "account", "tense": "future"}, "text": "is expected to account", "normalized": "be expect to account"}}, {"subject": {"text": "biosimilar antibody products", "keywords": [{"text": "biosimilar antibody"}, {"text": "products"}]}, "sentence": " On the basis of technology, biosimilar antibody products are the fastest growing segment.", "object": {"text": "the fastest growing segment", "keywords": [{"text": "fastest growing segment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "On the basis of therapeutic application, oncology", "keywords": [{"text": "therapeutic application"}, {"text": "oncology"}, {"text": "basis"}]}, "sentence": " On the basis of therapeutic application, oncology is the largest segment in next-generation antibody therapeutics market.", "object": {"text": "the largest segment", "keywords": [{"text": "largest segment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics, Takeda, Dyax Corp., and Immunogen", "keywords": [{"text": "Immunogen"}, {"text": "Takeda"}, {"text": "Seattle Genetics"}, {"text": "Dyax Corp."}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Dyax Corp."}, {"type": "Person", "text": "Immunogen"}]}, "sentence": " Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen are some of the leading players in the global market of next-generation antibody therapeutics.", "object": {"text": "some of the leading players", "keywords": [{"text": "players"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some of the other major players in next-generation antibody therapeutics market", "keywords": [{"text": "next-generation antibody therapeutics"}, {"text": "major players"}, {"text": "market"}]}, "sentence": " Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.", "object": {"text": "Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc", "keywords": [{"text": "Kyowa Hakko Kirin"}, {"text": "Biogen"}], "entities": [{"type": "Company", "text": "Amgen, Inc."}, {"type": "Company", "text": "Kyowa Hakko Kirin Co., Ltd."}, {"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "Xencor, Inc"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Immune system", "relevance": 0.9777, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Medicine", "relevance": 0.974031, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Antibody", "relevance": 0.633932, "dbpedia_resource": "http://dbpedia.org/resource/Antibody"}, {"text": "Disease", "relevance": 0.610624, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Antigen", "relevance": 0.539307, "dbpedia_resource": "http://dbpedia.org/resource/Antigen"}, {"text": "Immunology", "relevance": 0.531841, "dbpedia_resource": "http://dbpedia.org/resource/Immunology"}, {"text": "Infectious disease", "relevance": 0.50676, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Cancer", "relevance": 0.485039, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Immunohistochemistry", "relevance": 0.483887, "dbpedia_resource": "http://dbpedia.org/resource/Immunohistochemistry"}, {"text": "Market research", "relevance": 0.461587, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Cure", "relevance": 0.458616, "dbpedia_resource": "http://dbpedia.org/resource/Cure"}, {"text": "Epidemiology", "relevance": 0.455182, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Marketing research", "relevance": 0.44675, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_research"}], "categories": [{"score": 0.712416, "label": "/health and fitness/disease"}, {"score": 0.396178, "label": "/health and fitness/disease/cancer"}, {"score": 0.3809, "label": "/health and fitness/therapy"}], "relations": [{"type": "partOf", "sentence": "According to a new market report published by Persistence Market Research \"Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022\", the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.", "score": 0.511639, "arguments": [{"text": "Global Market Study", "location": [75, 94], "entities": [{"type": "Organization", "text": "Global Market Study"}]}, {"text": "Next-Generation Antibody Therapeutics", "location": [98, 135], "entities": [{"type": "Organization", "text": "Next-Generation Antibody Therapeutics"}]}]}, {"type": "locatedAt", "sentence": "According to a new market report published by Persistence Market Research \"Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022\", the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.", "score": 0.507348, "arguments": [{"text": "US$", "location": [285, 288], "entities": [{"type": "Facility", "text": "US$"}]}, {"text": "CAGR of", "location": [350, 357], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "partOfMany", "sentence": "Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc. Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3713", "score": 0.803704, "arguments": [{"text": "Some", "location": [2303, 2307], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [2327, 2334], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "agentOf", "sentence": "Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc. Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3713", "score": 0.958844, "arguments": [{"text": "Xencor, Inc.", "location": [2468, 2480], "entities": [{"type": "Organization", "text": "Xencor, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Request", "location": [2481, 2488], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "hasAttribute", "sentence": "Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc. Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3713", "score": 0.514537, "arguments": [{"text": "Xencor, Inc.", "location": [2468, 2480], "entities": [{"type": "Organization", "text": "Xencor, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "@", "location": [2509, 2510], "entities": [{"type": "Money", "text": "@", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "affectedBy", "sentence": "Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc. Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3713", "score": 0.743787, "arguments": [{"text": "Sample", "location": [2492, 2498], "entities": [{"type": "Person", "text": "Sample"}]}, {"text": "Request", "location": [2481, 2488], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "agentOf", "sentence": "Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc. Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3713", "score": 0.803417, "arguments": [{"text": "Sample", "location": [2492, 2498], "entities": [{"type": "Person", "text": "Sample"}]}, {"text": "Report", "location": [2502, 2508], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}], "keywords": [{"text": "next-generation antibody therapeutics", "sentiment": {"score": -0.411372, "label": "negative"}, "relevance": 0.948758}, {"text": "antibody therapeutics market", "sentiment": {"score": -0.411372, "label": "negative"}, "relevance": 0.762654}, {"text": "global next-generation antibody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.445151}, {"text": "Next-generation antibody-based therapeutics", "sentiment": {"score": -0.653964, "label": "negative"}, "relevance": 0.396045}, {"text": "America next-generation antibody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387956}, {"text": "Biosimilar Antibody Products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334014}, {"text": "monoclonal antibody technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318643}, {"text": "next-generation therapeutic antibodies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.30389}, {"text": "Persistence Market Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.218456}, {"text": "Global Market Study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2167}, {"text": "new market report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.215288}]}, "extracted_metadata": {"sha1": "4b9c6764314f4ee1e78e43174fae5030c0b0fa03", "filename": "1541300138596.zip-efed9d2ee673412a53146716e7590ebc.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/3713", "https://www.persistencemarketresearch.com/market-research/next-generation-antibody-therapeutics-market.asp"], "title": "Next Generation Antibody Therapeutics is expected to expand at a CAGR of 13.0% during 2015 \u2013 2022", "forum_title": "Business \u2013 Page 32 \u2013 Find Market Research"}, {"id": "lBJ6BI7S-oSKH0_AfCHKjMukUWqVNacWeNSaD4cchGWDK6hOy8OPIA4FpbCo9UeE", "result_metadata": {"score": 23.950588}, "author": "Sylvia Overstreet", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Marine Polymer Technologies", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genzyme", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Oncology\u2019s Millennium and Abbott Laboratories", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Abbott Laboratories", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}, {"text": "Biotechnology companies", "relevance": 0.882439, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Valproate semisodium", "relevance": 0.82944, "dbpedia_resource": "http://dbpedia.org/resource/Valproate_semisodium"}], "categories": [{"score": 0.547981, "label": "/health and fitness"}, {"score": 0.483625, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.468294, "label": "/health and fitness/drugs"}], "relations": [{"type": "partOf", "sentence": "Global Marine Derived Drugs Market Analysis and Forecast From 2018 - 23: Marine Polymer Technologies, Genzyme, Takeda Oncology's Millennium and Abbott Laboratories", "score": 0.50782, "arguments": [{"text": "Millennium", "location": [129, 139], "entities": [{"type": "Organization", "text": "Millennium", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda Oncology", "location": [111, 126], "entities": [{"type": "Organization", "text": "Takeda Oncology", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Derived Drugs Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.947251}, {"text": "Marine Polymer Technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.781147}, {"text": "Takeda Oncology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.753194}, {"text": "Abbott Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662118}, {"text": "Genzyme", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427539}, {"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350536}, {"text": "Millennium", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.317749}, {"text": "Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232963}]}, "crawl_date": "2018-11-03T15:13:40Z", "url": "http://registrardaily.com/2018/11/03/global-marine-derived-drugs-market-analysis-and-forecast-from-2018-23-marine-polymer-technologies-genzyme-takeda-oncologys-millennium-and-abbott-laboratories/", "host": "registrardaily.com", "text": "November 3, 2018 | Global Aircraft Turn Indicators Market Analysis and Forecast From 2018 \u2013 23: Bendix, Nu-Tek Aircraft Instruments, Mikrotechna Praha and Tokyo Aircraft Instrument Search for: Global Marine Derived Drugs Market Analysis and Forecast From 2018 \u2013 23: Marine Polymer Technologies, Genzyme, Takeda Oncology\u2019s Millennium and Abbott Laboratories", "main_image_url": "http://registrardaily.com/wp-content/uploads/2018/10/global-marine-derived-drugs-market.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-03T11:10:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Marine Derived Drugs Market", "relevance": 0.994234, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Marine Derived Drugs Market Genzyme", "relevance": 0.959674, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Marine Polymer Technologies", "relevance": 0.298634, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Oncology\u2019s Millennium and Abbott Laboratories", "relevance": 0.123038, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nu-Tek Aircraft Instruments", "relevance": 0.119848, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo Aircraft Instrument Search", "relevance": 0.109692, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genzyme", "relevance": 0.109427, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mikrotechna Praha", "relevance": 0.0937532, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "the supply chain analysis of top Key players", "keywords": [{"text": "supply chain analysis"}, {"text": "Key players"}], "entities": []}, "sentence": "November 3, 2018 | Global Aircraft Turn Indicators Market Analysis and Forecast From 2018 \u2013 23: Bendix, Nu-Tek Aircraft Instruments, Mikrotechna Praha and Tokyo Aircraft Instrument Search for: Global Marine Derived Drugs Market Analysis and Forecast From 2018 \u2013 23: Marine Polymer Technologies, Genzyme, Takeda Oncology\u2019s Millennium and Abbott Laboratories TOPICS: Global Marine Derived Drugs Market Outlook Global Marine Derived Drugs marine derived drugs report covers the supply chain analysis of top Key players.", "object": {"text": "marine derived drugs report", "keywords": [{"text": "marine derived drugs"}, {"text": "report"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "The marine", "keywords": [{"text": "marine"}]}, "sentence": " The marine derived drugs marine derived drugs report.", "object": {"text": "drugs marine derived drugs report", "keywords": [{"text": "marine derived drugs"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "The marine derived drugs marine", "keywords": [{"text": "marine derived drugs"}]}, "sentence": " The marine derived drugs marine derived drugs report.", "object": {"text": "drugs report", "keywords": [{"text": "drugs"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the marine", "keywords": [{"text": "marine"}]}, "sentence": " Also, the marine derived drugs analyses market contribution of each region and marine derived drugs market players.", "object": {"text": "drugs analyses market contribution of each region", "keywords": [{"text": "analyses market contribution"}, {"text": "drugs"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "each region and marine", "keywords": [{"text": "region"}, {"text": "marine"}]}, "sentence": " Also, the marine derived drugs analyses market contribution of each region and marine derived drugs market players.", "object": {"text": "drugs market players", "keywords": [{"text": "drugs market players"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "by the marine derived drugs market", "keywords": [{"text": "marine derived drugs"}, {"text": "market"}]}, "sentence": " Even the import/export details, consumer volume, marine derived drugs manufacturing capacity, and price analysis also provided by the marine derived drugs market.", "object": {"text": "price analysis", "keywords": [{"text": "price analysis"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "also provided", "normalized": "also provide"}}, {"subject": {"text": "Global Marine Derived Drugs Market 2018 report", "keywords": [{"text": "Marine Derived Drugs"}, {"text": "Market"}, {"text": "report"}], "entities": [{"type": "Company", "text": "Global Marine Derived Drugs Market"}]}, "sentence": " Global Marine Derived Drugs Market 2018 report provides a beneficial device to appraise the most recent marine derived drugs market position.", "object": {"text": "a beneficial device", "keywords": [{"text": "beneficial device"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "a beneficial device", "keywords": [{"text": "beneficial device"}]}, "sentence": " Global Marine Derived Drugs Market 2018 report provides a beneficial device to appraise the most recent marine derived drugs market position.", "object": {"text": "the most recent marine derived drugs market position", "keywords": [{"text": "marine derived drugs"}, {"text": "market position"}]}, "action": {"verb": {"text": "appraise", "tense": "future"}, "text": "to appraise", "normalized": "to appraise"}}, {"subject": {"text": "The analysis", "keywords": [{"text": "analysis"}]}, "sentence": " The analysis demonstrates that the marine derived drugs research and methodologies strategy chased to highlight the marine derived drugs report viewpoints.", "object": {"text": "that the marine derived drugs research and methodologies strategy chased to highlight the marine derived drugs report viewpoints", "keywords": [{"text": "marine derived drugs"}, {"text": "drugs research"}, {"text": "methodologies strategy"}, {"text": "viewpoints"}]}, "action": {"verb": {"text": "demonstrate", "tense": "present"}, "text": "demonstrates", "normalized": "demonstrate"}}, {"subject": {"text": "the marine derived drugs research and methodologies strategy", "keywords": [{"text": "marine derived drugs"}, {"text": "methodologies strategy"}, {"text": "research"}]}, "sentence": " The analysis demonstrates that the marine derived drugs research and methodologies strategy chased to highlight the marine derived drugs report viewpoints.", "object": {"text": "the marine derived drugs report viewpoints", "keywords": [{"text": "marine derived drugs"}, {"text": "viewpoints"}]}, "action": {"verb": {"text": "highlight", "tense": "future"}, "text": "to highlight", "normalized": "to highlight"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report evaluated the energetic entire worldwide marine derived drugs marine derived drugs Market.", "object": {"text": "the energetic entire worldwide marine derived drugs marine derived drugs Market", "keywords": [{"text": "marine derived drugs"}, {"text": "Market"}]}, "action": {"verb": {"text": "evaluate", "tense": "past"}, "text": "evaluated", "normalized": "evaluate"}}, {"subject": {"text": "the global marine", "keywords": [{"text": "global marine"}]}, "sentence": " Moreover, that the global marine derived drugs marine-derived-drugs-market/#request-sample Competitive Landscape of Global Marine Derived Drugs Market Inside this section, global competitive landscape and also supply/demand design of this global marine derived drugs current market was studied accurately.", "object": {"text": "drugs", "keywords": [{"text": "drugs"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "global competitive landscape and also supply/demand design of this global marine", "keywords": [{"text": "global competitive landscape"}, {"text": "global marine"}, {"text": "design"}]}, "sentence": " Moreover, that the global marine derived drugs marine-derived-drugs-market/#request-sample Competitive Landscape of Global Marine Derived Drugs Market Inside this section, global competitive landscape and also supply/demand design of this global marine derived drugs current market was studied accurately.", "object": {"text": "drugs current market", "keywords": [{"text": "drugs"}, {"text": "current market"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "global competitive landscape and also supply/demand design of this global marine derived drugs current market", "keywords": [{"text": "marine derived drugs"}, {"text": "global competitive landscape"}, {"text": "current market"}, {"text": "design"}]}, "sentence": " Moreover, that the global marine derived drugs marine-derived-drugs-market/#request-sample Competitive Landscape of Global Marine Derived Drugs Market Inside this section, global competitive landscape and also supply/demand design of this global marine derived drugs current market was studied accurately.", "object": {"text": "studied accurately"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The marine derived drugs report", "keywords": [{"text": "marine derived drugs"}, {"text": "report"}]}, "sentence": " The marine derived drugs report shows the top market players from these company profiles, marine derived drugs product information, construction plants, and capacity, market share, marine derived drugs marine derived drugs marine derived drugs report.", "object": {"text": "the top market players from these company profiles, marine derived drugs product information, construction plants, and capacity, market share, marine derived drugs marine derived drugs marine derived drugs report", "keywords": [{"text": "marine derived drugs"}, {"text": "drugs product information"}, {"text": "company profiles"}, {"text": "construction plants"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "shows", "normalized": "show"}}], "concepts": [{"text": "Marketing", "relevance": 0.897098, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "The Marine", "relevance": 0.7832, "dbpedia_resource": "http://dbpedia.org/resource/The_Marine"}, {"text": "Strategic management", "relevance": 0.761021, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Flight instruments", "relevance": 0.760792, "dbpedia_resource": "http://dbpedia.org/resource/Flight_instruments"}, {"text": "Abbott Laboratories", "relevance": 0.756963, "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}], "categories": [{"score": 0.659687, "label": "/health and fitness"}, {"score": 0.444574, "label": "/health and fitness/drugs"}, {"score": 0.391912, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "partOf", "sentence": "November 3, 2018 | Global Aircraft Turn Indicators Market Analysis and Forecast From 2018 - 23: Bendix, Nu-Tek Aircraft Instruments, Mikrotechna Praha and Tokyo Aircraft Instrument Search for: Global Marine Derived Drugs Market Analysis and Forecast From 2018 - 23: Marine Polymer Technologies, Genzyme, Takeda Oncology's Millennium and Abbott Laboratories TOPICS: Global Marine Derived Drugs Market Outlook Global Marine Derived Drugs marine derived drugs report covers the supply chain analysis of top Key players.", "score": 0.521448, "arguments": [{"text": "Millennium", "location": [322, 332], "entities": [{"type": "Organization", "text": "Millennium", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda Oncology", "location": [304, 319], "entities": [{"type": "Organization", "text": "Takeda Oncology", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Global Marine Derived Drugs Market 2018 report provides a beneficial device to appraise the most recent marine derived drugs market position.", "score": 0.983487, "arguments": [{"text": "2018", "location": [885, 889], "entities": [{"type": "Date", "text": "2018"}]}, {"text": "report", "location": [890, 896], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "locatedAt", "sentence": "This report evaluated the energetic entire worldwide marine derived drugs marine derived drugs Market.", "score": 0.197981, "arguments": [{"text": "drugs", "location": [1237, 1242], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Market", "location": [1243, 1249], "entities": [{"type": "Organization", "text": "Global Marine Derived Drugs Market Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The marine derived drugs report shows the top market players from these company profiles, marine derived drugs product information, construction plants, and capacity, market share, marine derived drugs marine derived drugs marine derived drugs report.", "score": 0.417629, "arguments": [{"text": "players", "location": [1610, 1617], "entities": [{"type": "Person", "text": "players"}]}, {"text": "company", "location": [1629, 1636], "entities": [{"type": "Organization", "text": "company"}]}]}], "keywords": [{"text": "marine derived drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.937345}, {"text": "Derived Drugs Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641311}, {"text": "Global Marine Derived", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540445}, {"text": "Drugs Market Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437671}, {"text": "Drugs Market Outlook", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434558}, {"text": "drugs market players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424145}, {"text": "drugs analyses market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423804}, {"text": "drugs market position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418415}, {"text": "Drugs Market Genzyme", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416831}, {"text": "drugs report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41317}, {"text": "drugs product information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.404978}, {"text": "drugs research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.394277}, {"text": "Marine Polymer Technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355015}, {"text": "Indicators Market Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353411}, {"text": "Nu-Tek Aircraft Instruments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349511}, {"text": "supply chain analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346527}, {"text": "entire worldwide marine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346395}, {"text": "Aircraft Instrument Search", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346336}, {"text": "Abbott Laboratories TOPICS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345482}, {"text": "global competitive landscape", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34009}, {"text": "Top-Rated Important Players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339991}, {"text": "request-sample Competitive Landscape", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.337605}, {"text": "recent marine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330417}, {"text": "Mikrotechna Praha", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326872}, {"text": "Takeda Oncology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326526}, {"text": "current market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325394}, {"text": "Key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325173}, {"text": "market share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324785}, {"text": "price analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.323295}, {"text": "import/export details", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.323252}, {"text": "consumer volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32257}, {"text": "beneficial device", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321719}, {"text": "methodologies strategy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321662}, {"text": "company profiles", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.320296}, {"text": "construction plants", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.320221}, {"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.308849}, {"text": "capacity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.307811}, {"text": "Bendix", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306476}, {"text": "viewpoints", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303997}, {"text": "region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303809}, {"text": "Turn", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303739}, {"text": "contribution", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303668}]}, "extracted_metadata": {"sha1": "be6cc42113bf05b80f671dd9d0aa799afb2b2275", "filename": "1541258020096.zip-089db110c366ec61b6d4a92dba3dd9f8.xml", "file_type": "json"}, "external_links": ["http://reporte.us/global-marine-derived-drugs-market/#request-sample"], "title": "Global Marine Derived Drugs Market Analysis and Forecast From 2018 \u2013 23: Marine Polymer Technologies, Genzyme, Takeda Oncology\u2019s Millennium and Abbott Laboratories", "forum_title": "Registrar Daily"}, {"id": "QuEgPALJ8dFCt6uRvL1rxWM8bmA9-fLPPtoBlZjVG-N2wpUqE5DCggTm5ZFiih9x", "result_metadata": {"score": 22.017199}, "author": "Britt Chester", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.855457, "label": "negative"}, "text": "Marijuana", "relevance": 0.33, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.855457, "label": "negative"}, "text": "Westword", "relevance": 0.33, "type": "PrintMedia", "disambiguation": {"subtype": ["Newspaper"], "name": "Westword", "dbpedia_resource": "http://dbpedia.org/resource/Westword"}}, {"count": 1, "sentiment": {"score": -0.855457, "label": "negative"}, "text": "Denver", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "PlaceWithNeighborhoods", "USCounty", "City"], "name": "Denver", "dbpedia_resource": "http://dbpedia.org/resource/Denver"}}], "sentiment": {"document": {"score": -0.855457, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Feature film", "relevance": 0.908907, "dbpedia_resource": "http://dbpedia.org/resource/Feature_film"}, {"text": "Short film", "relevance": 0.712, "dbpedia_resource": "http://dbpedia.org/resource/Short_film"}, {"text": "Social stigma", "relevance": 0.6928, "dbpedia_resource": "http://dbpedia.org/resource/Social_stigma"}], "categories": [{"score": 0.671731, "label": "/art and entertainment/movies"}, {"score": 0.518725, "label": "/art and entertainment/movies/film festivals and awards"}], "relations": [{"type": "residesIn", "sentence": "Denver Filmmaking Couple Touches on Medical Marijuana's Social Stigma in Short Film | Westword", "score": 0.73257, "arguments": [{"text": "Couple", "location": [18, 24], "entities": [{"type": "Person", "text": "Couple"}]}, {"text": "Denver Filmmaking", "location": [0, 17], "entities": [{"type": "GeopoliticalEntity", "text": "Denver Filmmaking"}]}]}, {"type": "partOfMany", "sentence": "Denver Filmmaking Couple Touches on Medical Marijuana's Social Stigma in Short Film | Westword", "score": 0.974159, "arguments": [{"text": "Touches", "location": [25, 32], "entities": [{"type": "Person", "text": "Touches"}]}, {"text": "Couple", "location": [18, 24], "entities": [{"type": "Person", "text": "Couple"}]}]}, {"type": "employedBy", "sentence": "Denver Filmmaking Couple Touches on Medical Marijuana's Social Stigma in Short Film | Westword", "score": 0.456173, "arguments": [{"text": "Touches", "location": [25, 32], "entities": [{"type": "Person", "text": "Touches"}]}, {"text": "Social Stigma", "location": [56, 69], "entities": [{"type": "Organization", "text": "Social Stigma"}]}]}, {"type": "partOf", "sentence": "Denver Filmmaking Couple Touches on Medical Marijuana's Social Stigma in Short Film | Westword", "score": 0.921458, "arguments": [{"text": "Social Stigma", "location": [56, 69], "entities": [{"type": "Organization", "text": "Social Stigma"}]}, {"text": "Medical Marijuana", "location": [36, 53], "entities": [{"type": "Organization", "text": "Medical Marijuana"}]}]}, {"type": "basedIn", "sentence": "Denver Filmmaking Couple Touches on Medical Marijuana's Social Stigma in Short Film | Westword", "score": 0.734255, "arguments": [{"text": "Social Stigma", "location": [56, 69], "entities": [{"type": "Organization", "text": "Social Stigma"}]}, {"text": "Short Film", "location": [73, 83], "entities": [{"type": "GeopoliticalEntity", "text": "Short Film"}]}]}], "keywords": [{"text": "Filmmaking Couple Touches", "sentiment": {"score": -0.855457, "label": "negative"}, "relevance": 0.942175}, {"text": "Social Stigma", "sentiment": {"score": -0.855457, "label": "negative"}, "relevance": 0.432991}, {"text": "Medical Marijuana", "sentiment": {"score": -0.855457, "label": "negative"}, "relevance": 0.397803}, {"text": "Westword", "sentiment": {"score": -0.855457, "label": "negative"}, "relevance": 0.252293}, {"text": "Short Film", "sentiment": {"score": -0.855457, "label": "negative"}, "relevance": 0.213709}]}, "crawl_date": "2018-11-03T16:00:13Z", "url": "https://www.westword.com/marijuana/denver-filmmaking-couple-touches-on-medical-marijuanas-social-stigma-in-short-film-10969628", "host": "westword.com", "text": "Denver YouTube Series Dives Into Cannabis and Immigration \u201cWe have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about,\u201d says director and co-writer Scott Takeda.", "main_image_url": "https://images1.westword.com/imager/u/original/10969641/scott-takeda-lori-alreder-movie2018.png", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-03T00:00:00-06:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": -0.296352, "label": "negative"}, "text": "medical cannabis", "relevance": 0.939005, "type": "Drug"}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Scott Takeda", "relevance": 0.825251, "type": "Person"}, {"count": 7, "sentiment": {"score": 0.202816, "label": "positive"}, "text": "TBI", "relevance": 0.714207, "type": "HealthCondition", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}, {"count": 5, "sentiment": {"score": 0.450055, "label": "positive"}, "text": "Lori Allred", "relevance": 0.659477, "type": "Person"}, {"count": 6, "sentiment": {"score": -0.527568, "label": "negative"}, "text": "Steve Novak", "relevance": 0.641276, "type": "Person", "disambiguation": {"subtype": ["Athlete", "BasketballPlayer"], "name": "Steve Novak", "dbpedia_resource": "http://dbpedia.org/resource/Steve_Novak"}}, {"count": 5, "sentiment": {"score": 0.32927, "label": "positive"}, "text": "Us", "relevance": 0.542322, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.379416, "label": "negative"}, "text": "Cannabis", "relevance": 0.519114, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.486101, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.0174163, "label": "positive"}, "text": "Denver", "relevance": 0.483689, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "PlaceWithNeighborhoods", "USCounty", "City"], "name": "Denver", "dbpedia_resource": "http://dbpedia.org/resource/Denver"}}, {"count": 1, "sentiment": {"score": -0.379416, "label": "negative"}, "text": "TBI", "relevance": 0.353772, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.82219, "label": "positive"}, "text": "director", "relevance": 0.340237, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.472207, "label": "negative"}, "text": "Nancy Reagan", "relevance": 0.303929, "type": "Person", "disambiguation": {"subtype": ["AwardWinner", "OfficeHolder", "FilmActor", "TVActor"], "name": "Nancy Reagan", "dbpedia_resource": "http://dbpedia.org/resource/Nancy_Reagan"}}, {"count": 1, "sentiment": {"score": -0.436546, "label": "negative"}, "text": "YouTube", "relevance": 0.303245, "type": "Company", "disambiguation": {"subtype": ["Website", "BroadcastDistributor", "FilmDistributor", "VentureFundedCompany", "AwardWinner"], "name": "YouTube", "dbpedia_resource": "http://dbpedia.org/resource/YouTube"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "KCNC", "relevance": 0.288391, "type": "Organization", "disambiguation": {"subtype": ["Broadcast", "AwardWinner", "TVProducer", "TelevisionStation"], "name": "KCNC-TV", "dbpedia_resource": "http://dbpedia.org/resource/KCNC-TV"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kate", "relevance": 0.27993, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.298886, "label": "negative"}, "text": "CBS", "relevance": 0.240444, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "producer", "relevance": 0.235682, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dani Payne", "relevance": 0.229372, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cheech", "relevance": 0.228746, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mike OStroski", "relevance": 0.213307, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chong", "relevance": 0.200645, "type": "Person"}], "sentiment": {"document": {"score": -0.152564, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "We"}, "sentence": " \u201cWe have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about,\u201d says director and co-writer Scott Takeda.", "object": {"text": "a history of creating films that start the conversation", "keywords": [{"text": "conversation"}, {"text": "history"}, {"text": "films"}], "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about,\u201d says director and co-writer Scott Takeda.", "object": {"text": "films that start the conversation", "keywords": [{"text": "conversation"}, {"text": "films"}], "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "creating", "normalized": "create"}}, {"subject": {"text": "a history of creating films", "keywords": [{"text": "history"}, {"text": "films"}], "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " \u201cWe have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about,\u201d says director and co-writer Scott Takeda.", "object": {"text": "the conversation", "keywords": [{"text": "conversation"}]}, "action": {"verb": {"text": "start", "tense": "present"}, "text": "start", "normalized": "start"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " \u201cWe have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about,\u201d says director and co-writer Scott Takeda.", "object": {"text": "n\u2019t", "keywords": [{"text": "n\u2019t"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "people don\u2019t", "keywords": [{"text": "people"}]}, "sentence": " \u201cWe have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about,\u201d says director and co-writer Scott Takeda.", "object": {"text": "to talk about"}, "action": {"verb": {"text": "want", "tense": "present"}, "text": "want", "normalized": "want"}}, {"subject": {"text": "director and co-writer Scott Takeda", "keywords": [{"text": "co-writer Scott Takeda"}, {"text": "director"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Person", "text": "Scott Takeda"}]}, "sentence": " \u201cWe have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about,\u201d says director and co-writer Scott Takeda.", "object": {"text": "We have a history of creating films that start the conversation, especially on topics that people don\u2019t necessarily want to talk about", "keywords": [{"text": "conversation"}, {"text": "history"}, {"text": "films"}, {"text": "topics"}], "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "says", "normalized": "say"}}, {"subject": {"text": "Takeda, a former producer with Denver CBS affiliate KCNC,", "keywords": [{"text": "CBS affiliate KCNC"}, {"text": "Takeda"}, {"text": "producer"}, {"text": "Denver"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "JobTitle", "text": "producer"}, {"type": "Location", "text": "Denver", "disambiguation": {"subtype": ["AdministrativeDivision", "PlaceWithNeighborhoods", "USCounty", "CityTown", "City"], "name": "Denver", "dbpedia_resource": "http://dbpedia.org/resource/Denver"}}, {"type": "Company", "text": "CBS"}, {"type": "Organization", "text": "KCNC", "disambiguation": {"subtype": ["Broadcast", "AwardWinner", "TVProducer", "TelevisionStation"], "name": "KCNC-TV", "dbpedia_resource": "http://dbpedia.org/resource/KCNC-TV"}}]}, "sentence": " In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "object": {"text": "a traumatic brain injury (TBI) that he and his wife, Lori Allred", "keywords": [{"text": "traumatic brain injury"}, {"text": "Lori Allred"}, {"text": "TBI"}, {"text": "wife"}], "entities": [{"type": "Organization", "text": "TBI"}, {"type": "Person", "text": "Lori Allred"}]}, "action": {"verb": {"text": "experience", "tense": "past"}, "text": "experienced", "normalized": "experience"}}, {"subject": {"text": "he and his wife, Lori Allred,", "keywords": [{"text": "Lori Allred"}, {"text": "wife"}], "entities": [{"type": "Person", "text": "Lori Allred"}]}, "sentence": " In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "object": {"text": "all"}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "he and his wife, Lori Allred,", "keywords": [{"text": "Lori Allred"}, {"text": "wife"}], "entities": [{"type": "Person", "text": "Lori Allred"}]}, "sentence": " In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "action": {"verb": {"text": "keep", "tense": "past"}, "text": "kept", "normalized": "keep"}}, {"subject": {"text": "herself", "entities": [{"type": "Person", "text": "Lori Allred"}]}, "sentence": " Allred, who herself boasts impressive credentials in directing and writing , is listed as a co-writer and director of the film.", "object": {"text": "impressive credentials in directing and writing", "keywords": [{"text": "impressive credentials"}]}, "action": {"verb": {"text": "boast", "tense": "present"}, "text": "boasts", "normalized": "boast"}}, {"subject": {"text": "Remembering Us", "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Remembering Us is an autobiographical account of Takeda's injury.", "object": {"text": "an autobiographical account of Takeda's injury", "keywords": [{"text": "autobiographical account"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The film", "keywords": [{"text": "film"}], "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The film takes place in Denver, and follows Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving: Steve suffers a TBI, and Kate is pushed into the position of caregiver and wife.", "object": {"text": "place", "keywords": [{"text": "place"}]}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "takes", "normalized": "take"}}, {"subject": {"text": "The film", "keywords": [{"text": "film"}], "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The film takes place in Denver, and follows Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving: Steve suffers a TBI, and Kate is pushed into the position of caregiver and wife.", "object": {"text": "Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving", "keywords": [{"text": "Dani Payne"}, {"text": "Mike OStroski"}, {"text": "Novak"}, {"text": "tribulations"}], "entities": [{"type": "Person", "text": "Kate"}, {"type": "Person", "text": "Dani Payne"}, {"type": "Person", "text": "Steve Novak"}, {"type": "Person", "text": "Mike OStroski"}, {"type": "Person", "text": "Steve Novak"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "follows", "normalized": "follow"}}, {"subject": {"text": "by Dani Payne) and Steve (Mike OStroski) Novak", "keywords": [{"text": "Dani Payne"}, {"text": "Novak"}, {"text": "Mike OStroski"}, {"text": "Steve"}], "entities": [{"type": "Person", "text": "Dani Payne"}, {"type": "Person", "text": "Steve Novak"}, {"type": "Person", "text": "Mike OStroski"}, {"type": "Person", "text": "Steve Novak"}]}, "sentence": " The film takes place in Denver, and follows Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving: Steve suffers a TBI, and Kate is pushed into the position of caregiver and wife.", "object": {"text": "Kate", "keywords": [{"text": "Kate"}], "entities": [{"type": "Person", "text": "Kate"}]}, "action": {"verb": {"text": "play", "tense": "past"}, "text": "played", "normalized": "play"}}, {"subject": {"text": "Steve", "keywords": [{"text": "Steve"}], "entities": [{"type": "Person", "text": "Steve Novak"}]}, "sentence": " The film takes place in Denver, and follows Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving: Steve suffers a TBI, and Kate is pushed into the position of caregiver and wife.", "object": {"text": "a TBI", "keywords": [{"text": "TBI"}], "entities": [{"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffers", "normalized": "suffer"}}, {"subject": {"text": "Kate", "keywords": [{"text": "Kate"}], "entities": [{"type": "Person", "text": "Kate"}]}, "sentence": " The film takes place in Denver, and follows Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving: Steve suffers a TBI, and Kate is pushed into the position of caregiver and wife.", "object": {"text": "pushed into the position of caregiver and wife", "keywords": [{"text": "caregiver"}, {"text": "position"}, {"text": "wife"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Kate", "keywords": [{"text": "Kate"}], "entities": [{"type": "Person", "text": "Kate"}]}, "sentence": " The film takes place in Denver, and follows Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving: Steve suffers a TBI, and Kate is pushed into the position of caregiver and wife.", "object": {"text": "into the position of caregiver and wife", "keywords": [{"text": "caregiver"}, {"text": "position"}, {"text": "wife"}]}, "action": {"verb": {"text": "push", "tense": "past"}, "text": "is pushed", "normalized": "be push"}}, {"subject": {"text": "they", "entities": [{"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}]}, "sentence": " On top of the stigma of TBIs and how they affect the individual, the story of using medical cannabis to treat Steve's medical issue is introduced.", "object": {"text": "the individual"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affect", "normalized": "affect"}}, {"subject": {"text": "medical cannabis", "keywords": [{"text": "medical cannabis"}], "entities": [{"type": "Drug", "text": "medical cannabis"}]}, "sentence": " On top of the stigma of TBIs and how they affect the individual, the story of using medical cannabis to treat Steve's medical issue is introduced.", "object": {"text": "to treat Steve's medical issue", "keywords": [{"text": "medical issue"}, {"text": "Steve"}], "entities": [{"type": "Person", "text": "Steve Novak"}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "using", "normalized": "use"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Steve Novak"}]}, "sentence": " \u201cIn the story, in the early part of the story, he (Steve Novak) has to fire someone at his workplace for not passing a drug test,\u201d Allred explains.", "object": {"text": "someone at his workplace", "keywords": [{"text": "workplace"}]}, "action": {"verb": {"text": "fire", "tense": "future"}, "text": "has to fire", "normalized": "have to fire"}}, {"subject": {"text": "Allred", "entities": [{"type": "Person", "text": "Lori Allred"}]}, "sentence": " \u201cIn the story, in the early part of the story, he (Steve Novak) has to fire someone at his workplace for not passing a drug test,\u201d Allred explains.", "object": {"text": "In the story, in the early part of the story, he (Steve Novak) has to fire someone at his workplace for not passing a drug test", "keywords": [{"text": "Steve Novak"}, {"text": "drug test"}, {"text": "workplace"}, {"text": "story"}], "entities": [{"type": "Person", "text": "Steve Novak"}, {"type": "Person", "text": "Steve Novak", "disambiguation": {"subtype": ["Athlete", "BasketballPlayer"], "name": "Steve Novak", "dbpedia_resource": "http://dbpedia.org/resource/Steve_Novak"}}]}, "action": {"verb": {"text": "explain", "tense": "present"}, "text": "explains", "normalized": "explain"}}, {"subject": {"text": "He"}, "sentence": " \u201cHe has a fear of using cannabis, because he may lose his own job.", "object": {"text": "a fear of using cannabis", "keywords": [{"text": "cannabis"}, {"text": "fear"}], "entities": [{"type": "Drug", "text": "medical cannabis"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "He"}, "sentence": " \u201cHe has a fear of using cannabis, because he may lose his own job.", "object": {"text": "cannabis", "keywords": [{"text": "cannabis"}], "entities": [{"type": "Drug", "text": "medical cannabis"}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "using", "normalized": "use"}}, {"subject": {"text": "he"}, "sentence": " \u201cHe has a fear of using cannabis, because he may lose his own job.", "object": {"text": "his own job", "keywords": [{"text": "job"}]}, "action": {"verb": {"text": "lose", "tense": "future"}, "text": "may lose", "normalized": "may lose"}}, {"subject": {"text": "he"}, "sentence": " But he tries many other things that are not effective for him.", "object": {"text": "many other things that are not effective for him", "keywords": [{"text": "things"}]}, "action": {"verb": {"text": "try", "tense": "present"}, "text": "tries", "normalized": "try"}}, {"subject": {"text": "many other things", "keywords": [{"text": "things"}]}, "sentence": " But he tries many other things that are not effective for him.", "object": {"text": "not effective for him"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "a long time to just try the cannabis", "keywords": [{"text": "long time"}, {"text": "cannabis"}], "entities": [{"type": "Drug", "text": "medical cannabis"}]}, "sentence": " It takes him a long time to just try the cannabis.\u201d", "object": {"text": "him"}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "takes", "normalized": "take"}}, {"subject": {"text": "him"}, "sentence": " It takes him a long time to just try the cannabis.\u201d", "object": {"text": "the cannabis", "keywords": [{"text": "cannabis"}], "entities": [{"type": "Drug", "text": "medical cannabis"}]}, "action": {"verb": {"text": "try", "tense": "present"}, "text": "to just try", "normalized": "to just try"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, "sentence": " Following his TBI, Takeda found himself searching for a pain management plan that worked for him and his career.", "object": {"text": "himself searching for a pain management plan that worked for him and his career", "keywords": [{"text": "pain management plan"}, {"text": "career"}]}, "action": {"verb": {"text": "find", "tense": "past"}, "text": "found", "normalized": "find"}}, {"subject": {"text": "he"}, "sentence": " At the suggestion of his wife, he opted to try medical cannabis to treat some of the issues that arose from his TBI.", "object": {"text": "to try medical cannabis to treat some of the issues that arose from his TBI", "keywords": [{"text": "medical cannabis"}, {"text": "TBI"}, {"text": "issues"}], "entities": [{"type": "Drug", "text": "medical cannabis"}, {"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}]}, "action": {"verb": {"text": "opt", "tense": "past"}, "text": "opted", "normalized": "opt"}}, {"subject": {"text": "he"}, "sentence": " At the suggestion of his wife, he opted to try medical cannabis to treat some of the issues that arose from his TBI.", "object": {"text": "medical cannabis to treat some of the issues that arose from his TBI", "keywords": [{"text": "medical cannabis"}, {"text": "TBI"}, {"text": "issues"}], "entities": [{"type": "Drug", "text": "medical cannabis"}, {"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}]}, "action": {"verb": {"text": "try", "tense": "future"}, "text": "opted to try", "normalized": "opt to try"}}, {"subject": {"text": "I"}, "sentence": " \u201cI think, for me, I had this stereotype: Cheech and Chong smoking these big bongs...Lori suggested if I thought about medical cannabis, and that\u2019s what I was thinking, that I was going to have to smoke something,\u201d Takeda says.", "object": {"text": "this stereotype", "keywords": [{"text": "stereotype"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Lori", "keywords": [{"text": "Lori"}], "entities": [{"type": "Person", "text": "Lori Allred"}]}, "sentence": " \u201cI think, for me, I had this stereotype: Cheech and Chong smoking these big bongs...Lori suggested if I thought about medical cannabis, and that\u2019s what I was thinking, that I was going to have to smoke something,\u201d Takeda says.", "object": {"text": "if I thought about medical cannabis, and that\u2019s what I was thinking, that I was going to have to smoke something", "keywords": [{"text": "medical cannabis"}], "entities": [{"type": "Drug", "text": "medical cannabis"}]}, "action": {"verb": {"text": "suggest", "tense": "past"}, "text": "suggested", "normalized": "suggest"}}, {"subject": {"text": "I"}, "sentence": " \u201cThen I found out there\u2019s all these ways to take it, and the most effective for TBIs is a tincture you put orally in your mouth.\u201d", "object": {"text": "these ways to take it, and the most effective for TBIs is a tincture you put orally in your mouth", "keywords": [{"text": "TBIs"}, {"text": "tincture"}, {"text": "mouth"}, {"text": "ways"}], "entities": [{"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}]}, "action": {"verb": {"text": "find", "tense": "past"}, "text": "found", "normalized": "find"}}, {"subject": {"text": "you"}, "sentence": " \u201cThen I found out there\u2019s all these ways to take it, and the most effective for TBIs is a tincture you put orally in your mouth.\u201d", "object": {"text": "a tincture", "keywords": [{"text": "tincture"}]}, "action": {"verb": {"text": "put", "tense": "past"}, "text": "put", "normalized": "put"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, "sentence": " Takeda admits he struggled initially with the idea of using medical cannabis due to his exposure to Nancy Reagan\u2019s heavily publicized Just Say No campaign in the '80s and '90s.", "object": {"text": "he struggled initially with the idea of using medical cannabis due to his exposure to Nancy Reagan\u2019s heavily publicized Just Say No campaign in the '80s and '90s", "keywords": [{"text": "Nancy Reagan"}, {"text": "medical cannabis"}, {"text": "90s"}, {"text": "idea"}], "entities": [{"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}, {"type": "Drug", "text": "medical cannabis"}, {"type": "Person", "text": "Nancy Reagan", "disambiguation": {"subtype": ["AwardWinner", "OfficeHolder", "FilmActor", "TVActor"], "name": "Nancy Reagan", "dbpedia_resource": "http://dbpedia.org/resource/Nancy_Reagan"}}]}, "action": {"verb": {"text": "admit", "tense": "present"}, "text": "admits", "normalized": "admit"}}, {"subject": {"text": "he", "entities": [{"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}]}, "sentence": " Takeda admits he struggled initially with the idea of using medical cannabis due to his exposure to Nancy Reagan\u2019s heavily publicized Just Say No campaign in the '80s and '90s.", "object": {"text": "with the idea of using medical cannabis due to his exposure to Nancy Reagan\u2019s heavily publicized Just Say No campaign in the '80s and '90s", "keywords": [{"text": "Nancy Reagan"}, {"text": "medical cannabis"}, {"text": "90s"}, {"text": "idea"}], "entities": [{"type": "Drug", "text": "medical cannabis"}, {"type": "Person", "text": "Nancy Reagan", "disambiguation": {"subtype": ["AwardWinner", "OfficeHolder", "FilmActor", "TVActor"], "name": "Nancy Reagan", "dbpedia_resource": "http://dbpedia.org/resource/Nancy_Reagan"}}]}, "action": {"verb": {"text": "struggle", "tense": "past"}, "text": "struggled", "normalized": "struggle"}}, {"subject": {"text": "he", "entities": [{"type": "HealthCondition", "text": "TBI", "disambiguation": {"subtype": ["RiskFactor"], "name": "Injury", "dbpedia_resource": "http://dbpedia.org/resource/Injury"}}]}, "sentence": " Takeda admits he struggled initially with the idea of using medical cannabis due to his exposure to Nancy Reagan\u2019s heavily publicized Just Say No campaign in the '80s and '90s.", "object": {"text": "medical cannabis", "keywords": [{"text": "medical cannabis"}], "entities": [{"type": "Drug", "text": "medical cannabis"}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "using", "normalized": "use"}}, {"subject": {"text": "Nancy Reagan", "keywords": [{"text": "Nancy Reagan"}], "entities": [{"type": "Person", "text": "Nancy Reagan", "disambiguation": {"subtype": ["AwardWinner", "OfficeHolder", "FilmActor", "TVActor"], "name": "Nancy Reagan", "dbpedia_resource": "http://dbpedia.org/resource/Nancy_Reagan"}}]}, "sentence": " Takeda admits he struggled initially with the idea of using medical cannabis due to his exposure to Nancy Reagan\u2019s heavily publicized Just Say No campaign in the '80s and '90s.", "object": {"text": "publicized Just Say No campaign in the '80s and '90s", "keywords": [{"text": "90s"}, {"text": "80s"}, {"text": "campaign"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "Just Say No campaign", "keywords": [{"text": "campaign"}]}, "sentence": " Takeda admits he struggled initially with the idea of using medical cannabis due to his exposure to Nancy Reagan\u2019s heavily publicized Just Say No campaign in the '80s and '90s.", "action": {"verb": {"text": "publicize", "tense": "past"}, "text": "heavily publicized", "normalized": "heavily publicize"}}, {"subject": {"text": "This struggle", "keywords": [{"text": "struggle"}]}, "sentence": " This struggle is portrayed in the film as both a professional and internal struggle.", "object": {"text": "portrayed in the film", "keywords": [{"text": "film"}], "entities": [{"type": "Location", "text": "Us", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This struggle", "keywords": [{"text": "struggle"}]}, "sentence": " This struggle is portrayed in the film as both a professional and internal struggle.", "action": {"verb": {"text": "portray", "tense": "past"}, "text": "is portrayed", "normalized": "be portray"}}, {"subject": {"text": "you"}, "sentence": " If you like this story, consider signing up for our email newsletters.", "object": {"text": "for our email newsletters", "keywords": [{"text": "email newsletters"}]}, "action": {"verb": {"text": "sign", "tense": "present"}, "text": "consider signing", "normalized": "consider sign"}}], "concepts": [{"text": "Traumatic brain injury", "relevance": 0.965447, "dbpedia_resource": "http://dbpedia.org/resource/Traumatic_brain_injury"}, {"text": "Cheech & Chong", "relevance": 0.631564, "dbpedia_resource": "http://dbpedia.org/resource/Cheech_&_Chong"}, {"text": "American film actors", "relevance": 0.558403, "dbpedia_resource": "http://dbpedia.org/resource/American_film_actors"}, {"text": "Thought", "relevance": 0.5398, "dbpedia_resource": "http://dbpedia.org/resource/Thought"}, {"text": "Suffering", "relevance": 0.495905, "dbpedia_resource": "http://dbpedia.org/resource/Suffering"}, {"text": "Cheech Marin", "relevance": 0.484369, "dbpedia_resource": "http://dbpedia.org/resource/Cheech_Marin"}, {"text": "Cannabis sativa", "relevance": 0.483042, "dbpedia_resource": "http://dbpedia.org/resource/Cannabis_sativa"}, {"text": "Pain", "relevance": 0.472148, "dbpedia_resource": "http://dbpedia.org/resource/Pain"}, {"text": "Film director", "relevance": 0.46431, "dbpedia_resource": "http://dbpedia.org/resource/Film_director"}, {"text": "Mind", "relevance": 0.453772, "dbpedia_resource": "http://dbpedia.org/resource/Mind"}, {"text": "Director", "relevance": 0.447162, "dbpedia_resource": "http://dbpedia.org/resource/Director"}, {"text": "Caregiver", "relevance": 0.44712, "dbpedia_resource": "http://dbpedia.org/resource/Caregiver"}, {"text": "Tommy Chong", "relevance": 0.446483, "dbpedia_resource": "http://dbpedia.org/resource/Tommy_Chong"}, {"text": "Steve Novak", "relevance": 0.437781, "dbpedia_resource": "http://dbpedia.org/resource/Steve_Novak"}, {"text": "Struggle", "relevance": 0.436006, "dbpedia_resource": "http://dbpedia.org/resource/Struggle"}, {"text": "American television actors", "relevance": 0.431871, "dbpedia_resource": "http://dbpedia.org/resource/American_television_actors"}, {"text": "Cannabis", "relevance": 0.4301, "dbpedia_resource": "http://dbpedia.org/resource/Cannabis"}, {"text": "Medical cannabis", "relevance": 0.422968, "dbpedia_resource": "http://dbpedia.org/resource/Medical_cannabis"}], "categories": [{"score": 0.564356, "label": "/health and fitness"}, {"score": 0.492431, "label": "/health and fitness/addiction/smoking addiction"}, {"score": 0.443102, "label": "/family and parenting/children"}], "relations": [{"type": "basedIn", "sentence": "Denver YouTube Series Dives Into Cannabis and Immigration \"We have a history of creating films that start the conversation, especially on topics that people don't necessarily want to talk about,\" says director and co-writer Scott Takeda.", "score": 0.911422, "arguments": [{"text": "YouTube Series Dives Into Cannabis", "location": [7, 41], "entities": [{"type": "Organization", "text": "YouTube Series Dives Into Cannabis"}]}, {"text": "Denver", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "Denver"}]}]}, {"type": "agentOf", "sentence": "\"In the story, in the early part of the story, he (Steve Novak) has to fire someone at his workplace for not passing a drug test,\" Allred explains.", "score": 0.996953, "arguments": [{"text": "Allred", "location": [1127, 1133], "entities": [{"type": "Person", "text": "Lori Allred"}]}, {"text": "explains", "location": [1134, 1142], "entities": [{"type": "EventCommunication", "text": "explains"}]}]}, {"type": "spouseOf", "sentence": "At the suggestion of his wife, he opted to try medical cannabis to treat some of the issues that arose from his TBI.", "score": 0.650719, "arguments": [{"text": "his", "location": [1460, 1463], "entities": [{"type": "Person", "text": "Steve Novak"}]}, {"text": "wife", "location": [1464, 1468], "entities": [{"type": "Person", "text": "Lori Allred"}]}]}, {"type": "agentOf", "sentence": "\"I think, for me, I had this stereotype: Cheech and Chong smoking these big bongs...Lori suggested if I thought about medical cannabis, and that's what I was thinking, that I was going to have to smoke something,\" Takeda says.", "score": 0.994933, "arguments": [{"text": "Lori", "location": [1640, 1644], "entities": [{"type": "Person", "text": "Lori Allred"}]}, {"text": "suggested", "location": [1645, 1654], "entities": [{"type": "EventCommunication", "text": "suggested"}]}]}, {"type": "agentOf", "sentence": "\"I think, for me, I had this stereotype: Cheech and Chong smoking these big bongs...Lori suggested if I thought about medical cannabis, and that's what I was thinking, that I was going to have to smoke something,\" Takeda says.", "score": 0.997936, "arguments": [{"text": "Takeda", "location": [1770, 1776], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, {"text": "says", "location": [1777, 1781], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "agentOf", "sentence": "Denver YouTube Series Dives Into Cannabis and Immigration \"We have a history of creating films that start the conversation, especially on topics that people don't necessarily want to talk about,\" says director and co-writer Scott Takeda.", "score": 0.80036, "arguments": [{"text": "director", "location": [201, 209], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, {"text": "says", "location": [196, 200], "entities": [{"type": "EventCommunication", "text": "explains"}]}]}, {"type": "employedBy", "sentence": "In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "score": 0.679844, "arguments": [{"text": "producer", "location": [264, 272], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, {"text": "affiliate", "location": [289, 298], "entities": [{"type": "Organization", "text": "KCNC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "score": 0.473088, "arguments": [{"text": "producer", "location": [264, 272], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, {"text": "KCNC", "location": [299, 303], "entities": [{"type": "Organization", "text": "KCNC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "score": 0.591695, "arguments": [{"text": "CBS", "location": [285, 288], "entities": [{"type": "Organization", "text": "CBS", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Denver", "location": [278, 284], "entities": [{"type": "GeopoliticalEntity", "text": "Denver"}]}]}, {"type": "partOf", "sentence": "In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "score": 0.348496, "arguments": [{"text": "affiliate", "location": [289, 298], "entities": [{"type": "Organization", "text": "KCNC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CBS", "location": [285, 288], "entities": [{"type": "Organization", "text": "CBS", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "spouseOf", "sentence": "In 2015, Takeda, a former producer with Denver CBS affiliate KCNC, experienced a traumatic brain injury (TBI) that he and his wife, Lori Allred, had all but kept private until now.", "score": 0.716756, "arguments": [{"text": "his", "location": [360, 363], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, {"text": "wife", "location": [364, 368], "entities": [{"type": "Person", "text": "Lori Allred"}]}]}, {"type": "playsRoleOf", "sentence": "The film takes place in Denver, and follows Kate (played by Dani Payne) and Steve (Mike OStroski) Novak through the trials and tribulations of caregiving: Steve suffers a TBI, and Kate is pushed into the position of caregiver and wife.", "score": 0.413227, "arguments": [{"text": "Mike OStroski", "location": [696, 709], "entities": [{"type": "Person", "text": "Mike OStroski"}]}, {"text": "Steve", "location": [689, 694], "entities": [{"type": "Person", "text": "Steve Novak"}]}]}, {"type": "agentOf", "sentence": "\"In the story, in the early part of the story, he (Steve Novak) has to fire someone at his workplace for not passing a drug test,\" Allred explains.", "score": 0.406225, "arguments": [{"text": "Steve Novak", "location": [1047, 1058], "entities": [{"type": "Person", "text": "Steve Novak"}]}, {"text": "fire", "location": [1067, 1071], "entities": [{"type": "EventPersonnel", "text": "fire"}]}]}, {"type": "affectedBy", "sentence": "\"In the story, in the early part of the story, he (Steve Novak) has to fire someone at his workplace for not passing a drug test,\" Allred explains.", "score": 0.967525, "arguments": [{"text": "someone", "location": [1072, 1079], "entities": [{"type": "Person", "text": "Scott Takeda"}]}, {"text": "fire", "location": [1067, 1071], "entities": [{"type": "EventPersonnel", "text": "fire"}]}]}], "keywords": [{"text": "medical cannabis", "sentiment": {"score": -0.36588, "label": "negative"}, "relevance": 0.974241}, {"text": "co-writer Scott Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.888349}, {"text": "YouTube Series Dives", "sentiment": {"score": -0.379416, "label": "negative"}, "relevance": 0.704109}, {"text": "CBS affiliate KCNC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.685559}, {"text": "traumatic brain injury", "sentiment": {"score": 0.366359, "label": "positive"}, "relevance": 0.657272}, {"text": "pain management plan", "sentiment": {"score": -0.438169, "label": "negative"}, "relevance": 0.608953}, {"text": "Lori Allred", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536993}, {"text": "TBI", "sentiment": {"score": -0.55024, "label": "negative"}, "relevance": 0.47368}, {"text": "Steve Novak", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460585}, {"text": "Dani Payne", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.456154}, {"text": "autobiographical account", "sentiment": {"score": -0.84565, "label": "negative"}, "relevance": 0.455468}, {"text": "impressive credentials", "sentiment": {"score": 0.700085, "label": "positive"}, "relevance": 0.452491}, {"text": "big bongs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443918}, {"text": "Mike OStroski", "sentiment": {"score": 0.202816, "label": "positive"}, "relevance": 0.443522}, {"text": "medical issue", "sentiment": {"score": -0.392746, "label": "negative"}, "relevance": 0.440445}, {"text": "long time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436846}, {"text": "drug test", "sentiment": {"score": -0.4039, "label": "negative"}, "relevance": 0.435709}, {"text": "Chong smoking", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424655}, {"text": "email newsletters", "sentiment": {"score": 0.378611, "label": "positive"}, "relevance": 0.422946}, {"text": "internal struggle", "sentiment": {"score": 0.624636, "label": "positive"}, "relevance": 0.419225}, {"text": "Nancy Reagan", "sentiment": {"score": -0.298886, "label": "negative"}, "relevance": 0.415065}, {"text": "story", "sentiment": {"score": -0.392746, "label": "negative"}, "relevance": 0.360684}, {"text": "wife", "sentiment": {"score": -0.472207, "label": "negative"}, "relevance": 0.35821}, {"text": "TBIs", "sentiment": {"score": 0.148593, "label": "positive"}, "relevance": 0.346653}, {"text": "Denver", "sentiment": {"score": 0.0348326, "label": "positive"}, "relevance": 0.33923}, {"text": "film", "sentiment": {"score": 0.620358, "label": "positive"}, "relevance": 0.327999}, {"text": "director", "sentiment": {"score": 0.82219, "label": "positive"}, "relevance": 0.289917}, {"text": "Kate", "sentiment": {"score": -0.472207, "label": "negative"}, "relevance": 0.285369}, {"text": "tincture", "sentiment": {"score": 0.675932, "label": "positive"}, "relevance": 0.256596}, {"text": "stereotype", "sentiment": {"score": -0.539015, "label": "negative"}, "relevance": 0.255358}, {"text": "Cheech", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253439}, {"text": "stigma", "sentiment": {"score": -0.527339, "label": "negative"}, "relevance": 0.253376}, {"text": "tribulations", "sentiment": {"score": -0.500616, "label": "negative"}, "relevance": 0.250344}, {"text": "caregiver", "sentiment": {"score": -0.472207, "label": "negative"}, "relevance": 0.248669}, {"text": "Immigration", "sentiment": {"score": -0.379416, "label": "negative"}, "relevance": 0.246499}, {"text": "history", "sentiment": {"score": 0.630928, "label": "positive"}, "relevance": 0.246199}, {"text": "films", "sentiment": {"score": 0.630928, "label": "positive"}, "relevance": 0.246166}, {"text": "topics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246077}, {"text": "people", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246055}, {"text": "suggestion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245753}, {"text": "conversation", "sentiment": {"score": 0.630928, "label": "positive"}, "relevance": 0.244863}, {"text": "producer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.243269}, {"text": "things", "sentiment": {"score": -0.835425, "label": "negative"}, "relevance": 0.242614}, {"text": "place", "sentiment": {"score": 0.414248, "label": "positive"}, "relevance": 0.241867}, {"text": "trials", "sentiment": {"score": -0.500616, "label": "negative"}, "relevance": 0.241641}, {"text": "job", "sentiment": {"score": -0.477921, "label": "negative"}, "relevance": 0.241209}, {"text": "individual", "sentiment": {"score": -0.527339, "label": "negative"}, "relevance": 0.241057}, {"text": "90s", "sentiment": {"score": -0.298886, "label": "negative"}, "relevance": 0.240653}, {"text": "fear", "sentiment": {"score": -0.648546, "label": "negative"}, "relevance": 0.239466}, {"text": "career", "sentiment": {"score": -0.438169, "label": "negative"}, "relevance": 0.238794}]}, "extracted_metadata": {"sha1": "a7e947f4860bf7e30b13292f9104aa68973c4bc4", "filename": "1541260813330.zip-f768bbc9d570005932ac7bcfe851b4da.xml", "file_type": "json"}, "title": "Denver Filmmaking Couple Touches on Medical Marijuana's Social Stigma in Short Film | Westword"}, {"id": "T_PFJgSr6EiIpgnSs7OQ7gnarvp2g_dSlwMokEGOkLci90BjpKrkjd1Kx9pRYEu6", "result_metadata": {"score": 21.8324}, "author": "Research and Markets", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.434623, "label": "positive"}, "text": "China", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.434623, "label": "positive"}, "text": "Entecavir", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0.687141, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Mass customization", "relevance": 0.857213, "dbpedia_resource": "http://dbpedia.org/resource/Mass_customization"}, {"text": "Painting", "relevance": 0.8345, "dbpedia_resource": "http://dbpedia.org/resource/Painting"}, {"text": "Supernova", "relevance": 0.826416, "dbpedia_resource": "http://dbpedia.org/resource/Supernova"}], "categories": [{"score": 0.689745, "label": "/real estate/buying and selling homes"}, {"score": 0.437762, "label": "/finance/investing/day trading"}, {"score": 0.366171, "label": "/finance/financial news"}], "relations": [{"type": "partOf", "sentence": "China Entecavir Investigation Market Report, 2018-2022 - Market Size, Competitive Landscape, Price by Manufacturer & Market Outlook", "score": 0.990638, "arguments": [{"text": "Entecavir Investigation Market Report", "location": [6, 43], "entities": [{"type": "Organization", "text": "Entecavir Investigation Market Report"}]}, {"text": "China", "location": [0, 5], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "China Entecavir Investigation Market Report, 2018-2022 - Market Size, Competitive Landscape, Price by Manufacturer & Market Outlook", "score": 0.911479, "arguments": [{"text": "Price", "location": [93, 98], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Manufacturer & Market Outlook", "location": [102, 131], "entities": [{"type": "Organization", "text": "Manufacturer & Market Outlook", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "China Entecavir Investigation", "sentiment": {"score": 0.434623, "label": "positive"}, "relevance": 0.969077}, {"text": "Market Outlook", "sentiment": {"score": 0.402413, "label": "positive"}, "relevance": 0.545019}, {"text": "Competitive Landscape", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513104}, {"text": "Market Report", "sentiment": {"score": 0.434623, "label": "positive"}, "relevance": 0.484412}, {"text": "Market Size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478539}, {"text": "Price", "sentiment": {"score": 0.402413, "label": "positive"}, "relevance": 0.322386}, {"text": "Manufacturer", "sentiment": {"score": 0.402412, "label": "positive"}, "relevance": 0.322079}]}, "crawl_date": "2018-11-04T02:35:59Z", "url": "https://www.prnewswire.com/news-releases/china-entecavir-investigation-market-report-2018-2022---market-size-competitive-landscape-price-by-manufacturer--market-outlook-300743012.html", "host": "prnewswire.com", "text": "Group Co., Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'", "main_image_url": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T14:00:00-06:00", "enriched_text": {"entities": [{"count": 25, "sentiment": {"score": 0.413639, "label": "positive"}, "text": "China Entecavir", "relevance": 0.888536, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.44481, "label": "positive"}, "text": "Entecavir", "relevance": 0.23669, "type": "Drug"}, {"count": 16, "sentiment": {"score": 0.0254756, "label": "positive"}, "text": "China", "relevance": 0.22566, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "relevance": 0.209542, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China Market", "relevance": 0.136896, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.308825, "label": "positive"}, "text": "Chia Tai Tianqing Pharmaceutical Group Co.", "relevance": 0.120833, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jiangxi Qingfeng Pharmaceutical Co.", "relevance": 0.117608, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shanghai Squibb Pharmaceuticals Ltd.", "relevance": 0.116501, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBV", "relevance": 0.115293, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause"], "name": "Hepatitis B virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Suzhou Dawnrays Pharmaceutical Co.", "relevance": 0.108681, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Fujian Cosunter Pharmaceutical Co.", "relevance": 0.108594, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.645441, "label": "negative"}, "text": "chronic Hepatitis B", "relevance": 0.106544, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Hepatitis B", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BristolMyers Squibb", "relevance": 0.10336, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.645441, "label": "negative"}, "text": "chronic Hepatitis B.", "relevance": 0.0948489, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ResearchAndMarkets.com", "relevance": 0.0946278, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.645441, "label": "negative"}, "text": "liver damage", "relevance": 0.0911024, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor"], "name": "Hepatotoxicity", "dbpedia_resource": "http://dbpedia.org/resource/Hepatotoxicity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "DUBLIN", "relevance": 0.0908102, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SOURCE Research and Markets", "relevance": 0.0799442, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.557435, "label": "positive"}, "text": "Custom Research Manager", "relevance": 0.0770717, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laura Wood", "relevance": 0.0755918, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CFDA", "relevance": 0.0755072, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.0730529, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.0720639, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Manager", "relevance": 0.0704915, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Enganding", "relevance": 0.0559821, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Baraclude", "relevance": 0.0544165, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Runzhong", "relevance": 0.0528674, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Weiliqing", "relevance": 0.0526956, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Leiyide", "relevance": 0.0526052, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "press@researchandmarkets.com", "relevance": 0.0526052, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "15.38%", "relevance": 0.0526052, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "23.96%", "relevance": 0.0526052, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "39.82%", "relevance": 0.0526052, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2022", "relevance": 0.0526052, "type": "Quantity"}], "sentiment": {"document": {"score": 0.0861478, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The \"Investigation Report on China Entecavir 2018-2022\" report", "keywords": [{"text": "China Entecavir"}, {"text": "Investigation Report"}], "entities": [{"type": "Company", "text": "China Entecavir"}, {"type": "Quantity", "text": "2022\""}]}, "sentence": " The \"Investigation Report on China Entecavir 2018-2022\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "added to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The \"Investigation Report on China Entecavir 2018-2022\" report", "keywords": [{"text": "China Entecavir"}, {"text": "Investigation Report"}], "entities": [{"type": "Company", "text": "China Entecavir"}, {"type": "Quantity", "text": "2022\""}]}, "sentence": " The \"Investigation Report on China Entecavir 2018-2022\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "object": {"text": "with hepatitis B virus", "keywords": [{"text": "hepatitis B virus"}]}, "action": {"verb": {"text": "infect", "tense": "past"}, "text": "infected", "normalized": "infect"}}, {"subject": {"text": "The number of people infected with hepatitis B virus (HBV)", "keywords": [{"text": "HBV)"}, {"text": "hepatitis B virus"}, {"text": "number"}, {"text": "people"}], "entities": [{"type": "HealthCondition", "text": "HBV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause"], "name": "Hepatitis B virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}}]}, "sentence": " The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "object": {"text": "100 million"}, "action": {"verb": {"text": "exceed", "tense": "present"}, "text": "exceeds", "normalized": "exceed"}}, {"subject": {"text": "20-30 million"}, "sentence": " The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "object": {"text": "from chronic Hepatitis B. About 0.5 million Chinese", "keywords": [{"text": "chronic Hepatitis B."}], "entities": [{"type": "HealthCondition", "text": "chronic Hepatitis B."}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "chronic Hepatitis B. About 0.5 million Chinese", "keywords": [{"text": "chronic Hepatitis B."}], "entities": [{"type": "HealthCondition", "text": "chronic Hepatitis B."}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "object": {"text": "to die of liver damage", "keywords": [{"text": "liver damage"}], "entities": [{"type": "HealthCondition", "text": "liver damage", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor"], "name": "Hepatotoxicity", "dbpedia_resource": "http://dbpedia.org/resource/Hepatotoxicity"}}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "by chronic Hepatitis B", "keywords": [{"text": "chronic Hepatitis"}], "entities": [{"type": "HealthCondition", "text": "chronic Hepatitis B", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Hepatitis B", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}}]}, "sentence": " The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "object": {"text": "liver cancer", "keywords": [{"text": "liver cancer"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "Entecavir, an oral drug of oral deoxyguanosine,", "keywords": [{"text": "oral drug"}, {"text": "oral deoxyguanosine"}, {"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "sentence": " Entecavir, an oral drug of oral deoxyguanosine, was developed by BristolMyers Squibb and approved to enter the market by FDA in Mar. 2005 .", "object": {"text": "developed by BristolMyers Squibb", "keywords": [{"text": "BristolMyers Squibb"}], "entities": [{"type": "Company", "text": "BristolMyers Squibb"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by BristolMyers Squibb", "keywords": [{"text": "BristolMyers Squibb"}], "entities": [{"type": "Company", "text": "BristolMyers Squibb"}]}, "sentence": " Entecavir, an oral drug of oral deoxyguanosine, was developed by BristolMyers Squibb and approved to enter the market by FDA in Mar. 2005 .", "object": {"text": "Entecavir, an oral drug of oral deoxyguanosine,", "keywords": [{"text": "oral drug"}, {"text": "oral deoxyguanosine"}, {"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "action": {"verb": {"text": "develop", "tense": "past"}, "text": "was developed", "normalized": "be develop"}}, {"subject": {"text": "Entecavir, an oral drug of oral deoxyguanosine,", "keywords": [{"text": "oral drug"}, {"text": "oral deoxyguanosine"}, {"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "sentence": " Entecavir, an oral drug of oral deoxyguanosine, was developed by BristolMyers Squibb and approved to enter the market by FDA in Mar. 2005 .", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "enter", "tense": "future"}, "text": "to enter", "normalized": "to enter"}}, {"subject": {"text": "by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "keywords": [{"text": "Shanghai Squibb Pharmaceuticals"}], "entities": [{"type": "Company", "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd"}]}, "sentence": " Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent.", "object": {"text": "Entecavir", "keywords": [{"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "keywords": [{"text": "Shanghai Squibb Pharmaceuticals"}, {"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}, {"type": "Company", "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd"}]}, "sentence": " Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent.", "object": {"text": "CFDA's approval", "keywords": [{"text": "CFDA"}, {"text": "approval"}], "entities": [{"type": "Organization", "text": "CFDA"}]}, "action": {"verb": {"text": "get", "tense": "past"}, "text": "got", "normalized": "get"}}, {"subject": {"text": "Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "keywords": [{"text": "Shanghai Squibb Pharmaceuticals"}, {"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}, {"type": "Company", "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd"}]}, "sentence": " Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent.", "object": {"text": "the Chinese market", "keywords": [{"text": "Chinese market"}]}, "action": {"verb": {"text": "enter", "tense": "past"}, "text": "entered", "normalized": "enter"}}, {"subject": {"text": "by many generic drugs which promote market growth to some extent", "keywords": [{"text": "generic drugs"}, {"text": "market growth"}, {"text": "extent"}]}, "sentence": " Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent.", "object": {"text": "the Chinese market in early 2006,", "keywords": [{"text": "Chinese market"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "many generic drugs", "keywords": [{"text": "generic drugs"}]}, "sentence": " Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent.", "object": {"text": "market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "promote", "tense": "present"}, "text": "promote", "normalized": "promote"}}, {"subject": {"text": "Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "keywords": [{"text": "Shanghai Squibb Pharmaceuticals"}, {"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}, {"type": "Company", "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd"}]}, "sentence": " Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.", "object": {"text": "the Chinese market", "keywords": [{"text": "Chinese market"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "Entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance", "keywords": [{"text": "lower resistance rate"}, {"text": "stronger antiviral effects"}, {"text": "faster onset"}, {"text": "drug resistance"}], "entities": [{"type": "Drug", "text": "China Entecavir"}, {"type": "HealthCondition", "text": "HBV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause"], "name": "Hepatitis B virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}}]}, "sentence": " Compared with the original nucleoside analogue, Entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance.", "object": {"text": "with the original nucleoside analogue", "keywords": [{"text": "original nucleoside analogue"}]}, "action": {"verb": {"text": "Compared", "tense": "past"}, "text": "Compared", "normalized": "Compared"}}, {"subject": {"text": "Entecavir", "keywords": [{"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "sentence": " Compared with the original nucleoside analogue, Entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance.", "object": {"text": "stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance", "keywords": [{"text": "lower resistance rate"}, {"text": "faster onset"}, {"text": "drug resistance"}, {"text": "fewer side effects"}], "entities": [{"type": "HealthCondition", "text": "HBV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause"], "name": "Hepatitis B virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "HBV", "keywords": [{"text": "HBV"}], "entities": [{"type": "HealthCondition", "text": "HBV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause"], "name": "Hepatitis B virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}}]}, "sentence": " Compared with the original nucleoside analogue, Entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance.", "object": {"text": "to drug resistance", "keywords": [{"text": "drug resistance"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibiting", "normalized": "inhibit"}}, {"subject": {"text": "Entecavir", "keywords": [{"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "sentence": " Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term.", "object": {"text": "possible"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "new drug's entering into the anti HBV drug market", "keywords": [{"text": "anti HBV drug"}, {"text": "new drug"}]}, "sentence": " As is known to all, new drug's entering into the anti HBV drug market are bound to pose a threat to old ones, forming a new competitive landscape.", "object": {"text": "a threat", "keywords": [{"text": "threat"}]}, "action": {"verb": {"text": "pose", "tense": "future"}, "text": "are bound to pose", "normalized": "be bind to pose"}}, {"subject": {"text": "new drug's entering into the anti HBV drug market", "keywords": [{"text": "anti HBV drug"}, {"text": "new drug"}]}, "sentence": " As is known to all, new drug's entering into the anti HBV drug market are bound to pose a threat to old ones, forming a new competitive landscape.", "object": {"text": "a new competitive landscape", "keywords": [{"text": "new competitive landscape"}]}, "action": {"verb": {"text": "form", "tense": "present"}, "text": "forming", "normalized": "form"}}, {"subject": {"text": "the market demand", "keywords": [{"text": "market demand"}]}, "sentence": " Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied.", "object": {"text": "far from being satisfied"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market demand", "keywords": [{"text": "market demand"}]}, "sentence": " Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied.", "object": {"text": "satisfied"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "Entecavir", "keywords": [{"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "sentence": " Therefore, Entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.", "object": {"text": "estimated to enjoy good market prospects", "keywords": [{"text": "good market prospects"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Entecavir", "keywords": [{"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "sentence": " Therefore, Entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.", "object": {"text": "to enjoy good market prospects and its sales value", "keywords": [{"text": "good market prospects"}, {"text": "sales value"}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "its sales value", "keywords": [{"text": "sales value"}]}, "sentence": " Therefore, Entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.", "action": {"verb": {"text": "grow", "tense": "future"}, "text": "will keep growing", "normalized": "will keep grow"}}, {"subject": {"text": "by different manufacturers", "keywords": [{"text": "different manufacturers"}]}, "sentence": " Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered:", "object": {"text": "Entecavir", "keywords": [{"text": "Entecavir"}], "entities": [{"type": "Drug", "text": "China Entecavir"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "you"}, "sentence": " Did you know that we also offer Custom Research?", "object": {"text": "that we also offer Custom Research", "keywords": [{"text": "Custom Research"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we"}, "sentence": " Did you know that we also offer Custom Research?", "object": {"text": "Custom Research", "keywords": [{"text": "Custom Research"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offer", "normalized": "offer"}}, {"subject": {"text": "a meeting", "keywords": [{"text": "meeting"}]}, "sentence": " Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.", "object": {"text": "with our Custom Research Manager", "keywords": [{"text": "Custom Research Manager"}], "entities": [{"type": "JobTitle", "text": "Custom Research Manager"}]}, "action": {"verb": {"text": "schedule", "tense": "present"}, "text": "schedule", "normalized": "schedule"}}], "concepts": [{"text": "Hepatitis B", "relevance": 0.981126, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Hepatitis", "relevance": 0.577873, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Cirrhosis", "relevance": 0.534664, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Entecavir", "relevance": 0.448583, "dbpedia_resource": "http://dbpedia.org/resource/Entecavir"}, {"text": "Hepatitis A", "relevance": 0.42365, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_A"}, {"text": "Hepatocellular carcinoma", "relevance": 0.409217, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Pharmacology", "relevance": 0.408683, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Marketing", "relevance": 0.399861, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Antiviral drug", "relevance": 0.39301, "dbpedia_resource": "http://dbpedia.org/resource/Antiviral_drug"}, {"text": "Hepatitis C", "relevance": 0.383148, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Drug", "relevance": 0.360786, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Hepatitis B virus", "relevance": 0.358156, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}, {"text": "Microeconomics", "relevance": 0.35267, "dbpedia_resource": "http://dbpedia.org/resource/Microeconomics"}, {"text": "Bristol-Myers Squibb", "relevance": 0.349414, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "China", "relevance": 0.347256, "dbpedia_resource": "http://dbpedia.org/resource/China"}, {"text": "Financial markets", "relevance": 0.339057, "dbpedia_resource": "http://dbpedia.org/resource/Financial_markets"}, {"text": "Han Chinese", "relevance": 0.326814, "dbpedia_resource": "http://dbpedia.org/resource/Han_Chinese"}, {"text": "Hepatitis D", "relevance": 0.322209, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_D"}, {"text": "Pharmaceutical drug", "relevance": 0.305371, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Fujian", "relevance": 0.29847, "dbpedia_resource": "http://dbpedia.org/resource/Fujian"}, {"text": "Hepatitis B vaccine", "relevance": 0.292158, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_vaccine"}, {"text": "Wu Chinese", "relevance": 0.291633, "dbpedia_resource": "http://dbpedia.org/resource/Wu_Chinese"}, {"text": "Yangtze River", "relevance": 0.288758, "dbpedia_resource": "http://dbpedia.org/resource/Yangtze_River"}, {"text": "Food and Drug Administration", "relevance": 0.288701, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Shanghai", "relevance": 0.278841, "dbpedia_resource": "http://dbpedia.org/resource/Shanghai"}, {"text": "Guangdong", "relevance": 0.27642, "dbpedia_resource": "http://dbpedia.org/resource/Guangdong"}, {"text": "Antivirals", "relevance": 0.275568, "dbpedia_resource": "http://dbpedia.org/resource/Antivirals"}, {"text": "People's Republic of China", "relevance": 0.271908, "dbpedia_resource": "http://dbpedia.org/resource/People's_Republic_of_China"}, {"text": "Jade Ribbon Campaign", "relevance": 0.260881, "dbpedia_resource": "http://dbpedia.org/resource/Jade_Ribbon_Campaign"}, {"text": "Hepadnaviridae", "relevance": 0.258787, "dbpedia_resource": "http://dbpedia.org/resource/Hepadnaviridae"}, {"text": "Supply and demand", "relevance": 0.253493, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}, {"text": "Suzhou", "relevance": 0.249526, "dbpedia_resource": "http://dbpedia.org/resource/Suzhou"}, {"text": "Market", "relevance": 0.248217, "dbpedia_resource": "http://dbpedia.org/resource/Market"}, {"text": "Market trends", "relevance": 0.247974, "dbpedia_resource": "http://dbpedia.org/resource/Market_trends"}, {"text": "World Hepatitis Day", "relevance": 0.247358, "dbpedia_resource": "http://dbpedia.org/resource/World_Hepatitis_Day"}, {"text": "Interferon", "relevance": 0.244055, "dbpedia_resource": "http://dbpedia.org/resource/Interferon"}, {"text": "Medicine", "relevance": 0.233591, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Tour de Georgia", "relevance": 0.226598, "dbpedia_resource": "http://dbpedia.org/resource/Tour_de_Georgia"}, {"text": "Consumer theory", "relevance": 0.225853, "dbpedia_resource": "http://dbpedia.org/resource/Consumer_theory"}, {"text": "Hepatitis B in China", "relevance": 0.225779, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_in_China"}], "categories": [{"score": 0.539368, "label": "/health and fitness/disease/aids and hiv"}, {"score": 0.518857, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.441947, "label": "/health and fitness/drugs"}], "relations": [{"type": "agentOf", "sentence": "DUBLIN , Nov The \"Investigation Report on China Entecavir 2018-2022\" report has been added to ResearchAndMarkets.com's offering.", "score": 0.669727, "arguments": [{"text": "Nov", "location": [9, 12], "entities": [{"type": "Person", "text": "Nov"}]}, {"text": "Report", "location": [32, 38], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "hasAttribute", "sentence": "According to a market survey, the annual sales value of Entecavir in China rose from CNY1126.04 million in 2013 to CNY 1995.69 million in 2017 and CAGR during this period reached up to 15.38%.", "score": 0.783413, "arguments": [{"text": "CNY", "location": [925, 928], "entities": [{"type": "Organization", "text": "CNY"}]}, {"text": "CNY1126.04 million", "location": [895, 913], "entities": [{"type": "Money", "text": "CNY1126.04 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOf", "sentence": "Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.", "score": 0.444684, "arguments": [{"text": "dominates", "location": [1070, 1079], "entities": [{"type": "EventCommunication", "text": "dominates"}]}, {"text": "made", "location": [1013, 1017], "entities": [{"type": "EventCommunication", "text": "made"}]}]}, {"type": "agentOf", "sentence": "Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.", "score": 0.798791, "arguments": [{"text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "location": [1021, 1069], "entities": [{"type": "Organization", "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd"}]}, {"text": "dominates", "location": [1070, 1079], "entities": [{"type": "EventCommunication", "text": "dominates"}]}]}, {"type": "basedIn", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.657634, "arguments": [{"text": "Entecavir", "location": [2019, 2028], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Chinese", "location": [1995, 2002], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.412037, "arguments": [{"text": "manufacturers", "location": [2047, 2060], "entities": [{"type": "Organization", "text": "Manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Entecavir", "location": [2019, 2028], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.616111, "arguments": [{"text": "Market", "location": [2070, 2076], "entities": [{"type": "Facility", "text": "Market Size"}]}, {"text": "China", "location": [2064, 2069], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide) 4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding) 5 Market Outlook of Entecavir in China , 2018-2022 5.1 Forecast on Market Size 5.2 Forecast on Market Trend For more information about this report visit https://www.researchandmarkets.com/research/5bfs75/china_entecavir?w=5 Did you know that we also offer Custom Research?", "score": 0.583895, "arguments": [{"text": "Market", "location": [3884, 3890], "entities": [{"type": "Facility", "text": "Market Size"}]}, {"text": "China", "location": [3915, 3920], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.887869, "arguments": [{"text": "Key Topics", "location": [2107, 2117], "entities": [{"type": "Organization", "text": "Key Topics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [2101, 2106], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.647312, "arguments": [{"text": "Entecavir", "location": [2312, 2321], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [2325, 2330], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.696554, "arguments": [{"text": "Entecavir", "location": [2625, 2634], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [2638, 2643], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.483665, "arguments": [{"text": "Volume", "location": [2495, 2501], "entities": [{"type": "Person", "text": "Volume"}]}, {"text": "Region", "location": [2505, 2511], "entities": [{"type": "GeopoliticalEntity", "text": "Region"}]}]}, {"type": "locatedAt", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.580355, "arguments": [{"text": "Dosage Form", "location": [2538, 2549], "entities": [{"type": "Person", "text": "Dosage Form"}]}, {"text": "China", "location": [2553, 2558], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "DUBLIN , Nov The \"Investigation Report on China Entecavir 2018-2022\" report has been added to ResearchAndMarkets.com's offering.", "score": 0.35782, "arguments": [{"text": "Report", "location": [32, 38], "entities": [{"type": "EventCommunication", "text": "Report"}]}, {"text": "Investigation", "location": [18, 31], "entities": [{"type": "EventLegal", "text": "Investigation"}]}]}, {"type": "employedBy", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.696369, "arguments": [{"text": "Chia Tai Tianqing", "location": [2769, 2786], "entities": [{"type": "Person", "text": "Chia Tai Tianqing"}]}, {"text": "Pharmaceutical Group Co.", "location": [2787, 2811], "entities": [{"type": "Organization", "text": "Pharmaceutical Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.493532, "arguments": [{"text": "Chia Tai Tianqing", "location": [2858, 2875], "entities": [{"type": "Person", "text": "Chia Tai Tianqing"}]}, {"text": "Pharmaceutical Group Co., Ltd.", "location": [2876, 2906], "entities": [{"type": "Organization", "text": "Pharmaceutical Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.57222, "arguments": [{"text": "Chia Tai Tianqing", "location": [3585, 3602], "entities": [{"type": "Person", "text": "Chia Tai Tianqing"}]}, {"text": "Pharmaceutical Group Co., Ltd.", "location": [3603, 3633], "entities": [{"type": "Organization", "text": "Pharmaceutical Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.518415, "arguments": [{"text": "Enterprise Profile", "location": [2824, 2842], "entities": [{"type": "Organization", "text": "Enterprise Profile"}]}, {"text": "Ltd.", "location": [2813, 2817], "entities": [{"type": "Organization", "text": "Jiangxi Qingfeng Pharmaceutical Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.739947, "arguments": [{"text": "Entecavir", "location": [2909, 2918], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Pharmaceutical Group Co., Ltd.", "location": [2876, 2906], "entities": [{"type": "Organization", "text": "Pharmaceutical Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.405637, "arguments": [{"text": "Squibb Pharmaceuticals Ltd.", "location": [2955, 2982], "entities": [{"type": "Organization", "text": "Sino-American Shanghai Squibb Pharmaceuticals Ltd."}]}, {"text": "Shanghai", "location": [2946, 2954], "entities": [{"type": "GeopoliticalEntity", "text": "Shanghai"}]}]}, {"type": "partOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.859108, "arguments": [{"text": "Entecavir", "location": [3076, 3085], "entities": [{"type": "Organization", "text": "Concepts of Entecavir"}]}, {"text": "Sino-American Shanghai Squibb Pharmaceuticals Ltd.", "location": [3023, 3073], "entities": [{"type": "Organization", "text": "Sino-American Shanghai Squibb Pharmaceuticals Ltd."}]}]}, {"type": "populationOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.332867, "arguments": [{"text": "3.4", "location": [3095, 3098], "entities": [{"type": "Cardinal", "text": "3.4"}]}, {"text": "China", "location": [3089, 3094], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.7751, "arguments": [{"text": "Entecavir", "location": [3225, 3234], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Jiangxi Qingfeng Pharmaceutical Co., Ltd.", "location": [3181, 3222], "entities": [{"type": "Organization", "text": "Jiangxi Qingfeng Pharmaceutical Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.7751, "arguments": [{"text": "Entecavir", "location": [3372, 3381], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Suzhou Dawnrays Pharmaceutical Co., Ltd.", "location": [3329, 3369], "entities": [{"type": "Organization", "text": "Jiangxi Qingfeng Pharmaceutical Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.7751, "arguments": [{"text": "Entecavir", "location": [3519, 3528], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Fujian Cosunter Pharmaceutical Co., Ltd.", "location": [3476, 3516], "entities": [{"type": "Organization", "text": "Jiangxi Qingfeng Pharmaceutical Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.370769, "arguments": [{"text": "Entecavir", "location": [3550, 3559], "entities": [{"type": "Organization", "text": "Concepts of Entecavir"}]}, {"text": "Entecavir", "location": [3519, 3528], "entities": [{"type": "Organization", "text": "Entecavir", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd. 3.4.1 Enterprise Profile 3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. 3.5.1 Enterprise Profile 3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 3.6 Fujian Cosunter Pharmaceutical Co., Ltd. 3.6.1 Enterprise Profile 3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China 4 Prices of Entecavir in China , 2017-2018 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong) 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude) 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)", "score": 0.72998, "arguments": [{"text": "Entecavir", "location": [3550, 3559], "entities": [{"type": "Organization", "text": "Concepts of Entecavir"}]}, {"text": "China", "location": [3563, 3568], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide) 4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding) 5 Market Outlook of Entecavir in China , 2018-2022 5.1 Forecast on Market Size 5.2 Forecast on Market Trend For more information about this report visit https://www.researchandmarkets.com/research/5bfs75/china_entecavir?w=5 Did you know that we also offer Custom Research?", "score": 0.671336, "arguments": [{"text": "Outlook of Entecavir", "location": [3891, 3911], "entities": [{"type": "Organization", "text": "Concepts of Entecavir"}]}, {"text": "China", "location": [3915, 3920], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "ownerOf", "sentence": "4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide) 4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding) 5 Market Outlook of Entecavir in China , 2018-2022 5.1 Forecast on Market Size 5.2 Forecast on Market Trend For more information about this report visit https://www.researchandmarkets.com/research/5bfs75/china_entecavir?w=5 Did you know that we also offer Custom Research?", "score": 0.467145, "arguments": [{"text": "Outlook of Entecavir", "location": [3891, 3911], "entities": [{"type": "Organization", "text": "Concepts of Entecavir"}]}, {"text": "Market", "location": [3884, 3890], "entities": [{"type": "Facility", "text": "Market Size"}]}]}, {"type": "hasAttribute", "sentence": "The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "score": 0.888463, "arguments": [{"text": "B.", "location": [278, 280], "entities": [{"type": "Person", "text": "B."}]}, {"text": "chronic Hepatitis", "location": [260, 277], "entities": [{"type": "HealthCondition", "text": "chronic Hepatitis"}]}]}, {"type": "participantIn", "sentence": "Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.", "score": 0.927497, "arguments": [{"text": "Manager", "location": [4248, 4255], "entities": [{"type": "Person", "text": "Laura Wood"}]}, {"text": "meeting", "location": [4215, 4222], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "employedBy", "sentence": "Media Contact: Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.684702, "arguments": [{"text": "press@researchandmarkets.com", "location": [4321, 4349], "entities": [{"type": "Person", "text": "press@researchandmarkets.com"}]}, {"text": "E.S.T Office Hours Call +", "location": [4354, 4379], "entities": [{"type": "Organization", "text": "E.S.T Office Hours Call +"}]}]}, {"type": "locatedAt", "sentence": "Media Contact: Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.415646, "arguments": [{"text": "GMT Office Hours Call +", "location": [4442, 4465], "entities": [{"type": "Organization", "text": "GMT Office Hours Call +"}]}, {"text": "Fax", "location": [4485, 4488], "entities": [{"type": "Facility", "text": "Fax"}]}]}, {"type": "ownerOf", "sentence": "Media Contact: Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.501062, "arguments": [{"text": "U.S.", "location": [4480, 4484], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Fax", "location": [4485, 4488], "entities": [{"type": "Facility", "text": "Fax"}]}]}, {"type": "hasAttribute", "sentence": "Media Contact: Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com", "score": 0.639318, "arguments": [{"text": "SOURCE Research and Markets\nRelated Links", "location": [4539, 4580], "entities": [{"type": "Organization", "text": "SOURCE Research and Markets\nRelated Links"}]}, {"text": "http://www.researchandmarkets.com", "location": [4581, 4614], "entities": [{"type": "Web", "text": "http://www.researchandmarkets.com"}]}]}, {"type": "residesIn", "sentence": "The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "score": 0.500509, "arguments": [{"text": "B.", "location": [278, 280], "entities": [{"type": "Person", "text": "B."}]}, {"text": "Chinese", "location": [299, 306], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "diedOf", "sentence": "The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "score": 0.419106, "arguments": [{"text": "B.", "location": [278, 280], "entities": [{"type": "Person", "text": "B."}]}, {"text": "liver cancer", "location": [348, 360], "entities": [{"type": "HealthCondition", "text": "liver cancer"}]}]}, {"type": "hasAttribute", "sentence": "The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China , among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.", "score": 0.602083, "arguments": [{"text": "Hepatitis B", "location": [379, 390], "entities": [{"type": "Organization", "text": "Hepatitis B"}]}, {"text": "CNY100 billion", "location": [415, 429], "entities": [{"type": "Money", "text": "CNY100 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "basedIn", "sentence": "Entecavir, an oral drug of oral deoxyguanosine, was developed by BristolMyers Squibb and approved to enter the market by FDA in Mar. 2005 .", "score": 0.604614, "arguments": [{"text": "FDA", "location": [564, 567], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Mar.", "location": [571, 575], "entities": [{"type": "GeopoliticalEntity", "text": "Mar."}]}]}, {"type": "agentOf", "sentence": "Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent.", "score": 0.89197, "arguments": [{"text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "location": [601, 649], "entities": [{"type": "Organization", "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd"}]}, {"text": "made", "location": [593, 597], "entities": [{"type": "EventCommunication", "text": "made"}]}]}, {"type": "agentOf", "sentence": "Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.", "score": 0.89968, "arguments": [{"text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd", "location": [1021, 1069], "entities": [{"type": "Organization", "text": "SinoAmerican Shanghai Squibb Pharmaceuticals Ltd"}]}, {"text": "made", "location": [1013, 1017], "entities": [{"type": "EventCommunication", "text": "made"}]}]}, {"type": "locatedAt", "sentence": "According to a market survey, the annual sales value of Entecavir in China rose from CNY1126.04 million in 2013 to CNY 1995.69 million in 2017 and CAGR during this period reached up to 15.38%.", "score": 0.974468, "arguments": [{"text": "Entecavir", "location": [866, 875], "entities": [{"type": "GeopoliticalEntity", "text": "Entecavir"}]}, {"text": "China", "location": [879, 884], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Topics covered: Market size of Entecavir in China Competitive landscape of Entecavir in Chinese market Price of Entecavir made by different manufacturers in China Market outlook of Entecavir in China Key Topics Covered: 1 Related Concepts of Entecavir 1.1 Indications for Entecavir 1.2 Development History of Entecavir in China 1.3 Governmental Approval for Entecavir in China 2 Survey on Sales Status of Entecavir in China , 2013-2017 2.1 Sales Value of Entecavir 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Entecavir 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Entecavir by Dosage Form in China , 2013-2017 2.3.1 Capsules 2.3.2 Tablets 3 Major Manufacturers of Entecavir in China , 2013-2017 3.1 Market Share of Major Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Chia Tai Tianqing Pharmaceutical Group Co.,", "score": 0.475699, "arguments": [{"text": "Entecavir", "location": [1982, 1991], "entities": [{"type": "GeopoliticalEntity", "text": "Entecavir"}]}, {"text": "China", "location": [1951, 1956], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Entecavir", "sentiment": {"score": 0.466344, "label": "positive"}, "relevance": 0.972333}, {"text": "Shanghai Squibb Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.817981}, {"text": "China Entecavir", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.741623}, {"text": "sales value", "sentiment": {"score": 0.524439, "label": "positive"}, "relevance": 0.640721}, {"text": "Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594004}, {"text": "Sino-American Shanghai Squibb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580662}, {"text": "Squibb Pharmaceuticals Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561832}, {"text": "Jiangxi Qingfeng Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559927}, {"text": "SinoAmerican Shanghai Squibb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556284}, {"text": "Chia Tai Tianqing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548725}, {"text": "Suzhou Dawnrays Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544698}, {"text": "Fujian Cosunter Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54439}, {"text": "Qingfeng Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543499}, {"text": "Tianqing Pharmaceutical Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538648}, {"text": "Tai Tianqing Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537242}, {"text": "Pharmaceutical Group Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533494}, {"text": "Dawnrays Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531536}, {"text": "Cosunter Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530871}, {"text": "sales volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51487}, {"text": "Enterprise Profile", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.500671}, {"text": "market", "sentiment": {"score": -0.0939821, "label": "negative"}, "relevance": 0.494269}, {"text": "Chinese market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475213}, {"text": "annual sales value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443312}, {"text": "China Market outlook", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443246}, {"text": "HBV drug market", "sentiment": {"score": -0.560262, "label": "negative"}, "relevance": 0.4405}, {"text": "Market Share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429537}, {"text": "Overall Sales Value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.428482}, {"text": "Custom Research", "sentiment": {"score": 0.557435, "label": "positive"}, "relevance": 0.428394}, {"text": "Chinese market Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426628}, {"text": "China Key Topics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425688}, {"text": "China Competitive landscape", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425344}, {"text": "good market prospects", "sentiment": {"score": 0.524439, "label": "positive"}, "relevance": 0.425188}, {"text": "Overall Sales Volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425153}, {"text": "chronic Hepatitis B.", "sentiment": {"score": -0.645441, "label": "negative"}, "relevance": 0.42321}, {"text": "market size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418095}, {"text": "stronger antiviral effects", "sentiment": {"score": 0.408249, "label": "positive"}, "relevance": 0.412871}, {"text": "original nucleoside analogue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411502}, {"text": "new antiviral drugs", "sentiment": {"score": -0.29832, "label": "negative"}, "relevance": 0.407356}, {"text": "new competitive landscape", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40629}, {"text": "lower resistance rate", "sentiment": {"score": -0.263569, "label": "negative"}, "relevance": 0.401399}, {"text": "Senior Manager press", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.400595}, {"text": "Custom Research page", "sentiment": {"score": 0.557435, "label": "positive"}, "relevance": 0.400054}, {"text": "U.S./CAN Toll Free", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399499}, {"text": "Custom Research Manager", "sentiment": {"score": 0.557435, "label": "positive"}, "relevance": 0.399166}, {"text": "Markets Laura Wood", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.398278}, {"text": "BristolMyers Squibb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.396801}, {"text": "Major Manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395737}, {"text": "report visit https://www.researchandmarkets.com/research/5bfs75/china_entecavir?w=5", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39511}, {"text": "market growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383857}, {"text": "market survey", "sentiment": {"score": 0.345659, "label": "positive"}, "relevance": 0.382553}]}, "extracted_metadata": {"sha1": "be4aa5cb9c3a6587629e823218d5b20c484c844f", "filename": "1541298959600.zip-0aa148c7c627e8b5b1aa3d49439f3c24.xml", "file_type": "json"}, "external_links": ["https://www.researchandmarkets.com/research/5bfs75/china_entecavir?w=5", "https://www.researchandmarkets.com/info/custom-research"], "title": "China Entecavir Investigation Market Report, 2018-2022 - Market Size, Competitive Landscape, Price by Manufacturer & Market Outlook", "forum_title": "All Surveys, Polls and Research News and Press Releases from PR Newswire"}]}